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 ABSTRACT 
 
The Leukocyte Immunoglobulin-Like Receptors (LILRs) are a family of immunomodulatory 
transmembrane receptors with both activatory and inhibitory forms, and are primarily 
expressed on myelomonocytic cells.  Group I LILRs include the well-characterised members 
LILRB1 and LILRB2, which bind MHC Class I and transduce inhibitory signals.  Group II 
LILRs, by comparison, are poorly understood.  Particular interest has arisen in the Group II 
receptor, LILRB4, and its role in the induction of immune tolerance via its actions upon 
dendritic cells and T cells.  I attempted ligand-identification and structural studies on 
LILRB4.  Staining of human PBMCs with multimeric LILRB4 revealed broad expression of 
the ligand, and upregulation on activated T cells.  Investigations into candidate ligands by 
surface plasmon resonance excluded binding to known costimulatory receptors of the 
B7/CD28 families.  X-ray crystallographic studies revealed LILRB4 has structural similarities 
to LILRA5, has novel structural features at the interdomain interface, is electrostatically and 
chemically unsuited to the recognition of MHC Class I, and identified potential ligand 
interaction sites.  Finally, investigations were conducted into the structure and ligand 
recognition of other Group II LILRs.  These studies define the distribution of the LILRB4 
ligand and represent the first structural analysis of this important immunoregulatory receptor. 
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CHAPTER 1 - INTRODUCTION 
1.1 Dendritic cells, immunity and tolerance 
1.1.1 The vertebrate immune system 
The vertebrate immune system has evolved complex mechanisms to enable the recognition 
and elimination of pathogens.  Innate immunity provides a rapid, first line of defence via the 
use of germ-line-encoded receptors specific for pathogen-restricted structures, many of which 
are evolutionarily ancient.  Crucially, innate responses are not enhanced upon antigen re-
encounter.  In contrast, adaptive immune responses are characterised by clonal selection of 
lymphocytes expressing genetically rearranged antigen receptors providing a high degree of 
specificity against a vast range of foreign antigens.  Although primary adaptive responses to a 
pathogen are initiated more slowly than innate responses, a key feature of adaptive immunity 
is the development of immunological memory via generation of memory lymphocyte 
populations, enabling a faster, augmented response upon re-encounter.  In reality, innate and 
adaptive immunity are intimately interwoven, with strong evidence for instruction of adaptive 
immunity by innate immune cells, allowing a coordinated response. 
 
Innate immune cells include phagocytes such as macrophages and neutrophils, which are able 
to surround and engulf microorganisms and can secrete inflammatory cytokines in response to 
microbial infection, and Natural Killer (NK) lymphocytes, which are able to recognise and 
destroy virally-infected or tumour cells.  Dendritic cells (DCs), which are specialised antigen 
presenting cells (APCs) that play a key role in initiation of adaptive responses, are also 
phagocytic in their immature state, as discussed below.  Monocytes, which circulate in the 
blood, are recruited to infection sites in response to inflammatory signals, where they can 
differentiate into macrophages or DCs, bolstering such responses. Other innate immune cells 
include granulocytes such as eosinophils and basophils, and tissue-resident mast cells, which 
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are involved in defence against parasitic infections, and are also implicated in allergic 
immune responses.  
 
The key cellular components of adaptive immunity are T and B lymphocytes, which recognise 
pathogens via the evolutionarily related T cell receptor (TCR) and B cell receptor (BCR) 
expressed on their surface.  The genes for TCRs and BCRs are somatically rearranged from a 
large range of Variable, Diversity and Joining segments, resulting in the generation of diverse 
clonotypically expressed antigen receptors, permitting exquisite specificity to pathogen-
derived antigens, and clonotypic expansion (Krangel et al. Immunol Rev 1998, Jung et al. 
Ann Rev Immunol 2006).  B cells contribute to humoral responses by generating antigen-
specific antibodies which help neutralise and eliminate pathogens.  αβ T cells use their TCRs 
to recognise foreign antigen in the form of peptides bound to Major Histocompatibility 
Complex (MHC) molecules at the surface of APCs, and contribute to cell-mediated immunity. 
Cytotoxic T lymphocytes (CTL) express the coreceptor CD8, and their functions include 
recognition and destruction of virally-infected or tumour cells, and cytokine production. 
Helper T (TH) cells express the CD4 coreceptor at their surface and have key regulatory 
functions.  Upon activation they secrete cytokines that have potent effects on downstream 
immune effector cells.  TH1 subsets produce Interferon (IFN)-γ and Tumour Necrosis Factor 
(TNF)-β, which facilitate the activation of macrophages and CTL and promote cellular 
immunity in the face of intracellular pathogens such as bacteria and viruses.  In contrast TH2 
cells produce IL-4, IL-5, IL-13 and IL-10, and contribute to inflammatory responses and 
humoral responses via stimulation of B cells.  TH17 cells appear to be a specialised subset of 
CD4
+
 T cells that produce IL-17, are developmentally distinct from TH1 and TH2 subsets, and 
are highly pro-inflammatory in nature (Weaver et al. Immunity 2006).  Regulatory T cells are 
discussed in Section 1.1.2. 
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In order for a protein to induce an antigen-specific T cell response, it must first be processed 
and presented on the surface of an APC, in the context of Major Histocompatibility Complex 
(MHC) molecules (Trombetta and Mellman Ann Rev Immunol 2005).  MHC Class I, which is 
expressed on all nucleated cells in the body, presents predominantly intracellular antigens, 
which are degraded in the cytosol by a multisubunit proteolytic complex termed the 
proteasome, transported into the Endoplasmic Reticulum by the transporter associated with 
antigen processing (TAP), and via the actions of chaperone proteins is assembled with 
appropriated MHC Class I heavy chains and β2-microglobulin light chain (β2m) before export 
to the cell surface via the secretory pathway.  In contrast, MHC Class II molecules, which are 
expressed on a more restricted set of cells (including DCs, B cells, activated macrophages), 
present peptides derived from predominantly exogenously derived antigens, which are 
degraded under acidic conditions in endosomal/lysosomal compartments to which nascent 
MHC Class II molecules are routed.  In these compartments, self-peptides bound to MHC 
Class II molecules (derived from MHC Class II-like invariant chain) are displaced by 
appropriate antigenic peptides, after which the MHC Class II molecules traffic to the cell 
surface for antigen presentation. 
 
Robust initiation of T cell responses requires interaction of naïve T cells with professional 
APCs, typically defined as DCs, macrophages, or B cells.  Although almost all cells in the 
human body are capable of capturing proteins by receptor-mediated endocytosis and 
presenting them via MHC Class I, most are inefficient at this process and also crucially lack 
accessory and costimulatory molecules that can promote priming of an immune response.  
Professional APCs are highly specialized cells, able to rapidly uptake proteins by endocytosis, 
load the resulting peptides onto MHC Class I or Class II molecules, and then display the 
peptide-MHC (pMHC) complexes on the cell surface for recognition by antigen receptor,  in 
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addition to providing the appropriate costimulatory signals.  Importantly, their ability to 
“cross-present” endogenously-derived antigen in MHC Class I molecules is a key feature.  
The antigen presentation abilities of professional APC are linked to their maturation status, 
which is itself dictated by environmental stimuli.  These properties distinguish professional 
APCs, and in particular the myeloid lineage-derived macrophages and DCs, as being a critical 
link between innate and adaptive immunity, and as discussed in the next section, instrumental 
in the regulation of immune tolerance.  
 
1.1.2 Control of the immune response via tolerance 
The necessity for tolerance – the failure of the adaptive immune system to respond to certain 
antigens – arises because of the competing demands of the requirement to generate diverse 
repertoires of antigen receptors, and of the requirement to regulate the immune response in 
order to prevent immune pathologies.  Tolerance is maintained through central and peripheral 
mechanisms; both are required, because central mechanisms are not 100 % efficient and do 
not account for an encounter with self neoantigens (for example, the release of sequestered 
self-antigens as a consequence of tissue damage) or innocuous non-self antigens (Kamradt 
and Mitchison N Engl J Med 2001, Walker and Abbas Nat Rev Immunol 2002). 
 
Central tolerance and thymic selection 
Central tolerance involves the deletion of potentially self-reactive T cells in the thymus, 
during T cell development.  The development of αβ T cells involves stepwise rearrangement 
and expression of the two antigen-receptor loci.  Rearrangement events occur during several 
steps of development in the thymic cortex, and this process is followed by cessation of 
recombination, then positive selection of those T cells bearing TCRs with affinity for MHC.  
Migration of semi-mature single-positive (CD4
+
 or CD8
+) αβ T cells to the medulla then 
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occurs, where they are subject to negative selection by clonal deletion; those cells bearing 
TCRs which are high-affinity ligands for self peptide-MHC (pMHC) undergo cell death by 
apoptosis.  Defects in negative selection lead to the development of autoimmunity (Siggs et 
al. Curr Opin Immunol 2006, von Boehmer and Melchers Nat Immunol 2010). Central 
tolerance to tissue-specific antigens (TSAs) is promoted by expression of the transcription 
factor AIRE in the medullary thymic epithelial cells (mTECs), leading to promiscuous 
expression of TSAs which drives negative selection of potentially autoreactive T cells  
(Anderson et al. Immunity 2005, Peterson et al. Nat Rev Immunol 2008, Kyewski and Klein 
Ann Rev Immunol 2006). Analogous selection processes occur for B lymphocytes in the bone 
marrow, although there is evidence that a degree of receptor editing at later checkpoints in B 
cell development can also occur (Nemazee Nat Rev Immunol 2006). 
 
Peripheral tolerance mechanisms 
Because central tolerance is not completely efficient, and is reliant upon the deletion of T 
cells with TCRs of high affinity for self pMHC, it follows that systems exist that keep self-
reactive T cells of low affinity for self pMHC, or those that fail to engage TSAs expressed at 
low levels by mTECs, in check in the periphery.  These peripheral tolerance mechanisms 
operate in at least three ways: by ignorance of self antigens (T cell anergy), by deletion of 
self-reactive T cells in the periphery, and via an actively regulatory subset of immune cells 
comprising regulatory T cells (Tregs) and tolerogenic DCs (Mueller Nat Immunol 2010). 
 
Anergy and Deletion 
Anergy is the state of hyporesponsiveness induced in T cells upon TCR engagement in the 
absence of costimulatory and/or inflammatory cytokine signals, or upon chronic antigenic 
stimulation (Schwartz Ann Rev Immunol 2003, Fathman and Lineberry Nat Rev Immunol 
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2007).  Anergy may also be induced by suboptimal engagement of the TCR by low avidity 
pMHC ligands (Sadegh-Nasseri et al. Immunology 2010).  Anergy has been described as an 
epigenetically maintained state, with active repression of transcription of genes involved in 
activation (Wells JI 2009).  The decision between anergy or activation is made by a series of 
intracellular proteins that actively oppose IL-2 induction – critical for T cell proliferation and 
survival - but are inactivated by signals from CD28 and/or the IL-2 Receptor (IL-2R) (Saibil 
et al. Curr Opin Immunol 2007).  Tregs have been described as being in an anergic state, 
although gene transcription analysis has demonstrated differences between Tregs and 
experimentally anergised cells.  The same study demonstrated that the signalling block in the 
anergic state could be reversed, whereas in Treg cells it could not (Knoechel et al. JI 2006).   
 
The role of deletion of autoreactive T cells in the periphery is comparatively poorly 
understood; however apoptosis driven by the down-regulation of the anti-apoptotic molecule 
Bcl-2 and the upregulation of the pro-apoptotic Bcl-2 family member, Bim, may be a 
consequence of low-affinity TCR engagement.  In addition, these studies suggest parallels 
between signalling pathways involved in anergy and deletion (Strasser et al Immunol Cell 
Biol 2008, Parish et al. Blood 2009). 
 
Regulatory and Suppressor T cells 
Although T cells with suppressive properties were described in the 1970‟s, the field then was 
highly controversial (for a historical perspective, see Sakaguchi et al. EJI 2007).  The 
identification of the high-affinity IL-2R α-chain, CD25, as a key marker (Sakaguchi et al. JI 
1995) in combination with the transcription factor FoxP3 (Hori et al. Science 2003) allowed 
for more reliable identification of a subset of CD4
+
 T cells with the ability to suppress 
immune responses, and these were subsequently named regulatory T cells (Tregs). Another 
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proposed Treg marker is the negative costimulatory receptor Cytotoxic T-Lymphocyte 
Antigen-4 (CTLA-4, discussed in Section 1.1.4). Tregs actively inhibit the activation, 
proliferation and cytokine production of other innate and adaptive immune cells. Neonatal 
mice thymectomized on day 3 – before Treg exit from the thymus – develop severe 
autoimmune pathologies, which can be reversed by infusion of CD4
+
 T cells from syngeneic 
mice (Sakaguchi et al. JEM 1982).  Mutations in FoxP3 cause the autoimmune conditions 
Scurfy in mice (Brunkow et al. Nat Genet 2001) and IPEX syndrome (Immune dysregulation, 
Polyendocrinopathy and Enteropathy, X-linked) in humans (Bennet et al. Nat Genet 2001).  
CD4
+
 CD25
+
 FoxP3
+
 Tregs enriched from normal mice dampen allergic reactions, establish 
tolerance to organ grafts, prevent graft-versus-host disease after bone marrow transplantation, 
and promote foetal-maternal tolerance (Sakaguchi Nat Immunol 2005).  Inversely, selective 
depletion of Tregs provokes effective anti-tumour immunity (Wang and Wang Curr Opin 
Immunol 2007) and augments microbial immunity in otherwise non-responding animals 
(Belkaid and Rouse Nat Immunol 2005).  Thus, Tregs play a crucial role in maintaining 
tolerance in a variety of contexts – autoimmunity, infection, cancer and transplantation. 
 
Treg subsets 
Tregs can be divided into two functionally and phenotypically overlapping subsets, natural 
Tregs (nTregs) and adaptive or inducible Tregs (iTregs).  nTregs develop in the thymus and 
are „pre-programmed‟ for the maintenance of central tolerance mechanisms (Wing and 
Sakaguchi Nat Immunol 2010).  Naive T cells differentiate into iTregs under the influence of 
tolerogenic signals in the periphery during ongoing immune responses (Horwitz et al. Trends 
Immunol 2008).  They can be subdivided into T regulatory Type 1 (Tr1) cells, which can be 
generated in the presence of the immunosuppressive cytokine IL-10, express high levels of 
IL-10 and low levels of TH1 cytokines, are anergic and functionally suppressive in vitro and 
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prevent the development of experimentally induced TH1 autoimmune diseases such as colitis 
when transferred in vivo (Groux et al. JEM 1996, Groux et al. Nature 1997, Wakkach et al. JI 
2001); and TH3 cells, first observed in the EAE (Experimental Autoimmune Encephalitis) 
model of human MS (Multiple Sclerosis), which preferentially secrete TGF-β and also 
suppress autoimmunity (Chen et al. Science 1994, Weiner et al. Immunol Rev 2001). In 
addition, a number of „non-conventional‟ regulatory cell subsets have been described.  These 
include CD8
+
 CD28
-
 T suppressor cells (Liu et al. Int Immunol 1998, Vlad et al. Hum 
Immunol 2008), CD8
+
 CD122
+
 Tregs (Endharti et al. JI 2005, Pomié et al. Hum Immunol 
2008), and  CD4
-
 CD8
-
 'double negative' Tregs (Thomson et al. Immun Res 2006). 
 
Proposed Treg suppressive mechanisms 
Identifying the mechanisms by which Tregs exert their tolerogenic effect is an active field of 
research.  A common theme is the production of IL-10 and TGF-β (Taylor et al. Immunology 
2006), a mechanism which underlies the effect known as „bystander suppression‟.  Tregs 
activated through their TCR can suppress immune responses via the release of suppressive 
cytokines, and therefore Tregs of one antigenic specificity can regulate T cells of other 
specificities. nTregs also operate directly on effector T cells via contact-dependant 
mechanisms, possibly via inhibitory receptor engagement.  Candidates include CTLA-4 and 
PD-1 (Habicht et al. JI 2007, Fife and Bluestone Immunol Rev 2008).  Tregs may directly kill 
effector T cells or activated APCs via granzyme and perforin release (Grossman et al. 
Immunity 2004).  Metabolic inhibition is another broad mechanism of Treg suppression, for 
example by competition for IL-2 (Pandiyan et al. Nat Immunol 2007, Wang et al. Immunol 
Lett 2010), generation of extracellular adenosine via expression of CD39 and CD73 (Tang 
and Bluestone Nat Immunol 2008), or tryptophan catabolism (discussed later). 
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Tregs also mediate suppression through modification of APC function, and in particular DCs, 
which are critical in initiating responses.  Tregs can convert DCs to a tolerogenic phenotype, 
in which key costimulatory molecules on the APC surface such as B7-1 and B7-2, and MHC 
Class I and II, are downregulated.  This leads to a reinforcement of the tolerogenic state, as 
such tolerogenic DCs can then induce the generation of additional Tregs from naive T cells, a 
process known as „infectious tolerance‟.  The role of tolerogenic DCs will be discussed 
further in Section 1.1.5, but in order to illustrate how DCs can contribute to tolerance it is first 
necessary to discuss how they initiate the immune response. 
 
1.1.3 Dendritic Cells and their contribution to the initiation of the Immune Response 
Dendritic cells (DCs) were first isolated and characterized by Ralph Steinman and Zanvil 
Cohn in the 1970‟s, on the basis of their necessity for in vitro antibody responses to sheep red 
blood cells (Steinman and Cohn JEM 1973, Steinman and Cohn JEM 1974, Steinman EJI 
2007).  They described a rare population of cells in the mouse spleen that had a characteristic 
stellate morphology, were highly motile and rich in mitochondria, and continually probed the 
surrounding media by extending and retracting branched processes or „dendrites‟.  Subsequent 
studies showed that DCs had high level expression of MHC Class II (Steinman et al. JEM 
1979).  Using the in vitro mixed leukocyte reaction (MLR), which mimics T cell–mediated 
rejection during transplantation, Steinman showed that DCs could initiate the reaction 
substantially more potently than bulk spleen cells (Steinman and Witmer PNAS 1978).  
Subsequent studies using purified cells showed that DCs were needed not only for 
presentation of MHC products, or immune recognition, but as potent accessories for immune 
responsiveness (Banchereau and Steinman Nature 1998, Banchereau et al. Ann Rev Immunol 
2000). 
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DC Lineages and Subsets 
Heterogeneity and functional plasticity are hallmarks of myelomonocytic cells, and have 
presented major challenges to their study.  There are two main lineages of DCs: plasmacytoid 
DCs (pDCs), and classical (myeloid) DCs.  Both are derived from common DC precursors, 
which differentiate from macrophage/DC progenitors (which also give rise to monocytes) that 
in turn have differentiated along a maturation pathway from CD34
+
 haematopoietic stem-cell 
(HSC) progenitors in the bone marrow (Liu et al. Immun Rev 2010, Geissman et al. Science 
2010).  Plasmacytoid DCs are involved in the early antiviral innate immune response, by 
producing large amounts of Type I Interferons (IFN-α, IFN-β) (Liu et al. Ann Rev Immunol 
2005).  They are relatively long lived and reside in all peripheral organs and the bone marrow.  
Classical DCs are migratory, moving from the blood (in humans; circulating DCs are rare in 
the mouse) to the tissues, and then to the lymphoid tissues via the lymphatic system, where 
they interact with T and B cells.  They can be classed as lymphoid DCs or non-lymphoid-
tissue DCs, and further subdivided based on function and surface markers (Table 1.1).  
Moreover, DCs can originate directly from monocytes exposed to inflammatory conditions in 
vivo (Randolph et al. Immunity 1999) and in in vitro culture (described later).  Evidence 
suggests that this is not a conventional route for DC generation in vivo in the steady state.  
Listeria monocytogenes infection activates monocytes via IFN-γ secreted by NK cells, and 
these activated monocytes – termed Tip-DCs or Inflammatory DCs due to their production of 
TNF and inducible nitric oxide synthase (iNOS) – have specialized antigen-presentation 
capacity and express some, but not all, of the cell-surface markers of DCs (Serbina et al. 
Immunity 2003).  This emphasises that cells of the mononuclear phagocytic system display 
considerable plasticity in terms of phenotype and function. 
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Tissue Organ DC Subset Function 
Lymphoid 
Spleen 
CD8
+
 DC 
MHC-I cross-presentation of self and 
bacterial antigens (immunity and 
tolerance) 
CD8
-
 DC 
 
MHC-II presentation 
Lymph Node 
Migratory DC Antigen transport from periphery 
CD8
+
 resident DC 
Cross-presentation of self and viral 
antigens (immunity and tolerance) 
CD8
-
 resident DC Unknown 
Non-Lymphoid 
Lung 
Liver 
Kidney 
CD103
+
 DC Cross-presentation of viral antigens 
CD11b
+
 DC Unknown 
Intestine 
PP CD103
+
 DC Unknown 
LP CD103
+
 DC Unknown 
LP CD103
-
 DC 
Antigen transport from lumen to 
mesenteric LN 
Skin (dermal) 
CD103
+
Langerin
+ Viral immunity, tolerance 
CD103
-
Langerin
- Unknown 
Non-classical 
DCs 
Skin (epidermal) Langerhans cells Regulatory? 
All/BM pDCs Innate antiviral response 
 
Table 1.1 Summary of DC subsets in lymphoid and non-lymphoid tissues.  
DC, dendritic cell. BM, bone marrow. pDC, plasmacytoid DC. PP, Peyer’s patches. 
LP, lamina propria. LN, lymph node. MHC-I/II, major histocompatibility complex class 
I/II. (Adapted from Liu and Nussenzweig Immun Rev 2010) 
 
DC Maturation 
DC maturation is the process by which immature DCs, which capture antigens in peripheral 
tissues, become efficient initiators of immunity in response to environmental stimuli 
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(Rescigno et al. J Leukoc Biol 1997).  DC maturation is a temporally separated two-stage 
process involving first antigen processing and peptide-MHC formation, and then T cell 
recognition and responsiveness in the context of costimulation (Schuler and Steinman JEM 
1985, Romani et al. JEM 1989). Immature DCs (iDCs) have high endocytic activity, low 
surface expression of MHC Class I and II and costimulatory molecules, and high migratory 
capacity, moving from the blood to the tissues, where they patrol for antigens, and then to 
draining lymph nodes via the lymphatics.  In contrast, maturing DCs have reduced endocytic 
capacity, increased surface MHC Class I and II, adhesion and costimulatory molecules 
(including B7-1 and B7-2), and rapidly home to lymphoid tissues via the chemokine receptor 
CCR7, where they can then interact with antigen-specific lymphocytes.  
 
DC maturation has been modelled in vitro using isolated human CD14
+
 monocytes.  Key 
signals that may be involved in initiating DC maturation include GM-CSF and IL-4.  
Monocytes in culture can be induced to differentiate into cells with properties similar to iDCs 
by the addition of GM-CSF and IL-4, and furthermore can undergo maturation to a phenotype 
with lower antigen-presentation capacity but increased ability to stimulate T-cell responses 
upon addition of the inflammatory cytokine TNF-α or costimulating CD40L (Sallusto and 
Lanzavecchia JEM 1994).  Further studies expanded upon this technique and noted the high 
expression of MHC Class I and II, the DC marker CD83, and the costimulatory molecules 
B7-1 and B7-2 on functionally-matured cells (Bender et al. J Immunol Methods 1996, Zhou 
and Tedder PNAS 1996, Kiertscher and Roth J Leukoc Biol 1996, Conti and Gessani 
Immunobiology 2008). 
 
The cytokine milieu influencing DC differentiation is an important factor in determining 
downstream responses, and under appropriate conditions, a wide variety of cytokines display 
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the capacity to differentiate and/or mature DCs from different precursors (Vieira et al. JI 
2000, Zou and Tam Eur Cytokine Netw 2002, Schmid et al. Immunol Rev 2010).  In the 
steady state cytokine production is tightly regulated but can be promptly induced both locally 
and systemically as a consequence of infection.  Importantly, under these conditions novel DC 
populations arise, which can themselves significantly alter the cytokine environment (e.g. 
Tip-DCs mentioned earlier, or DCs with regulatory properties – discussed later).  
  
DC Response to the Immune Environment 
Effective priming of an adaptive immune response requires DCs to be in an activated state; 
antigen itself is not sufficient and in the absence of costimulation may lead to tolerance.  
Myelomonocytic cells (such as DCs) are particularly sensitive to their immune environment, 
and can respond to both microbial products and products of tissue damage and inflammation.  
The discovery of germline-encoded receptors on the surface of these cells, which are able to 
detect not just distinct microbial structures but also endogenous signals e.g. necrotic cell 
products, led to the „danger hypothesis‟ suggested by Matzinger (Matzinger Ann Rev 
Immunol 1994; Matzinger Science 2002), as an attempt to reconcile findings conflicting with 
the established „self-nonself‟ (SNS) model, proposed by Bretscher and Cohn in 1970, and 
later expanded to include „self/nonself/altered self‟ (Medzhitov and Janeway Science 2002).  
This hypothesis proposed that initiation of the immune response was not primarily due to 
recognition of infectious „non-self‟ antigen but instead upon the recognition of endogenous 
„danger signals‟, thus accounting for non-infectious immune responses only partially 
explained by the SNS model (e.g. to tumours or during transplantation). 
 
PRRs and PAMPs  
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Pattern-Recognition Receptors (PRRs) are innate immune receptors that recognise structurally 
conserved motifs deriving from microbes, called Pathogen-Associated Molecular Patterns, 
(PAMPs) (Janeway CSH Symp Quant Biol 1989, Palm and Medzhitov Immunol Rev 2009).  
The four key characteristics of PRRs are the ability to discriminate between self and non-self, 
resistance to evolutionary escape through non-redundancy of their targets, the recognition of a 
large number of microorganisms via a limited number of germline-encoded receptors, and the 
ability to convey information concerning the type of invading pathogen for an effective 
response.  These characteristics derive from the nature of PAMPs, which represent molecular 
structures unique to pathogens, are essential for pathogen survival, are shared by classes of 
pathogens, and represent „molecular signatures‟ (for example, lipopolysaccharide (LPS) is 
produced by bacteria but not by eukaryotes; peptidoglycan is essential for the bacterial cell 
wall; all bacteria have lipoproteins; and LPS, lipoteichoic acid, and mannans are signatures of 
gram-negative, gram-positive, and fungal pathogens, respectively). 
 
The archetypal PRRs are the Toll-Like Receptors (TLRs).  The evolutionary ancestry of these 
receptors is highlighted by their homology to the Drosophila Toll protein; a homologous 
immune response system based on the Toll signalling domain is found in plants, insects and 
vertebrates (Medhzitov et al. Nature 1997).  TLRs are type I transmembrane proteins whose 
extracellular domains bind to PAMPs via leucine-rich repeats. They signal via intracellular 
Toll–IL-1 Receptor (TIR) domains.  TLRs recognise a wide range of PAMPS, both 
extracellular (TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11, which are surface-expressed 
and primarily recognise pathogen membrane components) and intracellular (TLR3, TLR7, 
TLR8 and TLR9, which are present in the ER and endolysosomal system and recognize 
pathogen nucleic acids).  TLRs are capable of co-operative signalling, and downstream 
signalling pathways can be classified as either MyD88-dependent, which drive the induction 
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of inflammatory cytokines, or TRIF-dependent, which in addition generate Type I IFNs.  
TLRs are expressed mainly on APCs and many TLR agonists trigger adaptive immunity via 
TH1 and TH17 responses as well as antibody responses (Ozinsky et al. PNAS 2000, Takeda et 
al. Ann Rev Immunol 2003, Kawai and Akira Nat Immunol 2010).  
 
Other important classes of PRRs include the C-type Lectin-like Receptors (CLRs) 
(Geijtenbeek et al. Ann Rev Immunol 2004), which interact with pathogens through 
recognition of carbohydrate structures and lead to their phagocytosis and antigen presentation 
by APCs; Scavenger receptors (Greaves and Gordon 2009 J Lipid Res); and cytosolic PRRs 
such as the Nucleotide-binding Oligomerization Domain-like receptors (NLRs) and Retinoic 
acid-Inducible Gene-I (RIG-I)-helicase Like Receptors (RLRs) capable of instructing adaptive 
immune responses to intracellular pathogens (Franchi et al. Immu Rev 2009), Nakhaei et al. 
Semin Immunol 2009, Ishii et al Nature 2008).  Fc receptors, which are involved in 
phagocytosis of opsonised pathogens, could also be considered to be PRRs. 
 
1.1.4 DC Accessory Signalling to and from the T cell 
The classical model for activation of the T cell involves a stepwise progression of signals 
necessary for activation leading to proliferation, effector functions and memory.  In the 
absence of the full signal repertoire, T cells may become anergic, be deleted, or adopt a 
tolerogenic phenotype.  Historically, this model was described as the „2-signal‟ model, with 
Signal 1 being engagement of the TCR (plus stabilising coreceptor – CD4 or CD8) with 
cognate pMHC complex displayed by APCs, and Signal 2 being costimulation via 
engagement of T cell CD28 with B7-1/B7-2 (CD80/CD86) on an activated APC surface.  An 
expansion of this model includes Signal 3, the involvement of inflammatory cytokines such as 
IL-12 that determine downstream TH commitment (Joffre et al. Immunol Rev 2009), and a 
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modification of Signal 2 to include negative costimulation (discussed below).  The 
costimulatory receptor repertoire includes newly discovered members of the B7 family (Wang 
et al. Cell Mol Immunol 2004) and other molecules such as the TNF receptor (TNFR) family 
members CD40-CD40L, OX-2 (CD200, Jenmalm et al. JI 2006), OX40 (CD134, Croft et al. 
Immunol Rev 2009) and 4-1BB (CD137, Wang et al. Immunol Rev 2009).  For a summary of 
costimulatory pathways, see Figure 1.1.  I will discuss selected members of the B7:CD28 
family, CD40-CD40L, and other IgSF receptors below. 
 
Negative and positive signalling – ITAMs, ITIMs and ITSMs 
Immunoreceptors can be activatory or inhibitory, and display conserved amino acid sequences 
in their cytoplasmic domains that recruit downstream kinases (for activation through 
phosphorylation of signalling intermediates) or phosphatases (for inhibition through 
dephosphorylation).  ITAMs (Immunoreceptor Tyrosine-based Activation Motifs) were first 
identified in the antigen receptors and later in activatory Fc receptors.  ITAMs may also be 
present in adaptor molecules (for example, in the FcR common γ-chain, which associates with 
activatory receptors lacking a cytoplasmic tail via charged transmembrane residues); their 
consensus sequence is YxxL/I x(6-12) YxxL/I, and upon phosphorylation at their key tyrosine 
residues they recruit tandem Src homology-2 (SH2)-domain containing kinases such as Syk.  
Their inhibitory counterparts, ITIMs (Immunoreceptor Tyrosine-based Inhibitory Motifs), 
have the consensus S/I/V/LxYxxI/V/L, and recruit SH2-domain containing phosphatases such 
as SHP-1.  However, some ITIM-containing receptors may be activatory, and conversely 
some ITAM-containing receptors may mediate inhibition; in addition, the definition of an 
Immunoreceptor Tyrosine-based Switch Motif (ITSM) that can mediate both outcomes has 
revealed the complexity of these signalling mechanisms (Barrow and Trowsdale EJI 2006). 
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Figure 1.1. Costimulatory molecules of the IgSF and TNFR family.  The 
bidirectional signalling interactions between T cells and DCs, B cells or macrophages 
mediated by costimulatory molecules of the IgSF (including B7 and CD28 families) 
and the TNFR family are illustrated, with the downstream consequences for the T 
and B lymphocyte shown. (Peggs and Allison Br J Haem 2005).
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Costimulation of the T cell via B7 family engagement of CD28 
Classical costimulation occurs via the interaction of B7-1 or B7-2 on the APC and CD28 on 
the T cell surface, in conjunction with TCR engagement by pMHC.  The CD28 family of 
transmembrane receptors are characterised by a single extracellular Ig Variable-like (IgV) 
domain and a short cytoplasmic tail, and homodimerise on the cell surface via an unpaired 
cysteine residue.  CD28 is expressed constitutively on 90 % of resting CD4
+
 T cells and 50 % 
of CD8
+ 
T cells.  CD28 binds to B7-1 and B7-2 with affinities of 4 and 20 µM, respectively, 
and expression patterns of B7-1 versus B7-2 are temporally separated; B7-2 is expressed at a 
low level in resting DCs and can be rapidly upregulated, whereas B7-1 is virtually absent 
from non-activated DCs and expressed on the cell surface later than the peak of B7-2 
expression.  However, engagement of either B7-1 or B7-2 is functionally redundant (Borriello 
et al. Immunity 1997).  CD28 engagement in concert with TCR ligation strongly amplifies 
weak TCR signals, resulting in dependency on Signal 2 when TCR occupancy is low (Viola 
and Lanzavecchia Science 1996, Diehn et al PNAS 2002; Riley et al. PNAS 2002). 
Downstream signalling of CD28 involves recruitment of multiple kinases to a phosphorylated 
YMNM sequence and proline-rich motifs in its cytoplasmic tail.  PI3K (Phosphatidyl-
Inositol-3-Kinase) activation of the AKT pathway via involvement of src-family kinases lck 
and fyn then activates multiple pathways linked to protein synthesis, cellular metabolism, and 
cell survival.  Activation of the NF-κB pathway has also been implicated (Raab et al PNAS 
1995, Frauwirth et al. Immunity 2002, Takeda et al. Int Immunol 2008).   
 
CD40-CD40L  and the DC licensing model 
CD8
+
 T cell immunity has been shown to be dependent on help from CD4
+
 TH cells to APCs, 
a process known as „DC licensing‟.  Although initially controversial, due to the dispensable 
requirement for antigen in some situations, DC licensing via the CD40-CD40L interaction is 
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now recognised to be necessary for effective CTL memory (Smith et al. Nat Immunol 2004, 
Ma and Clark Sem Immunol 2009).  On the basis of the phenotypes of CD40 -/- mouse 
models and CD40L-impaired patients with hyper-IgM syndrome, CD40-CD40L interactions 
were classically thought to be involved in T cell help to B cells (Allen et al. Science 1993, 
Korthauer et al. Nature 1993, Brown et al. Nat Med 1998).  Subsequently, CD40 engagement 
was shown to modulate APC function through upregulation of B7-1/B7-2 and MHC (Caux et 
al. JEM 1994, Pinchuk et al. Immunity 1994) and to enhance T cell activation via DC 
production of IL-12 (Cella et al. JEM 1996).  The cytoplasmic tail of CD40 contains sites for 
the recruitment of TRAFs (TNFR-Associated Factor family of proteins), which mediate 
downstream signalling pathways leading to cytokine production and upregulation of co-
stimulatory molecules (Kobayashi et al. Microbes Infect 2004).   
 
CD40 is widely expressed on many resting subsets, including B cells, monocytes and DCs, 
and also on activated CD4
+
 and CD8
+
 T cells.  Its ligand CD40L (CD154) is expressed on 
activated CD4
+
 T cells, activated B cells, and is induced on human DCs after CD40 
stimulation.  Thus, the potential exists for bidirectional CD40-CD40L interactions between 
APCs and lymphocytes (Mackey et al. JI 1998, Rissoan et al. Science 1999).   
 
Inhibitory costimulation by B7:CD28 family members 
CTLA-4 
CTLA-4 is the classical negative costimulator, providing an inhibitory „second-signal‟ to TCR 
engagement.  CTLA-4 is structurally similar to CD28, being a glycosylated disulphide-linked 
homodimer, but binds B7-1 with approximately 17-fold higher affinity (van der Merwe et al. 
JEM 1997).  In comparison to CD28, CTLA-4 acts to dampen T cell responses to antigen and 
is upregulated following T cell activation in order to limit the response.  CTLA-4 -/- mice die 
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from profound multi-organ autoimmunity within 3 weeks of birth (Waterhouse et al. Science 
1995).  CTLA-4 is primarily expressed intracellularly, in the trans-Golgi network and 
endolysosomal compartments.  Even after optimal T cell activation only a small percentage is 
redirected to the surface, and is localised at the immunological synapse, with the degree of 
externalisation dictated by TCR-pMHC affinity (Egen et al. Immunity 2002).  CTLA-4 
engagement reverses the „stop signal‟ induced by TCR ligation and required for stable T 
cell:APC interaction (Schneider et al. Science 2006), inhibits the formation of lipid rafts 
which contain adaptor proteins such as LAT (Martin et al. JEM 2001), and disrupts the 
formation of signalling microclusters necessary for Ca
2+
 influx concomitant to proliferation 
(Schneider et al. EJI 2008).  CTLA-4 may have a role in tolerance; transgenic mice with 
CTLA-4 deletion targeted specifically to FoxP3
+
 Tregs have reduced suppressive ability of 
these cells (Wing et al. Science 2008).  
 
PD-1, PD-L1 and PD-L2 
PD-1 is expressed on activated T cells, NK T cells, B cells, activated monocytes and myeloid 
DCs.  It negatively regulates signalling through the TCR or BCR; its expression on non-
lymphocytes is of unknown functional significance.  PD-1 ligation dampens TCR signalling 
but can be overcome by strong CD28 costimulation.  This negative signalling requires 
proximity of the PD-1 cytoplasmic domain with the TCR and PD-1 has been shown to 
redistribute to the immunological synapse upon activation.  Phosphorylation of the ITIM and 
ITSM motifs within the cytoplasmic tail of PD-1 by TCR-associated kinases leads to the 
recruitment of the phosphatases SHP-1 and SHP-2, which then dephosphorylate downstream 
signalling molecules.  PD-1 ligation downregulates IL-2, IFN-γ and TNF-α production, with 
weaker negative effects upon cell proliferation.  Effector cell differentiation and survival are 
impeded through disruption of signalling via CD28 and IL-2. 
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PD-1 binds to its ligands, PD-L1 and PD-L2.  PD-L1 is more widely expressed than PD-L2, 
and can be induced on T cells, B cells and myeloid cells as well as being constitutively 
expressed on a wide range of non-haematopoietic cells.  PD-L1 expression can be upregulated 
upon exposure to IFNs.  PD-L2 expression is more restricted to APCs – it is constitutively 
expressed on peritoneal B1 cells and can be induced on DCs, macrophages and bone marrow-
derived mast cells.  There is evidence for bidirectional signalling through PD-1:PD-L 
interactions.  Soluble PD-1-Fc inhibits DC activation and leads to a suppressive DC 
phenotype with increased production of IL-10 (Kuipers et al. EJI 2006).  Soluble PD-1 can 
also induce IL-10 secretion by CD4
+
 T cells (Dong et al. JCI 2003).  PD-L2 blockade of DCs 
by antibody treatment leads to increased production of proinflammatory IL-6 and TNF-α and 
increased proliferation of naive T cells (Nguyen et al. JEM 2002). 
 
PD-L1 can also bind to B7-1 and provide negative signals into T cells (Butte et al. Immunity 
2007).  This explains contradictory observations in the PD-1 field.  PD-L1 -/- T cells from 
PD-L1 deficient mice show increased inflammatory cytokine production (Latchman et al. 
PNAS 2004).  Bidirectional PD-L1/B7-1 interactions are possible between T cells, B cells, 
DCs and macrophages because both PD-L1 and B7-1 are expressed on these cell types. The 
presence of B7-1 as well as PD-1 on T cells allows regulation of T cell responses via the 
interaction with PD-L1 on non-haematopoietic cells.  Peripheral tissue expression of PD-1 
ligands may thus limit aggressive or self-reactive responses. 
 
ICOS and ICOSL 
ICOS, like CD28 and CTLA-4, is a glycosylated disulphide linked homodimer.  It is 
upregulated on CD4
+
 and CD8
+
 effector and memory T cells after activation via CD28 and 
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TCR signalling and contains a cytoplasmic PI3K-binding motif (Coyle et al. Immunity 2000).  
ICOS is also expressed on activated NK cells.  Its ligand, ICOSL, is expressed on a variety of 
cell types including endothelial and epithelial cells, B cells, DCs, macrophages and a subset of 
T cells.  ICOS/ICOSL interactions are essential for T cell help to B cells; mice lacking ICOS 
or ICOSL have impaired B cell responses (Hutloff et al. Nature 1999, McAdam et al. Nature 
2001, Tafuri et al. Nature 2001). Similarly, homozygous loss of ICOS has been identified as 
the cause of common variable immunodeficiency disease in a small number of human 
patients, who display profoundly impaired antibody responses and recurrent bacterial 
infections (Grimbacher et al. Nat Immunol 2003).  
 
Several studies suggest ICOS-ICOSL interactions are involved in CD4
+
 T cell suppression by 
iDCs.  This is proposed to be through upregulation of the IL-10R on T cells, which can lead to 
iTreg generation, thereby highlighting a potential role for ICOS/ICOSL interactions in 
tolerance induction. (Witsch et al. EJI 2002, Levings et al. Blood 2005, Tuettenberg et al. JI 
2009). 
 
Signalling through MHC Class I engagement – KIRs and LILRs 
Engagement of MHC Class I by inhibitory receptors has been shown to modulate the 
functions of a range of immune cells, including DCs, T cells and NK cells.  Class I MHC 
inhibitory receptors underlie „missing-self‟ recognition by NK cells, exemplified in humans 
by their Killer Ig-like Receptors (KIRs). KIRs are polymorphic and exhibit haplotype 
variability, and engage MHC Class I in a peptide and allele-specific fashion.  KIRs have 
either 2 or 3 extracellular Ig-like domains; inhibitory KIRs have long cytoplasmic tails 
containing ITIMs, and activatory KIRs have short cytoplasmic tails and associate with the 
ITAM-containing adaptor, DAP12.  Several inhibitory KIRs have well-defined MHC Class I 
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ligands, but activatory KIRs show either weak or undetectable binding to MHC Class I and 
their ligands remain unknown (Parham Immunol Lett 2004, Rajagopalan and Long JEM 
2005, Khakoo and Carrington Immunol Rev 2006).  Of more relevance to modulation of 
myelomonocytic cell function is a related family of immunoreceptors, the Leukocyte Ig-Like 
Receptors (LILRs), also encoded within the Leukocyte Receptor Complex (LRC) on human 
chromosome 19.  In contrast to KIRs, the LILRs are more widely expressed, and are found 
primarily on myelomonocytic cells as well as subsets of B and T cells.  This expression 
pattern has suggested their relevance to APC function and maturation.  The LILRs are 
discussed extensively in Section 1.2. 
 
1.1.5 DCs and their role in Tolerance 
Evidence that DCs are instrumental in tolerance arises from several observations.  Immature 
DCs induce anergy of naive T cells or induce the generation of Foxp3
+
 Tregs (Steinman and 
Banchereau Nature 2007, Steinman and Nussenzweig PNAS 2002).  The phagocytosis of 
apoptotic cells or self antigens by DCs in the steady state induces a tolerogenic phenotype 
(Steinman et al. JEM 2000, Hawiger et al. JEM 2001).  Disruption of E-cadherin-mediated 
DC-DC interactions triggers an alternative pathway of maturation and programs DCs to a 
tolerogenic state (Jiang et al. Immunity 2007).  Exposure of DCs to anti-inflammatory and 
immunosuppressive agents may also promote this effect (Mellor and Munn Nat Rev Immunol 
2004, Morelli and Thomson Nat Rev Immunol 2007).  Specific DC subsets in mucosal sites 
(for example, CD103
+
 DCs in intestinal lamina propria and mesenteric lymph nodes) are 
programmed to induce Treg cells (Coombes et al. JEM 2007, Denning et al. Nat Immunol 
2007).  Finally, certain microbial stimuli are also capable of subverting DCs to induce Treg 
cells (van der Kleij et al. JBC 2002, McGuirk et al. JEM 2002, Manicassamy et al. Nat Med 
2009). 
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Although iDCs were first considered to induce tolerance, due to their low costimulatory 
molecule expression, it is now accepted that mDCs may also play a role in Treg induction and 
maintenance (Tan et al. JLB 2005, Hubert et al. JLB 2007).  DCs with suppressive properties 
– tolerogenic DCs – exhibit many of the characteristics of iDCs (low costimulatory and MHC 
Class II expression, for example).  Indeed, the distinctions between iDC, mDC and 
tolerogenic DC are blurred and may reflect the inherent plasticity of DCs in both their 
phenotype and responsiveness to the immune microenvironment.   
 
Tolerogenic myeloid cells are likely to exert a powerful influence in the context of tumour 
immunity. Tolerogenic DCs may present self antigens to CD4
+
 T cells or cross-present to 
CD8
+
 T cells leading to Treg or TS cell induction (Lutz and Kurts EJI 2009), a process that 
may be critical to tumour immune evasion.  The tumour microenvironment is highly 
suppressive, with high levels of IL-10 and TGF-β secreted by Myeloid-Derived Suppressor 
Cells (MDSCs), tumour-associated macrophages, and iDCs.  In addition, tumour-antigen 
cross-presentation by DCs can induce anergy and deletion in T cells, and their conversion to 
Tregs.  Consequently, research to understand tumour-derived tolerance dysregulation is 
essential to progress new therapies (Peggs et al. Immunol Rev 2008, Melief Immunity 2008, 
Gallimore and Simon Oncogene 2008). 
 
The mechanisms involved in tolerogenic DC function are an area of active research. 
Tolerogenic DCs may exert their effects directly upon effector cells, or via the generation of 
Tregs that then mediate suppression (Cools et al. JLB 2007, Belkaid and Oldenhove 
Immunity 2008).  Established mechanisms for tolerogenic DC activity include the secretion of 
suppressive cytokines such as IL-10 and TGF-β, which also expand Treg populations; through 
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surface expression of indoleamine-2,3-deoxygenase (IDO), which metabolises extracellular 
tryptophan to kynurenines that inhibit T cell proliferation; via the lack of positive 
costimulation (through downregulation of B7-1, B7-2 and CD40); and finally via inhibitory 
receptor engagement and negative costimulation (e.g. the expression of CTLA4 or PD-1 
ligands) (Coquerelle and Moser Immunol Rev 2010, Pulendran et al. Nat Immunol 2010).  
This latter mechanism has recently highlighted the involvement of the LILRs, LILRB4 and 
LILRB2, in tolerance induction (Chang et al. Nat Immunol 2002).  In the next section I will 
discuss functional, structural and clinical aspects of the role of these immunoreceptors in 
myelomonocytic cell function and maturation. 
 
 
 
 
 
 
26 
 
1.2 The Leukocyte Immunoglobulin-Like Receptor Family 
1.2.1 Introduction and initial characterisation  
The Leukocyte Immunoglobulin-like Receptors (LILRs) are a family of immunoregulatory 
receptors located within the Leukocyte Receptor Cluster (LRC) on human chromosome 19.  
The LILRs share amino acid sequence homology with other immunoglobulin superfamily 
(IgSF) receptors encoded in the LRC, including the Killer Immunoglobulin-like Receptors 
(KIRs), the receptor for IgA FcαR, Leukocyte-Associated Immunoglobulin-like Receptors 
(LAIRs), the NK cell Natural Cytotoxicity Receptor (NCR) NKp46, and the platelet collagen 
receptor GpVI.  The genomic organisation of the LILR locus is shown in Figure 1.2a. 
 
LILRs are type I transmembrane proteins and have either two or four extracellular C2-type Ig 
domains.  Inhibitory members of the family have long intracellular tails containing ITIMs, 
and are designated as LILRB.  Activatory members of the family have short intracellular tails 
and a positively charged arginine residue within the transmembrane region which allows them 
to associate with the ITAM-containing adaptor protein FcRγ, and are designated LILRA.  
Figure 1.2b outlines the structural elements of each LILR.  LILRA3 lacks a transmembrane 
domain and is expressed solely in soluble form.  Although studies had detected soluble forms 
of LILRA5 and LILRB2 (Borges Blood 2003, Beinhauer EJI 2004), it was only recently that 
a common splicing mechanism was identified that generates mRNA transcripts for other 
soluble LILRs, thus providing another level of regulation of LILR function (Jones EJI 2009).  
Most members of the family have four Ig domains; LILRB4, LILRA5 and a splice variant of 
LILRA1 have only two. The LILRs were initially identified and characterised in parallel by 
three different groups.  Cosman et al. identified a novel IgSF member that bound to both the 
human Cytomegalovirus (CMV) MHC Class I homologue, UL18,  and to host MHC Class I 
molecules, and named that protein Leukocyte Immunoglobulin-like Receptor-1, LIR-1 
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(Cosman et al. Immunity 1997).  Samaridis and Colonna isolated novel cDNAs from the LRC 
with KIR homology and designated them Immunoglobulin-like Transcripts (ILTs) 1 and 2 
(Samaridis, Colonna EJI 1997).  Another group also identified a member of the family on the 
basis of its homology with the mouse gp49B1 receptor, which they designated HM18 (Arm et 
al. JI 1997).  The LILRs thus have slightly confusing alternative nomenclatures; in this thesis, 
the LILR designation will be used.  Table 1.2 summarises the alternative designations of the 
LILR family, along with their expression patterns. 
 
In contrast to the structurally-similar KIRs, the LILRs exhibit a conserved organization of 
gene structure, and do not usually display haplotypic variation in gene number.  
Polymorphisms within the coding sequence of the receptors are relatively rare by comparison 
with the KIRs, with the exception of LILRB3, which is highly polymorphic (Young et al. 
Immunogenetics 2001, Volz et al. Immunol Rev 2001).  In evolutionary terms, the LILRs 
may predate the KIRs (Volz et al. Immunol Rev 2001, Martin et al. Trends Immunol 2002, 
Canavez JI 2001).  Mice lack true orthologues of the KIRs, relying instead upon members of 
the Ly49 family for „missing-self‟ recognition by NK cells, but do have receptors with 
homology to some of the LILRs, the Paired Ig-like Receptors (PIRs), which have been 
relatively well characterised (Kubagawa et al. PNAS 1997, Pereira et al. JI 2004, Munitz et al. 
Blood 2008). 
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Figure 1.2.  Genomic and structural arrangement of the LILRs. (a): Organisation 
of the LILR clusters within the LRC on human chromosome 19. (Sambrook et al. 
BMC Genomics 2006). (b): Domain structure of the LILRs, showing extracellular (EC) 
Ig domains, plasma membrane (PM)-spanning transmembrane domains with 
Arginine residues for the activatory LILRs, the structure of the FcR γ-chain, and the 
ITIM sequences in the intracellular cytoplasmic tails for the inhibitory LILRs. 
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LILRB1 LIR-1, ILT2, CD85j, MIR7 ■ ■ ■ ■  ■ □ ■ ■ 1 
LILRB2 LIR-2, ILT4, CD85d, MIR10 ■ ■ ■ ■ ■ ■    2 
LILRB3 LIR-3, ILT5, CD85a, HL9 ■ ■ ■ ■ ■ ■     
LILRB4 LIR-5, ILT3, CD85k, HM18 ■ ■ ■ ■      3 
LILRB5 LIR-8, CD85c ?      ?   4 
LILRA1 LIR-6, CD85i  ■         
LILRA2 LIR-7, ILT1, CD85h ■ ■ ■  ■ ■ ■    
LILRA3 
LIR-4, ILT6, CD85e, HM43, 
HM31 ■          
LILRA4 ILT7, CD85g   □        
LILRA5 LIR-9, ILT11, CD85f ■          
LILRA6 ILT8, CD85b Unknown 
LILRP1 ILT9, CD85l Pseudogene 
LILRP2 ILT10, CD85m Pseudogene 
 
Table 1.2 LILR Family Nomenclature and Expression.  Filled squares indicate 
expression by all or the majority of the named cells, open squares indicate restricted 
subset expression, question marks for LILRB5 indicate donor variability or mRNA 
only.  Additional expression: 1, placental stromal cells; 2, placental vascular smooth 
muscle; 3, CLL and some cancers; 4, Mast cell granules. (Adapted from Anderson 
and Allen Immunology 2009). 
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1.2.2 Published functional studies of LILR family members 
LILRB1 
LILRB1 is broadly expressed on T cells, B cells, myeloid cells and subsets of NK cells. The 
first demonstration of an inhibitory function for LILRB1 was from redirected killing assays 
involving LILRB1
+
 NK cell lines (Colonna et al. JEM 1997).  Subsequent studies on NK cell 
clones confirmed HLA-A, HLA-B, HLA-C, and HLA-G molecules all inhibited NK killing in 
a LILRB1-dependent fashion, and suggested synergism with CD94/NKG2A (Vitale et al. Int 
Immun 1999).  
 
The inhibitory effects of LILRB1 ligation were also evident in T cells, B cells and myeloid 
cells.  LILRB1 interactions with MHC Class I were able to inhibit superantigen-mediated T 
cell killing of 721.221 cells (Colonna et al. JEM 1997).  Subsequently, LILRB1 was shown to 
down-regulate antigen-specific cytolytic activity of CD8
+
 T cells (Saverino JI 2000).  
Cytolytic CD4+ T cells specific for Mycobacterium tuberculosis purifed protein derivative 
(PPD) could be inhibited from killing by LILRB1 engagement, and also showed reduced IL-2 
and IFN-γ secretion (Merlo et al. Inf Immunity 2001).  Thus, LILRB1 has functional effects 
on both cytotoxic CD8
+
 T cells and helper CD4
+
 T cell subsets.  Engagement of LILRB1 on 
antigen-activated T cells had a dual effect on cytokine secretion, by upregulation of IL-10 and 
TGF-β whilst simultaneously downregulating the synergistic cytokines IL-2, IL-13 and IFN-γ.  
Importantly, the inhibitory effect of LILRB1 engagement could be overcome by the addition 
of exogenous IL-2.  In addition, both naive T cell responses to initial antigenic stimulation, 
and recall responses of resting/memory T cells were similarly affected (Saverino et al. JI 
2002).   
 
In addition to effects on T cells, Ca
2+
 mobilization triggered via BCR engagement in B cells 
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or HLA-DR triggering in myelomonocytic cells was reduced by co-crosslinking the triggering 
receptor to LILRB1, via the anti-LILRB1 antibody.  Furthermore, co-ligation of FcγRI on 
monocytes with LILRB1 or LILRB2 led to reduced γ-chain ITAM and downstream Syk 
phosphorylation and mobilisation of intracellular Ca
2+
.  Therefore, LILRB1 engagement by 
MHC Class I can negatively regulate the functions of innate and adaptive effector immune 
cells as well as APCs (Colonna et al. JEM 1997).   
 
LILRB2 
LILRB2 is a MHC Class I-binding inhibitory LILR receptor restricted in expression to the 
myeloid lineage.  Like LILRB1, LILRB2 can engage the non-classical MHC Class I molecule 
HLA-G with a higher affinity than to classical HLA alleles (Shiroishi et al. PNAS 2003).  
HLA-G is expressed on placental trophoblast cells, thymic epithelial cells and some tumours, 
suggesting an important in vivo role for its interaction with LILRB2 and LILRB1, and 
possible involvement in maternal-foetal tolerance (Allan et al. JEM 1999).  In particular, 
LILRB2 shows a stronger preference for HLA-G over other HLA alleles.  The LILRB2/HLA-
G interaction is thus postulated to be important for the function and maturation of 
myelomonocytic cells.  Ristich et al. presented in vivo data in support of this notion, using 
mice transgenic for LILRB2 and HLA-G1.  DCs from these mice have a tolerogenic 
phenotype with reduced expression of MHC Class II, B7-1 and B7-2, and promote skin 
allograft survival by the induction of Tregs (Ristich et al. Hum Immunol 2007).  HLA-G 
isoforms are capable of multimerisation; HLA-G1 tetramers and HLA-G5 homodimers signal 
efficiently through LILRB2 leading to the arrest of DC maturation in vitro and in vivo, 
through the recruitment of SHP-1 and SHP-2, which exerts its effects via the IL-6/STAT3 
pathway (Liang et al. PNAS 2008).   A subset of tolerogenic DCs termed DC-10 was recently 
identified that produces high levels of IL-10 and induces the differentiation of Tr1 cells via a 
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LILRB2/HLA-G dependant mechanism (Gregori et al. Hum Immunol 2009, Gregori et al. 
Blood 2010).  A T cell subset expressing HLA-G and with a regulatory phenotype has also 
been described (Feger et al. Blood 2007).  It is interesting to speculate that these novel 
suppressive T cells may exert tolerogenic effects via LILRB2 engagement on DCs. 
 
Tolerogenic functions of LILRB4 and LILRB2 
LILRB4 has two extracellular Ig-like domains and a long cytoplasmic tail containing three 
ITIM motifs.  Myeloid expression of LILRB4, functional effects of cross-linking and 
downstream signalling involving SHP-1 were first described by Cella et al. in 1997 (Cella et 
al. JEM 1997).  They also proposed a role for LILRB4 in antigen capture and processing, 
although that aspect of LILRB4 function has not since been expanded upon.  The ligand for 
LILRB4 has been elusive despite numerous publications on its functional role. 
 
Several functional studies have proposed a role for LILRB2 and LILRB4 in tolerisation of T 
cell responses, through the action of APCs such as DCs and monocytes that have been given a 
tolerogenic stimulus (e.g. IL-10, incubation with CD4
+
 Tregs or CD8
+
 suppressor T cells, TS).  
A key study by Chang et al. described the upregulation of LILRB4 and LILRB2 on APCs 
(monocytes, immature DCs generated from monocytes by treatment with GM-CSF/IL-4, or 
the myelomonocytic cell line KG1) upon incubation with alloantigen-specific CD8
+ 
CD28
-
 TS 
cells.  Such treatment reduced the allostimulatory capacity of these APCs towards CD4
+
 TH 
cells in co-cultures, apparently by reducing the surface expression of B7-1 and B7-2 through 
inhibition of the CD40-CD40L pathway.  Antibody blockade of LILRB4, or LILRB2 plus 
MHC Class I, reversed the inhibitory effect of CD8
+
 TS cells on CD4
+
 TH cell proliferation 
when all three cell types (TS, TH and APCs) were cultured together.  Overexpression of 
LILRB4 or LILRB2 by transfection of KG1 cells conferred a tolerogenic capacity, as 
33 
 
evidenced by a reduction in the proliferation of CD4
+
 TH cells and an inhibition of the 
upregulation of B7-1 on the APCs upon co-culture, an effect which could be overcome with 
exogenous IL-2.  The inhibitory effect of LILR over-expression was postulated to be due to 
disruption of NF-κB signalling.  Experiments with the PBMCs from heart allograft transplant 
patients confirmed a role for LILRB2 and LILRB4 in tolerance induction in vivo, as discussed 
further in Section 1.2.4 (Chang et al. Nat Immunol 2002). 
 
Manavalan et al. subsequently demonstrated that CD4
+
 TH cells incubated with tolerogenic 
APCs that have upregulated LILRB4 and LILRB2 expression develop a Treg phenotype.  
Priming with allogeneic DCs generated CD4
+
 Tregs that were MHC Class II restricted and 
induced „linked suppression‟ of DCs on which they recognized at least one MHC Class II 
antigen.  Antibody blockade of LILRB4, or LILRB2 plus MHC Class I, reduced this effect, 
supporting the hypothesis that LILRB4 and LILRB2 play a role in the suppression of immune 
responses by Tregs and in the phenomenon of „infectious tolerance‟.  IL-10 or TGF-β did not 
mediate the tolerogenic effect of these Tregs; cell-to-cell contact was found to be necessary.  
Importantly, this work also demonstrated that treatment of DCs with IL-10 plus IFN-α 
induced a tolerogenic phenotype with upregulation of LILRs in the same fashion as co-
incubation with CD8
+
 TS or CD4
+
 Tregs (Manavalan Trans Immun 2003), a result supported 
by another publication which also lent more credence to the notion that tolerogenic DCs are 
not simply immature, but have a distinct phenotype and gene signature (Velten et al. EJI 
2004).  Indeed, DCs stimulated via TLR9 triggering, or a variety of other inflammatory 
mediators, down-regulate LILRB1 and LILRB4 (Ju et al. Gene 2004) and this suggests that 
down-regulation of LILR expression may be involved in DC activation, possibly via reduced 
SHP-1 modulation of the NF-κB pathway. Furthermore, endothelial cells may also be 
tolerised and up-regulate LILRB4 and LILRB2 in a similar manner, providing further 
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evidence for their role as accessory APC and for the importance of studying this mechanism 
of tolerogenesis in the context of organ transplantation (Cortesini et al. Transpl Immunol 
2004, Manavalan et al. Int Immunol 2004, Lui et al. Transpl Immunol 2004, Gleissner et al. 
EJI 2007). 
 
Despite these findings, the molecular mechanism underlying LILRB4 tolerance induction is 
unclear.  Nevertheless, studies utilising APC transfected with recombinant LILRB4 lacking 
the intracellular ITIMs have demonstrated bidirectional signalling between APC and T cells, 
rendering the T cells anergic or converting them to Tregs (Kim-Schulze et al. JI 2006, Vlad et 
al. Int Immunol 2006).  This provides some clues to the nature of the LILRB4 ligand, which 
to date is unknown.  Such a ligand would have to be present on T cells and/or DCs and 
capable of signalling in an inhibitory fashion into those cells.  LILRB4-Fc staining 
experiments have shown the LILRB4 ligand to be up-regulated on CD4
+
 T cells after 3 days 
in an allogeneic MLR (Kim-Schulze et al. JI 2006). 
 
LILRA2 and LILRB3 
In contrast to the inhibitory LILRs, activatory LILRs remain poorly understood, both on a 
functional level and in terms of their ligand interactions.  Initial characterisation of LILRA2 
demonstrated its expression on monocytes, granulocytes, macrophages and DCs, and a small 
percentage of peripheral blood NK cells.  Antibody cross-linking of surface LILRA2 triggered 
serotonin release from transfected RBL cells, and Ca
2+
 mobilisation from transfected cells or 
isolated human monocytes.  FcεRI γ-chain was shown to co-precipitate with LILRA2 and was 
necessary for its surface expression (Nakajima et al. JI 1999).  LILRA2 was subsequently 
shown to be expressed on eosinophils and neutrophils, and antibody cross-linking stimulated 
activation, degranulation and IL-12 release in these cells (Tedla et al. PNAS 2003).  A similar 
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study highlighted LILRA2 expression on basophils and showed LILRA2-mediated activation 
and release of inflammatory mediators (including IL-4) after cross-linking.  Importantly, this 
study showed that co-engagement of LILRA2 with LILRB3 inhibited activation, and provides 
the only functional data to date on LILRB3 (Sloane et al. Blood 2004). 
 
LILRA4 
LILRA4 is a specific marker for pDCs as opposed to classical DCs, and it is co-expressed 
with its signalling adaptor protein, FcRγ-chain.  Both molecules are rapidly downregulated 
following activation by CpG-DNA stimulation of TLR9 (Ju et al. Gene 2004).  Generation of 
an anti-LILRA4 antibody allowed confirmation of the restricted cell-surface expression of 
LILRA4 on pDCs, and investigation of the functional effects of its ligation.  Antibody cross-
linking of LILRA4 generated Src family kinase and Syk phosphorylation events, via the 
ITAMs of the adaptor FcRγ chain, leading to intracellular Ca2+ mobilisation, an event 
generally associated with cellular activation.  Surprisingly, the effects of LILRA4 ligation 
upon TLR-mediated IFN-α and TNF-α production were instead inhibitory (Cao et al. JEM 
2006).  The authors speculated that this may be due to the bi-functional role of the FcεRI γ-
chain ITAM, which is capable of recruiting both Syk and SHP-1 (Pasquier et al. Immunity 
2005).  Alternatively, ligand affinity may determine the functional outcome of LILRA4 
engagement (Cho et al. Int Immunology 2007).   
 
Recently, the ligand for LILRA4 was identified as BST2 and shown to negatively regulate the 
innate immune functions of pDCs via the engagement of LILRA4.  Since BST2 is 
upregulated on a wide variety of cell types upon Type I IFN treatment, the LILRA4/BST2 
interaction may constitute a negative feedback mechanism to limit immunopathological 
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damage resulting from sustained IFN release from pDCs in the face of viral challenge (Cao et 
al. JEM 2009). 
 
LILRA5 
LILRA5 is closely related to LILRB4 in terms of primary sequence, and like LILRB4, it has 
only two Ig domains.  There are four splice variants, LILRA5m1, LILRA5m2, LILRA5s1 and 
LILRA5s2, where m stands for membrane-bound and s stands for soluble forms, respectively.  
The difference between the 1 and 2 forms of each receptor resides in the N-terminal amino 
acids, just after cleavage of the signal peptide, and generates a new N-linked glycosylation 
site in LILRA5m1 and LILRA5s1.  LILRA5m is expressed at the surface of monocytes, and 
cross-linking of the receptor induces Ca
2+
 mobilisation and the release of the inflammatory 
cytokines IL-1β, TNF-α and IL-6 (Borges et al. Blood 2003). 
 
LILR Signalling Mechanisms 
A small number of studies have investigated the signalling mechanisms downstream of 
LILRB ligation.  LILRB1 co-immunoprecipitates with  SHP-1 after sodium pervanadate 
treatment (Colonna et al. JEM 1997, Cosman et al. Immunity 1997).  In addition, Dietrich et 
al. showed SHP-1 recruitment to the second ITIM, which matches the SHP-1 consensus 
binding sequence VxYxxV/L, was dependent upon the Src tyrosine kinase p56
lck
 
phosphorylating the tyrosine residue.  The phosphorylation of key signalling molecules 
downstream of TCR ligation, namely the TCR δ-chain and the Linker for the Activation of T 
cells (LAT), was reduced upon LILRB1 co-engagement, and resulted in reduced recruitment 
of the downstream kinase ZAP-70.  Furthermore, actin polymerization, which is a key event 
in TCR-mediated signalling, was also markedly inhibited by LILRB1 engagement (Dietrich et 
al. JI 2001).  The cytoskeletal changes downstream of actin polymerization are necessary to 
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bring signalling molecules into the immune synapse and to polarize the T cell towards the 
APC (Monks et al. Nature 1998).  Thus, TCR engagement of cognate pMHC concomitant 
with T cell-expressed LILRB1 engagement of MHC Class I on the target cell interferes with a 
key stage of T cell activation. 
 
Bellon et al. probed the contribution of the four tyrosine residues in the cytoplasmic tail of 
LILRB1, by transfecting mutant receptors into the rat basophilic leukaemia (RBL) and COS-7 
cell lines and analysing the ability of the different mutants to recruit SHP-1 and to inhibit 
FcεR-induced serotonin secretion.  These experiments revealed that the LILRB1 C-terminal 
tyrosines 614 and 644 are crucial sites for binding to SHP-1. Mutation of residue Y562 had no 
effect, whereas residue Y533 seemed to be involved in the regulation of receptor tyrosine 
phosphorylation (Bellon et al. JI 2002).  A collaborating group showed that the C-terminal Src 
kinase (Csk) binds LILRB1 Y562 and hypothesised that Csk regulates the function of 
LILRB1 (Sayos et al. BBRC 2004). 
 
Data on the signalling cascades downstream of other LILR receptors is sparse.  Liang et al. 
published data showing that LILRB2/HLA-G engagement in vitro and in vivo recruits SHP-1 
and SHP-2 to the phosphorylated receptor, which activates the IL-6–STAT3 pathway leading 
to up-regulation of IL-6 expression and down-regulation of DC differentiation (Liang et al. 
PNAS 2008).  LILRB4 has been shown to be a potent inhibitor of monocyte activation, as 
discussed with reference to its tolerogenic effects earlier in this section.  Co-ligation of 
LILRB4 with FcγRI selectively inhibits the phosphorylation of the signalling molecules Lck, 
Syk, LAT, Erk, and c-Cbl but not the cytoskeletal protein α-actinin-4.  Treatment of cells with 
the broad-spectrum phosphatase inhibitor, sodium pervanadate, significantly reversed this 
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effect, but treatment with an SHP-1 specific inhibitor did not, suggesting the involvement of 
other phosphatases (Lu et al. JBC 2009). 
 
1.2.3 Ligand recognition and structural studies of the LILRs 
LILRB1 
LILRB1 was initially identified on the basis of immunoprecipitation with a UL18-Fc fusion 
protein.  Expression cloning and transfection of the resulting cDNA into COS cells generated 
a UL18-Fc-binding protein identical in mass to that previously detected. LILRB1-Fc also 
stained UL18 transfectants, confirming an interaction between the extracellular regions of 
LILRB1 and UL18.  Subsequent to this discovery, an attempt was made to identify the 
endogenous cellular ligand corresponding to UL18 that was bound by LILRB1, the obvious 
candidate being host MHC Class I.  This proved to be the case, as LILRB1-Fc was shown to 
stain a wide panel of cell lines and primary cells, and an expression library from a T 
lymphoblastic leukaemia cell line was probed for LILRB1-Fc binding, yielding two cDNAs 
encoding HLA-A2 and HLA-B44, respectively.  Binding of LILRB1-Fc to primary cells or 
cell lines could be blocked by pre-incubation with W6/32, a monoclonal antibody that binds 
all classical (HLA-A, -B, -C) MHC Class I alleles (Cosman et al. Immunity 1997). 
 
In similar experiments, the Cosman group used flow cytometry to test the ability of various 
LILR-Fc fusion proteins to bind peripheral blood T cells that had been activated non-
specifically with PHA and PMA, and showed that LILRB2-Fc, like LILRB1-Fc, could also 
bind MHC Class I, as this staining could be abrogated by pre-incubation with W6/32.  No 
other LILR-Fc stained these cells, and only LILRB1-Fc stained UL18-transfected cells 
(Borges et al. JI 1997).  Independently, Colonna et al. carried out analogous experiments, 
using soluble LILRB1-Fc to stain MHC Class I transfected 721.221 cells and analysed them 
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by flow cytometry, detecting binding to HLA-A, HLA-B, and HLA-G transfectants, but not to 
HLA-Cw3 (Colonna et al. JEM 1997).  LILRB1-Fc and LILRB2-Fc were used in further flow 
cytometry analyses for binding to a panel of HLA-allele transfected 721.221 cells, and were 
shown to bind to a broad range of „classical‟ MHC Class I alleles including one HLA-C allele 
(Fanger et al. EJI 1998).  This result was consistent with subsequent functional studies of 
LILRB1
+
 NK cells (Vitale et al.  Int Immunol 1999, Navarro et al. EJI 1999).  
 
The mode of ligand recognition used by LILRB1 was first addressed by Chapman et al 
(Chapman et al. Immunity 1999).  Soluble LILRB1 containing truncations of the extracellular 
domains were produced and LILRB1 – ligand binding was analysed by SPR.   The LILRB1 
ectodomain bound to UL18 with an equilibrium dissociation constant, Kd, in the nM range, 
with no demonstrable effect of varying the peptide loaded or glycosylation status of the UL18.  
A range of classical (HLA-B, HLA-C) and non-classical (HLA-G, HLA-E) MHC Class I 
alleles were also tested for binding, and shown to have Kd values in the range of 15-100 μM; 
thus, LILRB1 displays approximately 1000-fold lower affinity for MHC Class I than for 
UL18.  Three other MHC Class I homologues, HFE, FcRn, and ZAG, showed no binding to 
LILRB1. 
 
Comparative analysis of binding of fragments of LILRB1 containing domains D1, D1D2 or 
D3D4 allowed localization of the UL18 and MHC Class I binding site to the distal D1 
domain, with a minor contribution from D2.  Pre-equilibration of UL18 with D1D2 blocks 
binding of D1D2 to immobilized MHC Class I, thus both ligands for LILRB1 share the same 
binding site.  Domain-swap experiments from HFE into UL18 or MHC Class I and analysis of 
monomeric LILRB1 D1-D4 or LILRB1-Fc binding to the resulting chimeric proteins showed 
that the α3 domain of either UL18 or MHC Class I was necessary for binding to the molecule 
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by LILRB1.  This result explained the broad binding specificity of LILRB1 for MHC Class I 
alleles, since the α3 domain is relatively non-polymorphic, and provides a contrast with the 
recognition of MHC Class I alleles by KIRs, which are allele-specific and bind at the 
polymorphic α1-α2 peptide-binding platform of the MHC.  Based on the fact that isolated 
LILRB1 domains fold stably, and data from far UV circular dichroism experiments, it was 
proposed that LILRB1 would form an extended structure, with the distal D1 domain 
interacting in trans with the α3 domain of a MHC on an opposing cell membrane. 
 
Structural studies on LILRB1 
Crystallographic data for LILRB1 became available in 2000, when the structure of the D1D2 
construct was obtained to a resolution of 2.1 Å (Chapman et al. Immunity 2000).  Similar to 
KIRs, the two domains are arranged into a bent structure with an acute interdomain angle and 
each LILRB1 Ig domain is composed of two anti-parallel β-sheets.  LILRB1 D1D2 also has 
extensive helical structure not seen in other IgSF receptors, including a region of 310 helix in 
the C' strand of D1, and a polyproline type II helix in the strand F-G loop.  The interdomain 
interface between D1 and D2 is composed mainly of hydrophobic/aromatic residues that serve 
to stabilise the acute domain angle. 
 
Comparison of the interdomain residues across the LILR family showed considerable 
conservation, suggesting a common arrangement of D1 relative to D2 for the other LILR 
members.  Within LILRB1, similar analysis suggested that D2D3 domains might also form a 
similar interaction, whereas corresponding residues in D4 were non-conservatively 
substituted, implying that the D3D4 interaction would take a different form.  Based upon this 
analysis, three models for LILRB1 D1-D4 structure were proposed; a 'bent rod' structure of 
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~110 Å length, an intermediate form of ~125 Å, or a fully extended form of ~140 Å in which 
all the domains are nearly parallel. 
 
In parallel with crystallographic analyses, Chapman et al. also used a site-directed 
mutagenesis approach to probe the UL18 binding site of LILRB1.  Alanine scanning 
mutagenesis implicated residues clustered at the distal tip of D1 of LILRB1, in direct 
comparison to the residues in KIRs which bind MHC Class I, which are located at the D1D2 
interface.  As further evidence for the location of D1 as the UL18 binding site, this region was 
involved in crystal contacts, thus suggesting its suitability for protein-protein interactions.  
 
Co-crystallisation of LILRB1 with HLA-A2 allowed analysis of the mode of binding of 
LILRB1 with MHC Class I ligands and provided a model for the interaction with UL18 
(Willcox et al. Nat Immunol 2003).  LILRB1 D1D2 recognized the side of the MHC complex 
at two sites, the relatively non-polymorphic membrane-proximal α3 domain, and the 
conserved β2-microglobulin (β2m) domain.  This recognition event involved residues at the 
D1 tip interacting with the α3 domain and residues in the D1D2 hinge region interacting with 
β2m.  The LILRB1-HLA-A2 interface was approximately comparable in size to that of KIR-
MHC Class I and also TCR-MHC Class I interfaces; however, unlike these interfaces it 
involved a predominantly non-polymorphic surface on the MHC Class I molecule, thereby 
rationalising the broad binding specificity of LILRB1. 
 
Consistent with interactions across the HLA family, both classical and non-classical alleles 
exhibit high conservation of residues in the α3 domain shown in the crystal structure to 
interact with LILRB1. The most diverse molecule within this grouping is HLA-G, consistent 
with a substantially enhanced affinity of HLA-G for LILRB1/B2. In contrast, the MHC Class 
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I-like molecules FcRn, HFE and ZAG have non-conservative substitutions that are likely to 
ablate LILRB1 binding.  Comparison of the primary sequence of UL18 with the 
corresponding region of HLA-A2 α3 that contacts LILRB1 reveals the conservation of 
residues critical for the interaction of MHC Class I with LILRB1.  The structural basis of the 
high affinity interaction between LILRB1 and UL18 has been extensively studied (Wagner et 
al. JMB 2007, Oochino et al. JI 2008) and the crystal structure for the LILRB1-UL18 
complex has subsequently been generated (Yang and Bjorkman PNAS 2008). 
 
An important feature of the LILRB1/HLA-A2 crystal structure was that the LILR family 
could be separated into two groups based upon the sequence identity with LILRB1 at the 
HLA-A2 α3 and β2m contact sites.  Group I LILRs – LILRB1, LILRB2, LILRA3, LILRA1 
and LILRA2 – showed high sequence conservation as compared to LILRB1 in these regions, 
and thus were postulated to bind to MHC Class I or MHC Class I-like molecules.  In contrast, 
Group II LILRs – LILRB3, LILRB4, LILRB5, LILRA4 and LILRA5 – have several non-
conservative substitutions in these regions, and thus are unlikely to bind MHC Class I 
(Willcox et al. Nat Immunol 2003). 
 
Consistent with these structural data, SPR studies showed that LILRB1 or LILRB2 binding to 
MHC Class I could interfere with CD8 binding (Shiroishi et al. PNAS 2003).  Conceivably 
this could provide another functional inhibitory effect of LILRB1 ligation on T cells, by 
blocking T cell co-receptor binding.  The kinetics of binding of LILRB1 and LILRB2 to 
MHC Class I reached equilibrium and dissociated rapidly, typical of cell-cell recognition 
events.  LILRB1 and LILRB2 showed slightly higher affinities for HLA-G in comparison 
with other alleles; thus, LILRB1 might be important for regulating NK recognition of the 
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developing foetal trophoblast cells, or for thymocyte development upon interaction with 
thymic epithelial cells, both of which express HLA-G. 
 
LILRB2 
SPR analyses demonstrated binding of LILRB2 to UL18 and to MHC Class I in the µM range 
(Chapman et al. Immunity 2000, Shiroishi et al. PNAS 2003).  The crystal structure of the 
D1D2 domains of LILRB2 was solved to 1.8A resolution by Willcox et al. in 2002.  In 
comparison with LILRB1, LILRB2 D1D2 contained significantly less helical structure.  In 
particular, a single turn of 310 helix was observed in LILRB2 D1 whereas the corresponding 
region in LILRB1 D1 contained a much longer helix, resulting in a relative shift in the 
LILRB2 backbone.  The structure also highlighted alterations at the UL18 binding site that 
could account for the difference in affinity.  In LILRB2, the 76-84 residue loop was shifted by 
approximately 11 Å away from the molecular interface with the MHC Class I molecule 
relative to LILRB1, which would disrupt interaction with UL18 α3 residues, and may also 
account for the 3-to-4-fold difference in binding affinity for MHC Class I (Willcox et al. 
BMC Struc Bio 2002, Willcox et al. Nat Immunol 2003).  
 
One distinguishing feature of LILRB2 is a reduced requirement for β2m interaction.  LILRB2 
can bind to free heavy chains (fHC) of HLA-B27 (Allen et al. JI 2001).  These lack β2m and 
are expressed as monomers and disulphide-linked homodimers at the cell surface.  Tetrameric 
complexes of HLA-B27 fHC were shown to bind to LILRB2, but not LILRB1 transfected 
cells (Allen et al. JI 2001).  More recently, the crystallographic structure of LILRB2 in 
complex with HLA-G, which can also form fHC and homodimerise at the cell surface, was 
solved (Shiroishi et al. PNAS 2006).  This revealed important differences between the mode 
of binding of LILRB1 and LILRB2 to MHC Class I.  Like LILRB1 binding to HLA-A2, 
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LILRB2 binds to the α3 and β2m domains of HLA-G; however, LILRB2 uses a larger 
interface to interact with α3, involving the cleft in D1, whereas the interface with β2m is 
substantially smaller.  This suggests the interaction with β2m is considerably less important 
than for LILRB1.  The crystallographic data also provided structural rationalisation for the 
increased affinity of LILRB1 and LILRB2 for HLA-G over other MHC Class I members, in 
particular the hydrophobic interactions formed by F195 with LILRB1 and Y197 with 
LILRB2.  In addition, HLA-G dimerisation would increase receptor avidity, as reflected in the 
functional studies described earlier. 
 
LILRB2 has recently been described as binding to the MHC Class I-like lipid-presenting 
molecule, CD1d.  This interaction is reported to involve the distal two domains of LILRB2 
recognising the α1-α2 domains which comprise the lipid binding groove, and would therefore 
be distinct from the recognition of MHC Class I as described above (Li et al. JI 2009).  It is 
interesting to speculate that LILRB2 may have alternative modes of recognition of MHC 
Class I, although no direct evidence to support such a hypothesis has yet been described. 
 
LILRA1 
No structural data is yet available for LILRA1, although it was initially described as having 
both 2-domain and 4-domain splice variants (Borges et al. JI 1997).  However, fluorescent 
tetramers of HLA-B27, both conformed and β2m free, were shown to bind to LILRA1-
transfected 293T cells in a subsequent study (Allen et al. JI 2001). 
 
LILRA2 
The structure of LILRA2 D1D2 was recently solved by X-ray crystallography, after first 
overcoming problems with the intransigent refolding and crystallisation of the receptor by the 
45 
 
introduction of an artificial disulphide bond in the D2 domain of the receptor.  Initial SEC 
analysis of the mutated receptor unexpectedly demonstrated its ability to dimerise, as 
evidenced by a higher molecular weight peak.  Tetramerisation of LILRA2 and staining of 
transfected cells demonstrated a lack of binding to MHC Class I alleles (Chen et al. Prot Exp 
Pur 2007). 
 
Subsequently, X-ray data quality crystals were generated and the LILRA2 structure was 
solved to a resolution of 2.6 Å.  This demonstrated that the receptor formed a “domain-
swapped” dimer through the exchange of identical β-strands in the D2 domain.  Overall 
structural topology in D1 was similar to the other solved Group I LILR structures, with the 
exception that the C-C‟ loop containing 310 helical regions in LILRB1 and LILRB2 instead 
consisted of a β-strand.  Analysis of residues corresponding to the HLA-A2 α3 domain 
binding sites of LILRB1 demonstrated the unsuitability of LILRA2 for MHC Class I binding; 
however, conservation of the LILRB1-corresponding β2m-binding residues suggested that 
LILRA2 might be able to bind β2m, possibly in the context of specific alleles of MHC Class I 
(Chen et al. JMB 2009).  
  
LILRA4  
The ligand for LILRA4 was identified by expression cloning as the BST2 antigen.  SPR 
studies demonstrated recombinant LILRA4-Fc binding to immobilised BST2 with estimated 
micromolar affinity, which could be blocked by anti-BST2 antibody (Cao et al. JEM 2009).  
BST2 is a cell-surface antigen with an unusual topology, having both an N-terminal 
transmembrane domain and a C-terminal GPI-linked anchor.  Its extracellular domain 
contains two putative N-linked glycosylation sites, and three cysteine residues which allow it 
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to dimerise via disulphide bond formation at the cell surface (Ohtomo et al. BBRC 1999, 
Kupzig et al. Traffic 2003). 
 
LILRA5 
To date, the only Group II LILR to be structurally elucidated is LILRA5 (Shiroishi et al. JBC 
2006).  The overall structure of the receptor was similar to other LRC receptors, including 
LILRB1 and LILRB2, with an acute interdomain angle between D1 and D2.  The topology of 
the domains was similar but distinct from that of LILRB1 and LILRB2, and bore more 
resemblance to that of NKp46 or KIR2DL receptor subtypes, with substantially less helical 
regions in D1 as compared to LILRB1 and LILRB2.  The 310
 
helix in D1 of LILRB1 and 
LILRB2 that is directly involved in contacting α3 residues of MHC Class I was missing and 
replaced instead with a β-strand, lacking the hydrophobic core residues present in LILRB1.  
Residues critical for stabilising this β-strand are well-conserved across the Group II LILRs; 
thus, Group II LILRs are likely to have a similar motif and are unlikely to bind MHC Class I.   
 
Similarly, differences in the surface charge composition around the D-E strands in the D2 
domain of LILRA5 (a region that in KIRs and LILRB1/B2 is involved in interactions with the 
peptide-binding groove and β2m, respectively) suggested this region in LILRA5 was unlikely 
to be compatible with MHC Class I recognition.  In addition, the overall surface charge 
distribution of LILRA5 differs considerably from the other receptors. Whereas LILRB1 has a 
positively charged region that interacts with α3, and KIRs have a large negatively-charged 
area crucial for contacting the peptide-binding groove, LILRA5 has a more dispersed 
distribution of small positive and negative patches of electrostatic potential, with some 
hydrophobic regions also present. 
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Consistent with these structural observations, LILRA5 shows no binding to MHC Class I 
alleles by SPR analysis and LILRA5 tetramers do not stain HLA-Cw4 transfected 721.221 
cells.  Since LILRB4 binds a cellular counter-structure on T cells after allogeneic stimulation, 
it could be postulated that LILRA5 may bind a similar ligand, due to sequence conservation 
between the two proteins.  In addition, non-self ligands for the Group II LILRs cannot be 
excluded, since LILRB3 and LILRB5 have been shown to be upregulated in lepromatous 
leprosy patients with Mycobacterium leprae infection (Bleharski et al. Science 2003).  It is 
possible that Group II LILRs may have evolved to recognise bacterial or viral counter-
structures, in a similar manner to PRRs, although this is purely conjecture. 
 
Cis interactions of the LILRs  
A novel aspect of the mode of binding of the LILRs has been highlighted by recent findings 
that LILRB1 and LILRB2, and the mouse homologue PIR-B, are capable of binding in cis to 
MHC Class I on the same cell membrane.  Confocal microscopy and Fluorescence Resonance 
Energy Transfer (FRET) studies have demonstrated that this interaction can occur in mast 
cells and osteoclasts (Masuda et al. JEM 2007, Mori et al. JI 2008), in a similar manner to that 
described for the murine Ly49 receptors (Doucey et al. Nat Immunol 2004, Scarpellino et al. 
JI 2007).  The functional implications of these findings are unclear, however they may 
provide another level of regulation of the maturation and activation state of LILR-expressing 
cells based upon their MHC Class I expression, through constitutive inhibitory signalling via 
the LILRs. 
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1.2.4 LILR disease associations, polymorphisms and clinical relevance 
LILRs and viral infection 
The fact that CMV, a prevalent herpesvirus that is normally asymptomatic but can cause 
disease in immune-compromised individuals or neonates, encodes an MHC homologue 
(UL18) that binds to LILRB1 suggests a possible role for this interaction in viral immune 
evasion. Consistent with this, CMV has evolved numerous immune evasion strategies to 
enable viral persistence in immunocompetent hosts.  One involves downregulation of host 
MHC Class I molecules, a strategy likely to inhibit priming of CMV-antigen-specific T cells.  
Such a strategy could potentially leave virus-infected cells to attack by NK cells, on the basis 
of „missing self‟ recognition by non-engagement of inhibitory KIR receptors in combination 
with activatory receptor recognition of viral proteins or stress induced ligands on the infected 
cell surface.  Conceivably one role of the UL18/LILRB1 interaction may be to inhibit NK 
cells, potentially potent effectors in the anti-CMV response.  Indeed, LILRB1 has 
approximately 1000-fold higher affinity for UL18 than for MHC Class I (Chapman et al. 
Immunity 1999) potentially compensating for the low levels of UL18 expressed on CMV-
infected cells (Leong et al. JEM 1998).   
 
LILRB1 engagement by UL18 has indeed been shown to inhibit NK cell functions (Reyburn 
et al. Nature 1997, Kim et al. BBRC 2004) although some conflicting data has been published 
(Leong et al. JEM 1998, Odeberg et al. Scand J Immun 2002).  These conflicts have led to the 
hypotheses that NK cells may have an activating receptor that recognises UL18, and also that 
the differential distribution of LILRB1 in NK cell subsets may affect polyclonal responses to 
CMV infection (Prod‟homme et al. JI 2007).  In a similar fashion, despite the weight of 
evidence for an inhibitory role for LILRB1 engagement in T cells (discussed in Section 1.2.2), 
UL18 has been shown to induce CD8
+
 T cell activation in a LILRB1-dependent (Saverino et 
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al. JI 2004) or LILRB1-independent fashion (Wagner et al. JI 2007).  Similar hypotheses may 
explain these observations.  Importantly however, UL18 has also been shown to interfere with 
DC maturation and migration through engagement of LILRB1 (Wagner et al. JLB 2008).   
 
LILRB2 has been implicated in the pathogenesis of HIV-1.  Lichterfeld et al. showed that a 
variant of an immunodominant HIV-1 peptide epitope with a single amino-acid mutation 
exhibited stronger binding to LILRB2, leading to a tolerogenic phenotype of monocytes and 
DCs.  This result challenges the established notion that LILRB2 recognition of MHC Class I 
is peptide-independent and the authors suggest that the peptide presented may alter the 
conformation of the LILRB2 binding site in the α3 domain of the MHC molecule, or that an 
alternative mode of ligand recognition by LILRB2 may be operating (Lichterfeld et al. JEM 
2007).  In another study, an association between HLA-B*35-Px alleles and accelerated HIV-1 
disease progression was shown to be due to an increased affinity of those HLA-B molecules 
for LILRB2. Monocyte-derived DCs from these individuals showed reduced allostimulatory 
capacity attributed to the reduced expression of B7-2 and HLA-DR and decreased expression 
of IL-6 and IL-12 (Huang et al. JEM 2009).   
 
In summary, these findings demonstrate that viruses can use the immunomodulatory 
properties of MHC Class I interactions with LILRs as a means to decrease overall antiviral 
immune activities. Indeed, a recent paper showed that H1N1 influenza virus infection causes 
increased redistribution of MHC Class I molecules to the cell surface and their accumulation 
into lipid rafts, leading to enhanced inhibitory signalling via LILRB1 and KIR2DL1 on the 
surface of NK cells (Achdout et al. J Virol 2008).  Viral immune escape strategies may be 
counteracted by concomitant strategies in the human immune system, such as the evolution of 
activatory isoforms of innate inhibitory receptors, the so-called „counterbalance theory‟ 
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(Barclay and Hatherley, Immunity 2008), or the release of soluble decoy forms of the targeted 
inhibitory receptor, as is the case for LILRB1 and LILRB2 (Beinhauer et al. EJI 2004, Jones 
et al. EJI 2009).  The identification of BST2/Tetherin as the restrictive element preventing 
retroviral budding and release from infected cells (Neil et al. Nature 2008) and the 
confirmation of the role that the LILRA4/BST2 interaction plays in the control of innate 
antiviral immunity via pDCs (Cao et al. JEM 2009) further highlight the importance of 
studying LILRs in the context of viral infection. 
 
LILRs and bacterial infection 
Recent reports have suggested that some LILRs may recognise bacterial pathogens.  LILRB3 
and LILRB5 have been shown to be upregulated in lepromatous leprosy patients with 
Mycobacterium leprae infection (Bleharski et al. Science 2003).  LILRA2 protein expression 
was also found to be upregulated on monocytes and macrophages from lepromatous leprosy 
patients, but contrary to its expected activatory role instead impaired monocyte differentiation 
into immature DCs and antigen presentation to M. leprae specific T cells, somewhat 
reminiscent of the unexpected inhibitory effect of LILRA4 engagement (Lee et al. JI 2007).   
 
The mouse LILR orthologue PIR-B and the activatory PIR-A1 on macrophages bind to 
Staphylococcus aureus and in concert with TLR signalling direct inflammatory responses to 
the pathogen.  LILRB1 and LILRB3 were also reported to bind the bacterium.  The authors 
also suggest a potential link with septic arthritis, which supports a role for LILRs in RA, as 
discussed later (Nakayama et al. JI 2007).  Infection with Salmonella typhimurium has been 
shown to upregulate LILRB2 and LILRB4 (Brown et al. BMC Immunology 2009).  
Interestingly, the authors showed that continuous LILRB4 ligation during in vitro culture of 
DCs did not reduce costimulatory molecule expression as might be expected.  However, 
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ligation of LILRB4 led to increased secretion of IL-10 and decreased secretion of IL-8, an 
innate immune cell chemotactic cytokine, by in vitro cultured macrophages, in keeping with 
the inhibitory role of LILRB4 previously described (Brown et al. BMC Immunology 2009).   
 
LILRs and autoimmunity 
The LILRs have been implicated in a range of autoimmune diseases.  An early study 
determined the expression of activatory and inhibitory LILRs in rheumatoid arthritis (RA) 
samples (Tedla et al. Am J Pathol 2002).  Polymorphism in the promoter region of the 
LILRB1 gene was shown to be associated with RA in HLA-DRB1 shared epitope-negative 
patients (Kuroki et al. Hum Mol Gen 2005).  LILRB2, LILRB3 and LILRA2 were shown to 
be upregulated in synovial biopsies from RA patients, but reduced upon treatment (Huynh et 
al. Rheumatology 2007).  The association between HLA-B27 allele and the ankylosing 
spondyloarthropathies could be due to the engagement of HLA-B27 by the activatory 
LILRA1.   In addition, LILRB2 is able to bind to HLA-B27 fHCs (Allen et al. JI 2001) and 
fHC homodimers (Kollnberger et al. Arthritis and Rheumatism 2002), although the functional 
significance of this is unclear.  
 
LILRs have also been implicated in systemic lupus erythematosus (SLE), an autoimmune 
disease characterised by the polyclonal activation of B lymphocytes, the production of many 
different auto-antibodies and defective T cell function, possibly caused by impaired Treg and 
Ts cells (Miyara et al. JI 2005).  One study detected lower levels of LILRB1 on B cells and 
impaired inhibitory activity of LILRB1 in CD4
+
 and CD8
+
 T cell subsets from SLE patients 
(Monsivais-Urenda et al. J Autoimmunity 2007).  Polymorphism in the splice site for 
LILRA2 has also been linked with SLE (Mamegano et al. Genes Immun 2008). 
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The activatory receptor LILRA3 has been linked with MS, a degenerative neurological 
condition arising from demyelination of the CNS.  LILRA3 exhibits presence/absence 
variability more commonly ascribed to the KIRs and displays sequence variability in the 
putative ligand-binding domain (Torkar et al. EJI 2000, Moodie et al. EJ Immunogenetics 
2002, Norman et al. Immunogenetics 2003).  A study of German MS patients found evidence 
for a link between disease and the deletion of the LILRA3 locus (Koch et al. Genes and 
Immunity 2005).  However, this finding as at odds with a functional study showing that 
recombinant LILRA3 is able to stimulate T cell proliferation in a mixed lymphocyte reaction 
(Kabalak et al. Ann NY Acad Sci 2007). 
 
LILRs and cancer 
Subversion of LILR tolerogenic signalling would be a strong candidate for tumour immune 
evasion strategies.  Indeed, ectopic HLA-G expression in tumours has been noted (Paul et al. 
PNAS 1998, Maki et al. Leukaemia 2008) and may have just such an effect via the efficient 
engagement of LILRB2 (Urosevic et al. Blood 2004, LeMaoult et al. FASEB J 2005, Sun et 
al. Chest 2008).  Analogously ectopic B cell expression of LILRB2 and LILRB4 has been 
described in PBMCs from CLL patients (Colovai et al. CBCC 2007).  The presence of soluble 
LILRB4 with tolerogenic properties in the blood of certain cancer patients suggests the crucial 
function of this receptor in tolerance induction.  In addition, the demonstrated in vitro and in 
vivo inhibitory activity of soluble LILRB4 on T cell alloreactivity suggests the usefulness of 
this reagent for immunosuppressive treatment of allograft recipients or patients with 
autoimmune diseases, and a potentially important novel therapeutic avenue for the disruption 
of tumour immune evasion (Suciu-Foca et al. JI 2007, Cortesini JOP 2007).  Finally, a recent 
study addressed autoantibody and tumour-specific responses to LILRB3, which displays 
much more polymorphism than the other LILRs as well as presence/absence variation like 
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KIR receptors, in HSCT patients.  Polymorphism in LILRB3 was shown to be the underlying 
cause behind generation of autoantibodies in some HSCT patients, and LILRB3 was also 
shown to be expressed on myeloid leukaemic cells from these patients, thus eliciting the 
strong immune response to the polymorphic form of the receptor (Pfistershammer et al. Blood 
2009). 
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1.3 Aims and scope of the work conducted in contribution to this thesis 
In light of the potential functional roles of LILRs in tolerance and the regulation of 
myelomonocytic cells discussed above, it was decided they would be worthy of investigation.  
Due to the paucity of information with regards to Group II receptors both structurally and in 
terms of their ligand-binding interactions, the Group II receptors were made the focus of this 
investigation.  In particular, the suggestion in previous publications of the important role of 
LILRB4 in the control of tolerance induction mediated by DCs and Tregs, and in addition the 
recent optimisation of methods for recombinant LILRB4 expression and refolding, 
highlighted this as an interesting and potentially fruitful avenue for progression.  I had 
previously established methods for the generation of recombinant LILRB4 at high yields and 
purity (Garner et al. Prot Exp Pur 2006), which suggested X-ray crystallography as a strategy 
for successful structural determination of LILRB4 (an approach that had yielded considerable 
functional insight into the Group I LILRs, LILRB1 and LILRB2).  In addition, these methods 
would enable cell staining experiments using multimeric LILRB4 reagents, which might 
define a cellular distribution pattern for the unknown LILRB4 ligand, potentially contributing 
to its elucidation.  These studies would also enable the study of candidate ligand interactions 
utilising surface plasmon resonance techniques. 
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CHAPTER 2 - MATERIALS AND METHODS 
2.1 Molecular biology techniques 
2.1.1 Plasmids 
For high-level inducible expression of proteins as E. coli inclusion bodies, I utilised the 
pET23a vector (Novagen).  LILRB1, LILRB2, LILRB3, LILRB4, LILRB5 and LILRA5-
encoding pET23a plasmids had previously been generated in the laboratory prior to 
commencement of my PhD.  Constructs encoding biotinylated versions of the LILR proteins 
were also available, having been cloned into the biotinylation construct JMB002 (generated 
by Jonathan M. Boulter and based on the pGMT7 vector).  For investigation of LILRA4 
structure and ligand-binding, LILRA4-pCMV-Flag was provided by Dr. Rachel Allen and 
used as a template for subcloning into pET23a and the Drosophila expression vector 
pMT/BiP/V5-His-A (Novagen).  The hygromycin-encoding co-transfection plasmid, 
pCoHygro, was from Novagen.  The BST2-Fc construct, consisting of the BST2 gene in a 
modified CDM8 expression vector that contained a mouse CD150 leader segment at the N 
terminus and the Fc segment of human IgG1 at the C terminus (Arase et al. Science 2002), 
was provided by Prof. Wei Cao (Cao et al. JEM 2009). 
 
2.1.2 Primers, Polymerase Chain Reaction and Site-Directed Mutagenesis 
All custom primers were ordered from Invitrogen.  Primers were reconstituted in PCR-clean 
dH20 at 20 pmole/µl and stored at -20 ºC.  Primer sequences are listed in the relevant results 
chapters. 
 
For full-length cloning, PCRs were conducted using the following reaction mixture: 1 µl of 
each primer (20 pmoles), 1 µl of plasmid template DNA (approximately 200 ng), 1 µl of 10 
mM dNTP solution, 5 µl of PfuTurbo reaction buffer, 1 µl of cloned PfuTurbo DNA 
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polymerase enzyme (2.5 U) (Stratagene), in total 50 µl reaction volume made up with PCR-
clean dH20.  PCR conditions were as follows: Initial denaturation at 95 ºC for 2’, then 
denaturation at 95 ºC for 30”, annealing at 55 ºC for 30”, extension at 72 ºC for 1’ 30”, 25 
cycles followed by final extension step at 72 ºC for 10’. 
 
Site-Directed Mutagenesis (SDM) was conducted using the Quikchange SDM kit 
(Stratagene), according to the manufacturer’s instructions.  In brief, a PCR was conducted 
utilising the reaction mixture described above, using custom-designed SDM primers and the 
appropriate template plasmid, and the following PCR steps: denaturation at 95 ºC for 30”, 
annealing at 55 ºC for 1’, extension at 68 ºC for 4’ 30”, 16 cycles.  Following dpnI digestion 
(2 h at 37 ºC), the reaction mixture was used to transform chemically-competent E. coli 
DH5α, as described below, and transformed bacteria were plated onto LB-ampicillin agar 
plates for overnight selection and growth of colonies, prior to plasmid miniprep (described in 
2.2.1). 
 
2.1.3 Restriction enzyme DNA digestion and DNA ligation 
Restriction enzymes (NdeI, HinDIII, BglII, AgeI) and the appropriate buffers were from 
Roche.  Restriction digestion was conducted for 2 h at 37 ºC.  Cut vectors were treated with 1 
µl alkaline phosphatase (NEB) for 1 h at 37 ºC to prevent re-circularisation.  DNA ligation 
was conducted overnight using T4 DNA ligase plus ligation buffer, as per manufacturer’s 
instructions (NEB). 
 
2.1.4 Agarose gel electrophoresis and gel purification 
DNA samples were diluted in 5x DNA loading buffer consisting of 0.25 % bromophenol blue, 
0.25 % xylene cyanol FF, 15 % Ficoll in water, prior to gel loading. Agarose gel 
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electrophoresis was conducted using 1.2 % agarose gels in TBE buffer (89 mM Tris base 89 
mM boric acid 2 mM EDTA), at 80 V.  Visualisation of DNA was by the addition of 
Ethidium Bromide after gel melting (0.5 µg/ml final concentration), DNA sizing was with 
100 bp ladder (Roche) and digital pictures were recorded under UV illumination using a 
Syngene Image Capture system.  Gel purification of digested vectors and PCR product inserts 
was by QIAquick Gel Extraction Kit (QIAGEN). 
 
2.1.5 Mini and Maxi plasmid preparation 
Miniprep of plasmid DNA was conducted after overnight growth from a single colony of 
freshly-transformed E. Coli DH5α, selected the previous night by growth on an LB-ampicillin 
agar plate.  Overnight culture was in ~4 ml of LB with 100 µg/ml ampicillin in an orbital 
rotating shaker at 37 ºC, 200 RPM.  Miniprep was conducted using the QIAprep Spin 
Miniprep kit, following the manufacturer’s protocol (QIAGEN).  Elution was in PCR-clean 
dH20.  Maxiprep was by QIAGEN Plasmid Maxi Kit. Purity and yield were verified by 
agarose gel electrophoresis; successful cloning was verified by test digestion and 
electrophoresis followed by DNA sequencing.  All DNA samples were stored at -20 ºC to 
prevent nuclease degradation.   
 
2.1.6 DNA sequencing 
DNA sequencing was conducted by the Functional Genomics service, University of 
Birmingham, utilising the ABI BigDye Terminator v3.0 reaction and an ABI 3730 Sequencer. 
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2.2 Recombinant protein expression  
2.2.1 Bacterial transformation and general culture methods 
50 µl of chemically-competent E. coli strain BL21 (DE3) cells (for protein expression) or 
strain DH5α (for cloning work) were thawed on ice from storage at -80 ºC and incubated with 
~200 ng of plasmid DNA (typically 1 µl of a plasmid DNA miniprep elution) in a 1.5 ml 
eppendorf tube on ice for 30’, then subjected to 90” heat shock at 42 ºC in a waterbath.  150 
µl of pre-warmed SOC medium was then added followed by outgrowth at 37 ºC, 200 RPM in 
an orbital shaker for 1 h.  100 µl of the final transformation mix was then plated out onto pre-
warmed LB-ampicillin agar plates, and incubated overnight at 37 ºC. 
 
LB medium recipe: 10 g bactotryptone, 5 g yeast extract, 10 g Na Cl, make to 1 L with dH20 
and autoclave.  LB-agar was made using 7.5 g agar / 500 ml LB, followed by autoclaving.  To 
pour LB-ampicillin plates, solid LB-agar was melted in a microwave oven prior to cooling to 
55 ºC in a waterbath for addition of 100 µg/ml ampicillin. 
All plasmid preparations and protein expression experiments were conducted using fresh 
transformants, to minimise the risk of loss of plasmid from the bacterial colony. 
 
2.2.2 Insoluble inclusion body expression in E. coli 
Protein expression in E. coli was conducted as previously published.  Biotinylated 
recombinant LILRB4 D1D2-bt was previously generated in the laboratory (Garner et al. Prot 
Exp Pur 2006).  LILR D1 proteins were generated using similar techniques; in brief: For test 
expression, single colonies of LILR D1-pET23a transformed E. coli BL21 (DE3) cells were 
inoculated into ~4 ml of LB plus 100 µg/ml ampicillin and grown in an orbital shaker at 37 
ºC, 200 RPM to OD600 of 0.4-0.6 units.  A pre-induction sample was taken at this point.  
Induction was by the addition of 500 µM isopropyl β-D-1-thiogalactopyranoside (IPTG).  
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Post-induction samples were taken after 4 h.  Samples were centrifuged briefly at 13,000 g 
and resuspended in SDS-PAGE sample buffer for analysis by gel electrophoresis (see below). 
 
For bulk expression, single colonies of LILR D1-pET23a transformed E. coli BL21 (DE3) 
cells were inoculated into ~4 ml of LB plus 100 µg/ml ampicillin for starter growth for ~2-3 h 
in an orbital shaker at 37 ºC, 200 RPM until the culture became cloudy, then this culture was 
used to inoculate 4 L of autoclaved LB medium in 4x 2 L conical flasks with the addition of 
100 µg/ml ampicillin to maintain selection.  Cultures were grown in an orbital shaker at 37 
ºC, 200 RPM to OD600 of 0.4-0.6 units, induced by the addition of 500 µM IPTG, and grown 
for a further 4 h.  Cells were then pelleted by centrifugation at 4500 rpm for 20 min in a 
Sorvall RC26Plus centrifuge, supernatant was discarded and the pellet resuspended in 50 ml 
of PBS.  Cells were then lysed by sonication on ice with 8 bursts of 45” maximal power using 
a Misonix sonicator equipped with a flat-head probe, and inclusion bodies were harvested by 
centrifugation at 15,000 g for 30’. 
 
Inclusion bodies were then subjected to three rounds of homogenisation in 25 ml of Triton 
Wash Buffer (500 mM Tris-HCl, 0.5 % Triton X-100, 200 mM Na Cl, 10 mM EDTA, 0.1 % 
(w/v) Na azide, 2 mM DTT, pH 8.0) followed by centrifugation at 15,000 g for 15’ at the end 
of each wash step, to remove cellular membranes and soluble proteins, and then homogenised 
in 25 ml of Resuspension Wash Buffer (50 mM Tris-HCl, 100 mM Na Cl, 1 mM EDTA, 1 
mM DTT, pH 8.0) followed by centrifugation at 15,000 g for 15’ to pellet insoluble, purified 
inclusion bodies.  A small sample was removed at this point for overnight solubilisation in 
Urea Solubilisation Buffer (8 M Urea, 50 mM MES pH 6.5, 10 mM EDTA, 2 mM DTT) to 
allow analysis of purity by SDS-PAGE.  The remaining sample was solubilised overnight at 4 
ºC in ~20 ml of Guanidine Solubilisation Buffer (6 M Guanidine HCl, 50 mM MES pH 6.5, 
 60 
 
0.1 mM EDTA, 0.1 mM DTT).  Protein concentration was determined by Bradford assay 
(BioRad).   
 
2.2.3 Chemical refolding from inclusion bodies 
In vitro refolding of inclusion bodies was conducted by the standard Garboczi method 
(Garboczi et al. PNAS 1992), utilising 30 mg of each protein in 500 ml of Refold Buffer (100 
mM Tris pH 8.0, 400 mM L-arginine, 2 mM EDTA, 5 mM reduced glutathione, 0.5 mM 
oxidized glutathione and 0.1 mM PMSF) overnight at 4 ºC with stirring.  The refolds were 
then concentrated to approximately 10 ml volume using N2 pressurised stir cells (Amicon), 
filtered with 0.2 μM syringe filters and loaded into the superloop of the Akta FPLC machine 
for purification by size-exclusion chromatography (SEC). 
 
2.2.4 Size Exclusion Chromatography and general protein handling 
SEC was conducted using a Sephadex S200 column connected to an Akta FPLC machine 
(consisting of a Pump P-920 unit, a Monitor UPC-900 unit and a Frac-950 collector unit 
under the control of a PC running UNICORN software, GE Healthcare).  Pre-equilibration 
was conducted prior to each protein run using the appropriate final protein buffer.  All buffers 
and protein samples were sterile-filtered prior to use.  A standardisation run eluted markers of 
the following weights and elution volumes: 669 kDa, 112.5 ml; 232 kDa, 145 ml; 67 kDa, 195 
ml; 45 kDa, 215 ml; 12 kDa, 260 ml. 
 
Proteins were kept on ice as far as possible during manipulations, and stored at -20 ºC or -80 
ºC to prevent aggregation.  Concentration of proteins for volumes up to 15 ml or up to 0.5 ml 
was conducted using Amicon or Microcon centrifugal filtration devices, respectively.  
Quantification of refolded, purified proteins was conducted by A280 spectrophotometry using 
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calculated absorbance coefficients.  Buffer optimisation was conducted by thermal shift 
screening using Sypro Orange dye and a Thermofluor thermal cycler.  Buffer exchange was 
by PD-10 column (GE Healthcare). 
 
2.2.5 SDS-PAGE 
5x Non-Reducing SDS-PAGE Sample Buffer was prepared (1 M Tris pH 6.8, 3 g SDS, 1 g 
bromophenol blue, to 25 ml with dH2O).  5x Reducing SDS-PAGE Sample Buffer was 
prepared by adding 100 µL of 2 M DTT to 300 µl of non-reducing buffer. A 15 % acrylamide 
resolving gel was prepared (2.3 ml dH2O, 5 ml 30 % acrylamide, 2.5 ml Tris pH 8.8, 100 µL 
SDS 10 %, 100 µL APS) and then the stacking gel (2.7 ml dH2O, 0.67 ml 30 % acrylamide, 
0.5 ml 1 M Tris ph 6.8, 40 µl 10 % SDS, 40 µl APS).  Both gels were polymerised by adding 
4 µl of TEMED.  Approximately 10 µg of protein was loaded per lane, in addition to 
molecular weight standards (BioRad, low molecular weight range).  Electrophoresis was 
carried out using the Mini-PROTEAN 3 system (BioRad), at 120 V for the stacking gel and 
180 V for the resolving gel.  Gels were then stained with Coomassie Stain (1.25 g Coomassie 
Brilliant Blue, 250 ml dH2O, 50 ml acetic acid) for 30’, and destained with Destain Solution 
(300 ml dH2O, 150 ml of methanol and 50 ml of acetic acid) for 30’ or until protein bands 
were clearly visible. 
 
2.2.6 Recombinant protein expression in Drosophila S2 cells 
Drosophila Schneider 2 (S2) cells and reagents for protein expression in the Drosophila 
system were obtained from Invitrogen.  S2 cells were cultured in Schneider’s Medium 
supplemented with 10 % heat-inactivated FBS (foetal bovine serum) in a tissue-culture 
incubator maintained at 28 ºC with ambient CO2 levels.  Cells were split approximately 1:5 
every 3-4 days by dilution.  For freezing, cells were resuspended in Schneider’s medium 
 62 
 
supplemented with 10 % DMSO and 10 % FBS, frozen at -80 ºC overnight and then stored in 
liquid nitrogen. 
 
Transfection was by calcium phosphate kit (Invitrogen) using the manufacturer’s 
recommended protocol (Invitrogen Schneider S2 Cell Manual) and 10 µg of expression vector 
plasmid DNA.  For transient transfection, cells were grown for 24 h post-transfection then 
induced with 500 µM CuSO4.   Protein expression was assayed at 3 days and 4 days post-
induction by SDS-PAGE and western blotting.  For stable transfection, calcium phosphate 
transfection was conducted as described above with the addition of 1 µg of pCoHygro 
selection vector plasmid DNA, and followed by 2-3 weeks of selection with 300 µg/ml 
hygromycin-B (Invitrogen), until resistant cells began to grow out.  Frozen stocks were then 
generated and stored as described previously. 
 
For bulk expression, cells were inoculated into 1 L of Schneider medium in 4x 500 ml flasks 
and grown for 3-4 days in an orbital shaker at RT to log phase density (~2-4 x 10
6
/ml) then 
induced with 500 µM CuSO4 and grown for a further 3 days.  Supernatant was harvested by 
15’ gentle centrifugation at 1000 g to prevent cell lysis and stored at 4 ºC with the addition of 
0.01 % Na azide to prevent microbial growth. 
 
For purification of His-tagged proteins, 1 L of supernatant was dialysed overnight in 10 L of 
dialysis buffer (150 mM Na Cl 20 mM HEPES pH 7.0), 500 ml of dialysed supernatant was 
applied to a Ni-NTA column overnight at 4 ºC, and then the column was moved to RT and 
washed with 10 mM Imidazole to remove unbound proteins.  Elution was carried out with 250 
mM Imidazole.  To prevent precipitation of the eluted protein, the protein fractions were 
stored on ice. 
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2.2.7 Western blotting 
Western blotting was conducted by wet transfer electroblotting of proteins (including 
prestained protein markers, NEB) from 15 % SDS-PAGE gels to PVDF (Polyvinylidene 
Fluoride) membranes in the presence of Transfer Buffer (25 mM Tris pH 8.0, 192 mM 
glycine, 10 % methanol), followed by a wash in TBS-T (100 mM Tris pH 7.5, 150 mM Na 
Cl, 0.1 % Tween-20) and overnight blocking at 4 Cº in TBS-T plus 5 % powdered milk.  
Anti-His antibody (Invitrogen) staining (1:1000 in TBS-T plus 5 % milk) was then conducted 
for 2 h at RT with agitation, followed by three 10’ washes with TBS-T and then incubation 
with goat anti-mouse-HRP-conjugated secondary antibody (1:10,000 in TBS-T) for 1 h 
followed by three washes in TBS-T.  Enhanced Chemilumniscence detection was conducted 
using the Amersham ECL Kit.  Exposure of Kodak Scientific Imaging film (Kodak) was 
conducted in a darkroom using an intensifier cassette and a developer machine. 
 
2.3 Flow cytometry 
Anti-CD3-FITC, CD8-PEcy5, CD4-PE, CD4-PEcy5, CD19-PEcy5, CD14-FITC, CD56-
FITC, CD3-PEcy5 and CD69-PEcy5 monoclonal antibodies were from Becton Dickinson.  
Streptavidin-PE was from BD Pharmingen. Cell lines were kindly donated by various in-
house collaborators and Dr. Alison Leese (Cancer Sciences, University of Birmingham).  
Tetramerisation of LILRB4 was by gradual addition of Streptavidin-PE to biotinylated 
LILRB4 (100 µg/ml) at a molar ratio of 1:4 over 6 h.  Blood was collected from healthy 
donors by venupuncture, into heparinised syringes.  PBMC separation was by density gradient 
centrifugation in Lymphoprep
TM
 (AXIS-SHIELD UK Limited, Huntingdon, UK).   
 
For antibody and tetramer staining, PBMCs were washed in ice-cold MACS buffer (0.5 % 
BSA, 2 mM EDTA in PBS), resuspended in 500 µl aliquots (approximately 1 x10
6
 cells/tube), 
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and stained with 5 µl of antibodies, or 10 µl tetramer or Streptavidin-PE (diluted in MACS 
buffer to the same concentration as that used to make tetramer) for 30’ on ice in the dark, 
washed again with MACS buffer then resuspended in 500 µl MACS buffer plus propidium 
iodide (1 µg/ml final concentration).  Flow Cytometry was conducted using a Beckman-
Coulter EPICS XL FACS machine.  Flow cytometry data files were analysed using WinMDI 
2.9 software (http://facs.scripps.edu/software.html).  Statistical analyses were conducted using 
Graphpad Prism 4 (Graphpad Software, Inc.). 
 
2.4 Surface Plasmon Resonance 
SPR binding studies were performed at 25 C using a BIAcoreTM 3000 (BIAcore AB St. 
Albans, UK) using HBS-EP as a running buffer (10 mM HEPES pH 7.4, 150 mM Na Cl, 3.4 
mM EDTA, 0.005% surfactant P20.  Streptavidin (Sigma) was covalently coupled to 
Research Grade CM5 sensor chips (BIAcore AB) via primary amines using the Amine 
Coupling Kit (BIAcore AB).   Streptavidin was dissolved in 10 mM sodium acetate pH 5.5 
and injected over the sensor chips at 0.5 mg/ml during coupling.  R10z8e9 antibody was a 
kind gift from Dr. Margaret Goodall.  Analytes were kept on ice and centrifuged at 13,000 
rpm prior to use to remove aggregated proteins.  Analytes were injected serially over all four 
flow cells at a flow rate of 10 µl/min.  For test injections, 10 µl was injected (60 s contact 
time).  Data were collected at 10 Hz.  Data analysis was conducted using BIAeval software 
(BIAcore AB) and OriginPro 8 graphing and statistical analysis software (OriginLab 
Corporation). 
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2.5 X-ray crystallography 
2.5.1 Introduction to the theory and process of X-ray crystallography 
X-ray crystallography is a technique used to determine the 3-dimensional structure of 
molecules, by determining the position of atoms within a crystal of a molecule on the basis of 
the ability of electrons to diffract X-ray radiation.  Crystallisation of macromolecules such as 
proteins involves their production at high concentrations and subjection to conditions in 
which water molecules are encouraged to diffuse from the protein in solution, causing the 
protein molecules to interact and form a crystal lattice.  In practice, the hanging-drop method 
is commonly used and involves sealing a small drop of the protein solution, mixed with a 
crystallisation condition (typically containing a salt, a buffer, and a precipitant such as 
polyethylene glycol (PEG)), in an enclosed chamber with a well containing the crystallisation 
condition.  Due to the difference in osmolarity between the drop and the well solution, water 
molecules leave the drop via vapour diffusion, gradually increasing protein and precipitant 
concentration towards a supersaturated state.  Screening of crystallisation conditions is 
necessary to identify those conditions that promote intermolecular interactions leading to 
crystal nucleation and growth, and is an empirical process.  The purity of the protein solution 
is critical since impurities will disrupt the crystal lattice leading to early cessation of growth 
or amorphous (poorly-ordered) crystals, which are unsuitable for data collection by X-ray 
diffraction.  Once a crystal of a suitable size and morphology has been grown, it can be flash-
cooled and then subjected to a focussed X-ray beam, generating a diffraction pattern.   
 
In order to solve the three dimensional structure of a protein the diffraction pattern data is 
processed which involves calculating three variables (frequency, amplitude and phase) for 
each reflection. The frequency can be obtained from the wavelength of the X-ray beam used 
in the X-ray diffraction experiment.  The amplitude is directly derived from the intensities of 
 66 
 
each reflection. The phase angles of the reflections cannot be experimentally determined (the 
‘phase problem’) but can instead be calculated by comparison with a previously-determined 
homologous structure (a process known as molecular replacement).  By combining 
amplitudes with estimated phase information an electron density map is calculated which can 
be interpreted, allowing a molecular model to be built.  The molecular model is then improved 
by a process called refinement, in which the atomic model is adjusted to improve the 
agreement with the measured diffraction data. The progress of refinement and model building 
is assessed by monitoring the reduction of two statistics, Rwork and Rfree. 
 
2.5.2 Crystallisation screens and protocols used 
Commercially-available crystal screens were obtained from Hampton Research, Molecular 
Dimensions Ltd. and Emerald Biosystems.  Small-scale screens were set up in 96-well plates 
using a Mosquito nanolitre crystallisation robot (TTP Labtech).  Scale-up screens were set up 
in Linbro plates, using vacuum grease to seal glass coverslips over the wells.  Except where 
noted, screens were incubated in a crystallisation incubator at 23 ºC and checked for 
microcrystal formation at 3 days and weekly thereafter for up to three months using a Leica 
light microscope. 
 
2.5.3 Data collection and processing 
For LILRB4 D1 data collection, ethylene glycol was screened as a cryoprotectant, before 
flash cooling at 100 K in N2 (Oxford Cryosystems).  X-ray data were collected on an in-house 
MicroMax 007HF rotating anode X-ray generator (Rigaku) using a Saturn CCD detector 
(University of Birmingham Macromolecular X-ray Facility).  LILRB4 D1 diffraction data sets 
were integrated, scaled and merged using the XDS suite. Molecular replacement was 
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conducted using the Crystallography and NMR System suite (CNS), model refinement with 
CNS and REFMAC5, and model manipulation with COOT.  
 
2.5.4 Data analysis and presentation 
Analysis was conducted with the CCP4 and Uppsala software suites, using LSQMAN, 
PROCHECK, and CONTACT.  Electrostatic surfaces were calculated using GRASP.  
Protein-protein interaction sites were predicted with the SPPIDER web server. Molecular 
graphic figures were generated with MOLSCRIPT and rendered using POVRAY, or using 
Swiss-PDB Viewer (for SPPIDER output). 
 68 
 
2.6 Nuclear Magnetic Resonance spectroscopy 
2.6.1 Basic introduction to NMR theory 
Nuclear magnetic resonance spectroscopy derives from two fundamental properties of atomic 
nuclei.  The first is a quantum theoretical property, called spin, which in a highly abstract 
form can be considered as a rotation of the nucleus about an axis and has an angular 
momentum, and can be positive or negative.  NMR spectroscopy is usually limited to those 
nuclei which have odd mass numbers and a nuclear spin quantum number, I, of ½; for the 
study of biomolecules, the most important nuclei with I = ½ are 
1
H, 
13
C, and 
15
N.   
 
The second property is magnetism; those nuclei with nonzero spin also possess a magnetic 
moment.  When an external magnetic field is applied, the spin of the nuclei begin to precess 
about the axis of the magnetic field and the nuclear spins all align either parallel, or anti-
parallel to the field.  The frequency of this precession is termed the Larmor frequency.  At 
high magnetic field strengths, introduction of a radiofrequency (RF) pulse – a second 
oscillating magnetic field perpendicular to the static magnetic field – causes disturbance in the 
magnetic field which fluctuates as the RF pulse is removed (a process called relaxation).  The 
resulting electrical signal generated in a metal coil surrounding the sample – the free 
induction decay (FID) – can be analysed by Fourier transform and used to graph a one-
dimensional proton spectrum 
 
The electron density around each nucleus varies according to the types of nuclei and bonds in 
the molecule.  Shielding of the nucleus from the magnetic field by the electron cloud alters the 
Larmor frequency; this is called the chemical shift phenomenon.  The FID will be composed 
of a mixture of many different frequencies, which when Fourier transformed will reveal a 
spectrum of chemical shifts containing peaks for each chemical environment in which each 
 69 
 
atom finds itself.  The scale is described in parts per million (ppm) due to the fact that the 
Larmor frequency of a particular nucleus is proportional to the applied magnetic field. 
 
Heteronuclear Single Quantum Coherence spectroscopy (HSQC) is a two dimensional method 
that allows correlation between protons and directly attached heteroatoms (in this case 
15
N).  
When the protein is doubly-labelled (
13
C and 
15
N), it is possible to record a three dimensional 
experiment consisting of an HSQC plane expanded with a carbon dimension.  Six 
experiments are conducted, HNCO, HNCACO, HNCA, HNCOCA, HNCACB and 
CBCACONH, which refers to the ‘through-bond’ resonance transfer across the atoms in the 
peptide backbone (Amide proton H, amide nitrogen N, alpha carbon - Cα, beta carbon – Cβ, 
and the carbonyl carbon, CO).   
 
Analysis of this 3D spectrum allows ‘assignment’ of peaks in the spectrum to particular atoms 
within particular residues.  In the HNCACO the spectrum contains peaks at the chemical 
shifts of the CO in the residue of the HSQC peak and the previous one in the sequence. The 
HNCO only contains the peak from the previous residue, and it is thus possible to assign the 
CO shifts that correspond to each HSQC peak and the one previous to that one. Sequential 
assignment can then be undertaken by matching the shifts of each spin system's own and 
previous carbons. The HNCA and HNCOCA allow assignment of the Cα, and the HNCACB 
and the CBCACONH allow assignment of the Cβ.  Computational methods then allow for 
movement of fragments of the primary sequence assignment to regions of the spectrum, and 
the assigned chemical shifts can then be finalised and used to elucidate structural information. 
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2.6.2 Protein expression and optimisation for NMR 
LILRA4-pET23a was used to transform E. coli BL21(DE3) cells, and colonies from overnight 
transformants selected on LB-ampicillin agar plates were grown in 2 L of M9 minimal 
medium with the addition of 2 g/L uniform 
13
C glucose, 1 g/L 
15
N NH4Cl as the sole carbon 
and nitrogen sources.  Growth, induction, harvesting of inclusion bodies and chemical 
refolding were essentially as previously described.  Thermal shift screening was used to 
identify optimal buffer composition as previously described. 
2.6.3 NMR experiments conducted 
Backbone assignment spectra were recorded using a Varian Inova 800 MHz spectrometer 
equipped with an HCN 5 mm z-PFG cryogenic probe with enhanced 
13
C and 
1
H sensitivity.  
Absolute spectrometer frequencies were as follows: 
1
H, 799.762564; 
15
N, 81.0392352; 
13
C, 
201.0999208 and were used to calibrate the spectrometer to 0 ppm.  Initially, unlabelled 
LILRA4 was use to generate a 1D proton NMR spectrum (using the Watergate protocol) to 
show that the protein was folded and suitable for further analysis.  3D NMR was then 
conducted on doubly-labelled protein, using the experiments ghnca, ghn_co_ca, ghn_cacb, 
ghn_co, ghn_ca_co and gCBCA(CO)NH provided by Varian Ltd. 
 
2.6.4 Data processing and analysis packages used 
Data processing was conducted using the NMRPipe program.  Protein backbone assignments 
were conducted using the program SPARKY 3.  Secondary structure prediction was 
conducted using the TALOS web server. 
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CHAPTER 3 – LILRB4 LIGAND IDENTIFICATION STUDIES 
3.1 Introduction  
The physiological function of LILRB4 remains to date unknown, however several studies 
have suggested this receptor is crucially involved in tolerance induction mechanisms, as 
discussed in the introduction to this thesis (Section 1.2.2).  In particular the reader’s attention 
is drawn to the work of Chang et al. (Nat Immunol 2002) which established the central role of 
LILRB4 in the generation of tolerogenic DCs.  Subsequent studies probed the expression of a 
potential ligand for LILRB4 on human T cell subsets utilising a recombinant LILRB4-Fc 
fusion protein and showed that this ligand is upregulated upon T cell activation in an 
allogeneic antigen-specific model, specifically, mixed-lymphocyte reaction  (Kim-Schulze et 
al. JI 2006).  Although identification of this potential ligand was not attempted in that or 
subsequent studies, these experiments were important in suggesting clues as to the identity of 
the LILRB4 counterstructure based upon its expression and upregulation upon stimulation.  
Identification of the LILRB4 ligand would be fundamentally important in suggesting potential 
ligands for the other receptors within this group, which with the exception of LILRA4 are 
currently all orphan receptors of unknown physiological function. 
 
Chang et al. (Nat Immunol 2002) utilised a mixed-lymphocyte reaction model, in which the 
only cell types present were DCs and CD4
+
 T cells.  A logical suggestion arising from these 
studies is that blocking of the tolerogenic effect utilising anti-LILRB4 antibodies disrupts the 
interaction between LILRB4 and its ligand on target cells i.e. the LILRB4 counterstructure is 
present on either DCs or CD4
+
 T cells (or possibly both).  A subsequent paper from members 
of this group using LILRB4-Fc staining showed the expression of the ligand on CD4
+
 T cells 
at low levels (5% of CD4
+
 T cells staining positive) but significant upregulation upon 
stimulation (to approximately 25 % of CD4
+
 T cells staining positive) (Kim-Schulze et al. JI 
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2006).  A homotypic interaction of LILRB4 with itself could thus be ruled out as the sole 
interaction since LILRB4 is only expressed in cells of the myeloid lineage and not in T 
lymphocytes.  This paper also showed that the LILRB4 ligand is capable of inhibitory 
signalling, since the tolerogenic effects of membrane-bound LILRB4 (e.g. LILRB4 
transfected KG1 APCs) could be equally replicated with soluble recombinant LILRB4-Fc, or 
expression of a truncated form of the receptor which lacks any cytoplasmic ITIM signalling 
motif.  Bidirectional signalling through the LILRB4 ligand was therefore suggested.  Thus, 
this paper provided further information which might assist in identifying the LILRB4 ligand. 
 
The mode and type of ligand recognized by the Group II LILRs remains unclear, although the 
recent identification of BST2 as the ligand for LILRA4 has provided some data (Cao et al. 
JEM 2009).  Indeed the very definition of Group I vs. Group II LILRs hinges on the amino 
acid conservation at those sites in LILRB1 and LILRB2 which have been shown to contact 
MHC Class I (Willcox et al. Nat Immunol 2003).  It is entirely possible that Group II LILRs 
might bind distinct and diverse ligands even within this group, so subsequent studies might 
feasibly delineate the group further into Group III, Group IV etc.  Nevertheless, identification 
of the ligand for LILRB4 would be of major interest and potentially therapeutically important 
for the modulation of tolerance, either to enhance it in the context of autoimmunity or impair 
it in the presence of infection or tumourigenesis. In this chapter of my thesis I will discuss 
work conducted with the aim of identifying the LILRB4 ligand. 
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3.2 Defining the distribution of LILRB4 ligand using multimeric receptor 
Defining the distribution of the LILRB4 ligand or ligands on primary cells would be a 
significant step forwards in the process of identifying any potential ligands.  However, many 
cell surface immune receptor-ligand pairs that have previously been characterised have low 
affinity constants, and for the LILRs these are generally in the micromolar range (Chapman et 
al. Immunity 2000, Shiroishi et al. JMB 2006), which render monomeric forms of these 
receptors unsuitable for cell-staining-based ligand identification studies, as such low-affinity 
interactions may not be detectable by flow cytometry.   However, numerous studies have used 
multimeric forms of immune receptors as reagents to identify distribution of target ligands, 
and in some cases as a direct tool to ligand identification (Braud et al. Nature 1998, Allan et 
al. JEM 1999, Voulgaraki et al. Immunology 2005).  In particular, the use of MHC Class I 
tetramers to define TCR-MHC specificities by flow cytometry is now widespread (Altman et 
al. Science 1996). The only published study on LILRB4 in this regard involved the use of 
LILRB4-Fc proteins to suggest the presence of LILRB4 ligands on the surface of T cells 
(Kim-Schulze et al. JI 2006), but did not examine other cell types. 
 
I had previously developed and optimised methods for recombinant production of soluble 
LILRB4 using an E. coli system. These methods involved overexpression of the two 
extracellular Ig-like domains (D1D2) by cloning the LILRB4 gene into the pET23a 
expression vector, purification of the protein from insoluble inclusion bodies, solubilisation of 
inclusion bodies in 6M Guanidine HCl buffer, in vitro dilution refolding using the well-
established methods of Garboczi et al (PNAS 1992) and purification by Size Exclusion 
Chromatography (SEC).  SDS-PAGE analysis indicated the resulting protein was both 
monomeric and suggested correct folding, which was supported by antibody reactivity as 
shown by surface plasmon resonance (SPR). I had also produced a biotinylation sequence-
 74 
tagged protein - LILRB4bt - by the same methods, allowing generation of soluble LILRB4 
D1D2 tetramers by conjugation with Streptavidin-PE, for use as a staining reagent to identify 
the distribution of LILRB4 ligands on target cells by flow cytometry (Garner et al. Prot Exp 
Pur 2006). 
 
3.2.1 Detection of LILRB4 Tetramer Staining Using Flow Cytometry 
LILRB4 tetramers were generated using protocols developed for generation of MHC Class I 
tetramers (Altman et al. Science 1996, and see Chapter 2), and used to stain PBMCs from a 
cohort of eight healthy lab donors. Staining was carried out in combination with anti-CD3, 
anti-CD4 and anti-CD8 antibodies to analyse T cell subsets, anti-CD19 antibody to analyse B 
cells, and anti-CD14 antibody to analyse monocytes.  Unconjugated Streptavidin-PE was used 
as a control for LILRB4 tetramer staining. T cell subsets were also analysed for LILRB4 
tetramer binding after a 3 h period of activation by the mitogen, phytohaemagglutinin (PHA) 
at 10 µg/ml final concentration to assess whether cellular activation had any effect on 
expression of LILRB4 ligands. PBMCs were analysed using a Beckman-Coulter EPICS XL 
flow cytometer.  Flow cytometry data files were analysed using WinMDI 2.9 software 
(http://facs.scripps.edu/software.html).  Statistical analyses were conducted using Graphpad 
Prism 4 (Graphpad Software, Inc.) to carry out Wilcoxon Signed-Rank statistical tests.  
 
Forward Scatter (FS, related to size of detected particles) and Side Scatter (SS, on a 
logarithmic scale, related to particle granularity) profiles were used to exclude debris.  
Staining with the DNA intercalating agent Propidium Iodide (PI) was used to exclude necrotic 
and late apoptotic cells from analysis, as PI is able to enter cells that have lost plasma 
membrane integrity but is unable to permeate viable cells.  The signal from PI was detected in 
fluorescence channel 3 (FL3).  This process of gating on live cells is depicted in Figure 3.1. 
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Figure 3.1. Flow cytometry gating on live cells. (a): FS/SS contour plot of 
unstained cells. (b): Dot plot of FL2 channel against FL4 channel signals showing 
characteristic non-specific fluorescence from debris. (c): Histogram of data from the 
FL3 channel showing PI staining of cell debris (necrotic/ late apoptotic cells). R1 is a 
region set to exclude this signal (d) Dot plot of FL2 channel against FL4 channel 
gated on region R1 showing cleanup of non-specific signal. 
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Compensations were set using CD3-FITC for fluorescence channel 1 (FL1), CD4-PE for 
fluorescence channel 2 (FL2) and CD19-PEcy5 for fluorescence channel 4 (FL4). 
 
3.2.2 Tetramer Staining of Resting PBMC Subsets 
FS/SS profiles, in addition to back-gating using the subset markers, were used to set gates for 
lymphocyte populations.  Examples from one donor are shown in Figure 3.2.  In Figure 3.2a 
and Figure 3.2b, CD3-FITC staining is used to define a region within the FL1/FL4 dot plot 
and that region is used as a gate on the FS/SS contour plot.  This allows definition of a region 
within the FS/SS plot that is then used to gate for lymphocytes.  Figure 3.2c and Figure 3.2d 
show that the majority of CD3
+
 and CD4
+
 T cells fall within this gate, as do the majority of 
CD19
+
 B cells (Figure 3.2e and Figure 3.2f).  All subsequent analysis of lymphocytes was 
conducted with this gate. 
 
For analysis of resting CD4
+
 T cells, PBMCs from eight healthy normal lab donors were 
stained with a combination of CD3-FITC, CD4-PEcy5 and either LILRB4 tetramer-PE or 
Streptavidin-PE as a control. Donors were in two groups of four, and the same gates and 
regions were applied to donors in each group. Figure 3.3 shows representative data from one 
donor.  
 
A dot plot of CD3-FITC against CD4-PEcy5 staining was used to define quadrants for 
analysis.  As shown in Figure 3.3b, 55 % of cells within the FS/SS-defined lymphocyte gate 
were CD3
+
 T cells and 32 % of cells within the lymphocyte gate were CD3
+
CD4
+
 T cells. 
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Figure 3.2. Establishing a gate for flow cytometric analysis of lymphocyte 
populations. (a), (c), (e): Dot plots of CD3-FITC (FL1), CD4-PE (FL2) and CD19-
PEcy5 (FL4) staining, respectively, against an unstained fluorescence channel.  
These plots were used to set compensations during data collection and regions for 
back-gating during data analysis. (b): Back-gating of CD3+ cell region, R2, onto 
FS/SS contour plot showing definition of lymphocyte gate.  This plot was used to 
draw a region, R3, around the lymphocyte population as shown in panels (d) and (f). 
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Figure 3.3 (continued and legend overleaf) 
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Figure 3.3. Staining of resting CD3+CD4+ T cells with LILRB4 tetramer. (a) FS/SS 
contour plot for one donor, showing the position of the lymphocyte gate (defined here 
as region R3). (b) Dot plot of CD3-FITC against CD4-PEcy5 antibody staining 
showing T cell subsets. R4 includes all CD3+ T cells and R2 includes CD3+CD4+ 
cells. (c) and (e): Control staining with Streptavidin-PE for total CD3+ and CD3+CD4+ 
gates, respectively. (d) and (f): corresponding staining with LILRB4 tetramer. 
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This plot was also used to define two regions, R4 which encompassed all CD3
+
 cells and R2 
which contained only CD3
+
CD4
+
 double-stained cells.   
 
 
In Figure 3.3c and Figure 3.3e, the signal from CD3-FITC or CD4-PEcy5 was plotted 
against the signal from Streptavidin-PE to illustrate the low background staining using this 
control reagent.  Quadrants were set to define cells staining positive with the LILRB4 
tetramer on the basis of this control reagent staining across each group of four donors.  
Histograms of the fluorescence signal in the second channel (FL2, labelled as SPE Control) 
are also shown along with the corresponding Mean Fluorescence Intensity (MFI) values. 
 
In Figure 3.3d and Figure 3.3f, data were gated on total CD3
+
 T cells or CD3
+
 CD4
+
 T cells 
respectively and staining with the LILRB4 tetramer is shown.  For this donor, approximately 
11 % of the total CD3
+
 T cells and a similar value for CD3
+
 CD4
+
 T cells stained positively 
with the LILRB4 tetramer.  Corresponding histograms are shown below the dot plots.  MFI 
for LILRB4 tetramer staining for this donor was 12.0 for total CD3
+
 T cells (SPE control: 4.0) 
and 10.7 for the CD3
+
 CD4
+
 T cell subset (SPE control: 4.1).   
 
Tetramer staining of resting CD8
+
 T cells was conducted in a similar fashion, using CD3-
FITC and CD8-PEcy5 antibodies.  Figure 3.4 shows representative data from a different 
healthy donor.  Figure 3.4a shows that approximately 25 % of cells within the lymphocyte 
gate were CD3
+
 CD8
+
 T cells.  Figure 3.4b shows control staining with Streptavidin-PE and 
Figure 3.4c shows that a low percentage (approximately 4 %) of CD3
+
 CD8
+
 T cells stain 
positive with the LILRB4 tetramer. 
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Figure 3.4. Staining of resting CD3+ CD8+ T cells with LILRB4 tetramer. (a) Dot 
plot of CD3-FITC against CD8-PEcy5 antibody staining showing CD3+CD8+ T cell 
subset, defined as a region, R3. (b) Control staining with streptavidin-PE of total 
CD3+ cells (c) Staining of CD3+CD8+ T cells with the LILRB4 tetramer.  This dot plot 
has been gated on Region R3. 
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These results confirmed that multimeric LILRB4 stained ex vivo freshly isolated populations 
of T cells.  Similar results were obtained for other donors.  Pooled data for CD4
+
 and CD8
+
 T 
cells for all eight donors are collated and discussed in Section 3.2.5. 
 
For analysis of resting CD14
+
 monocytes and CD19
+
 B cells, PBMCs from the same eight 
healthy normal lab donors were stained with a combination of CD14-FITC, CD19-PEcy5 and 
either LILRB4 tetramer-PE or Streptavidin-PE as a control. As for T cell analysis, donors 
were in two groups of four, and the same gates and regions were applied to donors in each 
group. A dot plot of CD14-FITC against CD19-PEcy5 staining (Figure 3.5a) was used to 
back-gate on FS/SS to define a region, R5, containing both cell populations (Figure 3.5b-d).  
Subsequent analyses of the CD14
+ 
monocyte and CD19
+
 B cell populations were conducted 
with this gate in place.  
 
Representative data from one donor are shown in Figure 3.6.  Figure 3.6a shows a contour 
plot of FS/SS, illustrating the position of the gate for analysis of the two populations as 
defined by region R5.  Figure 3.6b shows a dot plot of CD14-FITC (detected in channel FL1) 
against CD19-PEcy5 (detected in channel FL4) antibody staining for that donor, which was 
used to define a region containing CD14
+
 monocytes (R4) and a region containing CD19
+
 B 
cells (R2). 
 
In Figure 3.6c and Figure 3.6e, CD14-FITC or CD19-PEcy5 were plotted against the signal 
from Streptavidin-PE to indicate control staining.  Quadrants were set to define cells staining 
positive with the LILRB4 tetramer on the basis of this control staining pattern across each 
group of four donors.  Histograms of the fluorescence signal in the second channel  
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Figure 3.5. Establishing a gate for flow cytometric analysis of resting CD19+ B 
cells and CD14+ monocytes. (a): Dot plot of CD14-FITC against CD19-PEcy5 
antibody staining showing region definitions used to gate on monocytes (region R4) 
and B cells (region R2), respectively. (b) – (d): Back-gating strategy used to define 
regions of the FS/SS contour plot containing B cells (region R3) and both B cells and 
monocytes (region R5). 
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Figure 3.6 (continued and legend overleaf) 
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Figure 3.6. LILRB4 tetramer staining of resting CD14+ monocytes and CD19+ B 
cells. (a): FS/SS plot for one representative donor. (b): Dot plot of CD14-FITC 
antibody staining against CD19-PEcy5 antibody staining showing definition of gates 
for CD19+ B cells and CD14+ monocytes. (c): Control staining with Streptavidin-PE 
for CD14+ monocytes. (d): Corresponding staining with LILRB4 tetramer for CD14+ 
monocytes. (e): Control staining with Streptavidin-PE for CD19+ B cells (f): 
Corresponding staining with LILRB4 tetramer for CD19+ B cells. 
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(corresponding to signal from Streptavidin-PE) are also shown along with the corresponding 
MFI values. 
 
In Figure 3.6d, data were gated on CD14
+
 monocytes using region R4 and staining with the 
LILRB4 tetramer is shown.  For this donor, it can be seen that a high proportion of the CD14
+
 
monocytes (approximately 65 %) stained positive with the LILRB4 tetramer.  Corresponding 
histograms are shown below the dot plots.  MFI for LILRB4 tetramer staining for this donor 
was 53.5 for CD14
+
 monocytes (SPE control: 3.4). 
 
In Figure 3.6f, data were gated on CD19
+
 B cells using region R2 and staining with the 
LILRB4 tetramer is shown.  Approximately 30 % of the CD19
+
 B cells stained positive with 
the LILRB4 tetramer for this donor and this staining pattern has a higher range of tetramer 
positive cells, with some brightly staining cells apparent.  Corresponding histograms are 
shown below the dot plots.  MFI for LILRB4 tetramer staining for this donor was 68.4 for 
CD19
+
 B cells (SPE control: 3.5). 
 
These results present a new finding, which is that freshly-isolated human monocytes and B 
cells stain brightly with multimeric LILRB4, suggesting that the ligand for LILRB4 is highly 
expressed upon these PBMC subsets.  Pooled data for CD14
+
 monocytes and CD19
+
 B cells 
for all eight donors are collated and discussed in Section 3.2.5. 
 
For analysis of resting CD3
-
 CD56
+
 NK cells, PBMCs from one group of four healthy normal 
lab donors were stained with a combination of CD56-FITC, CD3-PEcy5 and either LILRB4 
tetramer-PE or Streptavidin-PE as a control.  The same gates and regions were applied for 
each donor.  Representative data from one donor is shown in Figure 3.7. 
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Figure 3.7. LILRB4 tetramer staining of resting CD3- CD56+ NK cells. (a):  FS/SS 
contour plot for one representative donor. (b): Dot plot of CD56-FITC against CD3-
PEcy5 staining used to define a region for analysis of NK cells, R4. (c): Control 
staining with Streptavidin-PE against CD56, gated on region R4. (d): Corresponding 
staining of CD3- CD56+ NK cells with the LILRB4 tetramer. 
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A dot plot of CD56-FITC against CD3-PEcy5 staining (Figure 3.7b) was used to define a 
region, R4, which was CD3
-
 and CD56
+
.  This region was then used to back-gate on a FS/SS 
contour plot to generate a lymphocyte gate, R3 (Figure 3.7a).  Subsequent analysis of the NK 
cell population was conducted with this gate in place. In Figure 3.7c, the signal from CD56-
FITC antibody staining has been plotted against the signal from Streptavidin-PE to indicate 
control staining.  This staining pattern was used to set quadrants to define cells staining 
positive with the LILRB4 tetramer as previously described. These data were gated on CD3
-
 
CD56
+
 NK cells using region R4 (Figure 3.7b). 
 
In Figure 3.7d, data were gated on CD3
-
 CD56
+
 NK cells using region R4 and staining with 
the LILRB4 tetramer is shown.  For this donor, it can be seen that a small number (less than 1 
%) of the CD3
-
 CD56
+
 NK cells stained positive with the LILRB4 tetramer. 
 
In summary, these data show that NK cells are essentially negative for surface expression of 
the LILRB4 ligand and this could be evidence against non-specific binding of the LILRB4 
tetramer to PBMCs. 
 
3.2.3 LILRB4 Tetramer Staining of Activated T Cells 
To study the expression of the LILRB4 ligand upon T cell activation, flow cytometry analysis 
was conducted as previously described for total CD3
+
, CD3
+
 CD4
+
 and CD3
+
 CD8
+
 T cells 
after a 3 h incubation with the mitogen, PHA, at a concentration of 10 μg/ml.  Gates were 
redefined to allow for changes in FS/SS profile of activated T cell blasts.  The same eight 
donors were used in two groups of four donors as in the previous experiments. 
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Figure 3.8 shows representative data from one of the donors. A dot plot of CD3-FITC against 
CD4-PEcy5 antibody staining (Figure 3.8a) was used to define a region containing total 
CD3
+
 T cells (R4) which was then back-gated onto the FS/SS contour plot shown in Figure 
3.8b to define the lymphocyte gate (region R3). Subsequent analysis was conducted with this 
gate in place.  Analysis of CD3-FITC against CD4-PEcy5 antibody staining was simplified 
with this gate, allowing better discrimination between cellular subtypes as can be seen from 
the dot-plot shown in Figure 3.8c. Region R2 defines the CD3
+
 CD4
+
 T cell population. 
 
Representative data from another donor are shown in Figure 3.9, to illustrate the LILRB4 
tetramer staining pattern for activated CD3
+
 CD4
+
 T cells. Figure 3.9a shows a contour plot 
of FS against log SS and shows the lymphocyte gate as defined by region R3 which is 
discussed above.  Regions for analysis of CD3
+
 cells and CD3
+
 CD4
+
 T cells were defined 
using a dot plot of CD3-FITC against CD4-PEcy5 staining (Figure 3.9b). 
 
In Figure 3.9c and Figure 3.9e, the signal from Streptavidin-PE was plotted against CD3-
FITC or CD4-PEcy5, respectively, to illustrate background staining patterns.  As before, 
staining with this control reagent is defined as negative.  Quadrants were set to define cells 
staining positive with the LILRB4 tetramer for each group of four donors, based on the 
Streptavidin-PE control.  Histograms of the fluorescence signal in the second channel are 
shown along with the corresponding MFI values. 
 
In Figure 3.9d and Figure 3.9f, staining with the LILRB4 tetramer is shown with data gated 
on total activated CD3
+
 T cells or activated CD3
+
 CD4
+
 T cells respectively.  For this donor, 
approximately 27 % of the total CD3
+
 T cells and 33 % of the CD3
+
 CD4
+
 T cells stain 
positive with the LILRB4 tetramer after activation.  Corresponding histograms are shown 
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Figure 3.8.  Establishing a gate setup for flow cytometric analysis of PHA-
activated T cells. (a): Dot plot of CD3-FITC staining against CD4-PEcy5 staining for 
PBMCs activated with PHA for 3h.  A region, R4 has been defined to include the 
majority of CD3+ T cells for back-gating on FS/SS.  (b): Back-gating of R4 on FS/SS 
contour plot.  Another region, R3 has been defined to isolate the lymphocyte 
population.  (c): Gating of R3 on the CD3-FITC staining against CD4-PEcy5 staining 
dot plot ‘cleans up’ the plot allowing better visualisation of each T cell subset.  Region 
R2 defines CD3+CD4+ T cells. 
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Figure 3.9 (continued and legend overleaf) 
 
91 
Gate:R2
Quad Events %Total %Gated
UL 72 0.07 0.29
UR 28 0.03 0.11
LL 22885 22.85 90.88
LR 2197 2.19 8.72
Quad Events %Total %Gated
UL 0 0 0
UR 447 0.45 33.21
LL 0 0 0
LR 899 0.9 66.79
(e) (f)
CD4
S
P
E
 C
o
n
tr
o
l
CD4
L
IL
R
B
4
 T
e
tr
a
m
e
r
MFI: 4.39 MFI: 75.31
LILRB4 TetramerSPE Control
E
v
e
n
ts
E
v
e
n
ts
 
Figure 3.9. LILRB4 tetramer staining of activated CD3+ and CD3+ CD4+ T cells. 
(a) FS/SS contour plot for one donor showing altered profile after activation. (b) CD3-
FITC against CD4-PEcy5 antibody staining showing T cell subsets after activation 
with PHA. (c): Control staining with Streptavidin-PE for total CD3+ T cells. (d): 
Corresponding staining with LILRB4 tetramer for total CD3+ T cells. (e): Control 
staining with Streptavidin-PE for CD3+CD4+ T cells. (f): Corresponding staining with 
LILRB4 tetramer for CD3+CD4+ T cells. 
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 below the dot plots.  MFI for LILRB4 tetramer staining for this donor was 49.6 for total 
CD3
+
 T cell (SPE control: 4.2) and 75.3 for CD3
+
 CD4
+
 T cells (SPE control: 4.4).  
 
For comparison, the percentages of CD3
+
 and CD3
+
 CD4
+
 T cells staining positive with the 
LILRB4 tetramer under resting conditions for this donor were 9 % for both respectively, 
indicating a substantial upregulation in surface expression of the LILRB4 ligand by these 
lymphocyte subsets upon polyclonal stimulation. 
 
Figure 3.10 shows representative data from one donor, demonstrating the LILRB4 tetramer 
staining pattern for activated CD3
+
 CD8
+
 T cells. Quadrants for analysis were defined using a 
dot plot of CD3-FITC against CD8-PEcy5 staining (Figure 3.10b). 
 
Quadrants were set to define cells staining positive with the LILRB4 tetramer for each group 
of four donors.  In Figure 3.10c, control staining with Streptavidin-PE is shown as a dot plot 
against CD8-PEcy5 antibody staining.  Gating on CD3
+
 CD8
+
 T cells using region R4 shows 
approximately 20 % staining with the LILRB4 tetramer after activation with PHA (Figure 
3.10d). 
 
Under resting conditions the percentage of CD3
+
 CD8
+
 T cells that stained positive with the 
LILRB4 tetramer for this donor was 6 % indicating upregulation in LILRB4 ligand surface 
expression upon treatment with PHA in a similar fashion to that for CD4
+
 T cells. 
 
To summarise these data for the expression of the LILRB4 ligand on T cell subsets after 3 h 
activation with PHA, in accordance with previously published data CD4
+
 T cells upregulate 
their expression of the LILRB4 ligand upon activation (Kim-Schulze et al. JI 2006).  In 
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Figure 3.10. LILRB4 tetramer staining of activated CD3+ CD8+ T cells. (a): FS/SS 
contour plot for one donor showing altered profile after activation. (b): CD3-FITC 
against CD8-PEcy5 antibody staining showing T cell subsets after activation with 
PHA. (c): Control staining with Streptavidin-PE for total CD3+ T cells. (d): 
Corresponding staining with LILRB4 tetramer for CD3+ CD8+ T cells. 
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addition, a novel finding of this work is that CD8
+
 T cells also upregulate LILRB4 ligand 
surface expression to a comparable degree.  It is worth noting that my work utilises a strong 
non-specific polyclonal activation stimulus (i.e. PHA treatment) and analysis is conducted at 
an early time point (3 h) as compared to seven days in a mixed lymphocyte reaction used in 
the aforementioned publication. 
 
The data for all eight donors are summarised and compared alongside the data for resting 
PBMC subsets in Section 3.2.5. 
 
3.2.4 CD69 and LILRB4 Tetramer Staining 
In a separate experiment, surface expression of the T cell early activation marker CD69 was 
analysed to confirm activation of the lymphocytes upon PHA stimulation.  PBMCs were 
harvested from four donors from the original pool of eight and stained with Streptavidin-PE 
or LILRB4 tetramer-PE plus CD3-FITC and CD69-PEcy5 antibody. 
 
Representative data from one donor is shown in Figure 3.11.  These data show that a small 
number (approximately 1 %) of CD3
+
 T cells are activated and express the CD69 early 
activation marker in resting PBMCs (Figure 3.11a).  A dot plot of CD69 staining against 
LILRB4 tetramer staining, gated on CD3
+
 T cells, shows no apparent correlation between 
CD69 expression and LILRB4 ligand expression for resting T cells (Figure 3.11b).   From 
Figure 3.11c it can be seen that CD69 is rapidly upregulated on CD3
+
 T cells upon 
stimulation for 3 h with PHA, with approximately 22 % of T cells staining positively for 
CD69.  Figure 3.11d shows that LILRB4 tetramer staining of PHA-activated CD3
+
 T cells 
appears to correlate to some degree with the level of CD69 surface expression in this PBMC 
(a) (b)
Quad Events %Total %Gated
UL 548 0.54 1.34
UR 336 0.33 0.82
LL 10644 10.57 26.06
LR 29322 29.11 71.78
Quad Events %Total %Gated
UL 1579 1.57 5.32
UR 55 0.05 0.19
LL 27743 27.54 93.54
LR 281 0.28 0.95
R2
Gate:R2
CD69
L
IL
R
B
4
 T
e
tr
a
m
e
r
C
D
6
9
CD3
(c) (d)
R2
C
D
6
9
CD3
Gate:R2
CD69
L
IL
R
B
4
 T
e
tr
a
m
e
r
Quad Events %Total %Gated
UL 6918 6.9 19.16
UR 1233 1.23 3.42
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LR 4304 4.29 11.92
Quad Events %Total %Gated
UL 489 0.49 8.83
UR 300 0.3 5.42
LL 3897 3.89 70.38
LR 851 0.85 15.37
 
Figure 3.11. CD69 staining of resting and activated T cells. (a): Dot plot of CD3-
FITC against CD69-PEcy5 antibody staining for resting PBMCs.  Region R2 has 
been defined to include all CD3+ T cells. (b): Dot plot of CD69-PEcy5 antibody 
staining against LILRB4 tetramer staining for resting PBMCs, gated on CD3+ cells 
using region R2. (c): Dot plot of CD3-FITC against CD69-PEcy5 antibody staining for 
PHA-activated PBMCs.  Region R2 has been defined to include all CD3+ T cells. (d): 
Dot plot of CD69-PEcy5 antibody staining against LILRB4 tetramer staining for PHA-
activated PBMCs, gated on CD3+ cells using region R2. 
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 subset, and therefore with the activation status of these lymphocytes, with the cells staining 
brightest for LILRB4 tetramer also staining brightly for CD69 expression. 
 
3.2.5 Summary and Analysis of LILRB4 Tetramer Staining of PBMCs 
Pooled data for all eight donors is shown in Table 3.1 and also as a scatter plot in Figure 
3.12.  Each donor is plotted as a data point for each subset and the horizontal bars show the 
mean percentage of cells staining positive with the LILRB4 tetramer for each subset.  Mean 
percentages of cells staining positive for the LILRB4 ligand were approximately 12 % for 
total CD3
+
 T cells (23 % after PHA activation),  12 % for CD3
+
 CD4
+
 T cells (27 % after 
PHA activation), 5 % for CD3
+
 CD8
+
 T cells (17 % after PHA activation), 64 % for CD14
+
 
monocytes and 28 % for CD19
+
 B cells.  For each subset of T cells Wilcoxon Signed-Rank 
statistical analysis was conducted and showed that the upregulation of LILRB4 tetramer 
staining on the T lymphocyte subsets upon PHA stimulation is statistically significant (P < 
0.05). 
Donor 
CD3 CD4 CD8 CD14 CD19 
Resting +PHA Resting +PHA Resting +PHA Resting Resting 
1 10.72 27.36 10.42 29.30 3.23 21.00 82.76 29.54 
2 13.75 23.07 13.60 23.82 3.37 6.91 52.10 23.82 
3 12.07 19.69 12.27 22.57 3.61 13.55 40.54 30.50 
4 16.31 18.67 16.68 19.60 4.57 16.49 29.22 28.19 
5 11.67 23.66 11.40 30.05 7.25 19.68 90.25 31.01 
6 8.73 15.77 8.45 23.27 5.45 19.24 70.29 20.65 
7 12.20 25.58 11.82 34.76 6.37 20.48 64.51 30.31 
8 9.31 27.49 9.31 33.21 9.85 18.81 79.98 26.06 
Mean 11.85 22.66 11.74 27.07 5.46 17.02 63.71 27.51 
P-value 0.0078  0.0078  0.0078   
Table 3.1. Collated LILRB4 tetramer staining data. Tabulated data showing the 
percentage of cells staining with the LILRB4 tetramer for PBMC subsets for all eight 
donors.  Values are listed for resting and PHA-activated CD3+, CD3+ CD4+ and CD3+ 
CD8+ T cells and for resting CD14+ monocytes and CD19+ B cells.  Mean values are 
listed as well as calculated P-values for Wilcoxon Signed-Rank statistical tests 
between resting and PHA-activated cells for each subset of T cells. 
  
 
 
 
Figure 3.12. Summary of LILRB4 Tetramer Staining of PBMCs. Scatter plot 
summarising LILRB4 tetramer staining data for all eight donors.  Each data point 
within each category is a single donor, with PBMC subsets as categories on the y-
axis and the percentage of cells staining positive with the LILRB4 tetramer on the x-
axis.  Horizontal bars indicate the mean percentage for each subset. ‘+P’ indicates 
the addition of PHA. 
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3.2.6 LILRB4 Tetramer Staining of Human Cell Lines 
In order to identify a cellular population that was uniformly positive for LILRB4 ligand and 
that therefore might be a useful tool in downstream ligand identification approaches the 
LILRB4 tetramer was used to stain a panel of immortalised human cell lines. These included 
T cell lines (Jurkat), B cell lines (K422 and REC-1), and a monocyte cell line (THP-1) as well 
as EBV-positive and EBV-negative immortalised B cell lines derived from lab donors 
(generated and kindly provided by Alison Leese), plus the adherent melanoma and sarcoma 
cell lines, LB373 and LB23.  The monkey fibroblast cell line COS was also used.  The 
percentage of cells staining positive for the LILRB4 ligand or for Streptavidin-PE as a control 
are shown in Table 3.2. 
 
Cell Line Origin Strept-PE Tetramer-PE 
AH LCL B LCL 0.3 2.0 
LM LCL B LCL 0.6 5.3 
NB4 Promyelocyte, APL 0.1 5.1 
HL60 Promyeloblast, APL 0.1 1.7 
BL-2 Burkitts – low PN 0.4 5.8 
BL-37 Burkitts – high PN 0.6 5.2 
BL-40 Burkitts – high PN 0.1 2.4 
Jurkat 1 T cell ALL 0.1 1.4 
Jurkat 2 T cell ALL 0.1 1.6 
K422 B cell NHL 0.1 2.2 
REC-1 B cell NHL 0.2 2.9 
THP-1 AMoL 0.1 2.4 
COS Monkey fibroblast 0.1 0.8 
LB373mel Melanoma, adherent 0.8 1.5 
LB23sarc Sarcoma, adherent 0.2 1.0 
 
Table 3.2. Cell line staining data. Tabulated data showing the percentage of 
LILRB4 tetramer or Streptavidin-PE staining of cell lines.  LCL, lymphoblastoid cell 
line; APL, Acute Promyelocytic Leukaemia; ALL – Acute Lymphoblastic Leukaemia; 
NHL – Non-Hodgkins Lymphoma; AMoL – Acute Monocytic Leukaemia. PN =  
passage number. 
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Unfortunately, none of the cell lines stained gave a convincingly positive staining pattern with 
the LILRB4 tetramer. Although the percentage of cells staining with LILRB4 tetramer was 
higher than that obtained with Streptavidin-PE control, the absolute levels of staining were 
low (< 6 %).  
 
3.2.7 Summary and Discussion of Flow Cytometry Data 
In summary, these data show that multimeric LILRB4 is capable of staining freshly isolated 
human PBMC.  Similarly to previous studies, they show staining to CD4
+
 T cells which is 
increased upon activation with PHA.  As LILRB4 is not expressed by resting or activated T 
cells, this staining pattern cannot be due solely to homotypic interactions. 
 
However, my dataset extends previous studies considerably, by showing staining of 
tetramerised LILRB4 on CD8
+
 subset T cells in addition to CD4
+
 T cells, and this staining 
was increased by activation with PHA.  Previous studies used mixed lymphocyte reaction 
over several days to show this increase upon activation by comparison with 3 h treatment with 
PHA used in this study, which is a strong and non-specific stimulus to T cells.  However, the 
levels of expression on CD4
+
 T cells and the degree of upregulation of expression of the 
proposed LILRB4 ligand are comparable to these studies.  In this study I used CD69 
expression as a read-out of T cell activation and found a trend for LILRB4 and CD69 co-
expression, suggesting that LILRB4 ligand expression may be linked to the activation status 
of lymphocytes. 
 
Furthermore, I have demonstrated staining of multimeric LILRB4 on other subsets of 
PBMCs, specifically monocytes, which stain at a high frequency and with high levels, and B 
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cells, which stain at an intermediate frequency and level between that of monocytes and T 
cells.  The wide span of MFI values is indicative of a wide variation in the level of LILRB4 
ligand expression both within and between subsets of PBMCs, and is an observation also seen 
with LILRB4-Fc staining of PBMC subsets reported in earlier studies (Kim-Schulze et al. JI 
2006). 
 
The novel nature of these data may be due to the progression from an Fc-fusion protein with a 
dimeric avidity used in previous studies to the LILRB4 tetrameric protein with a tetrameric 
affinity as used in this study.  In addition, the use of Fc-fusion proteins is complicated by the 
presence of Fc receptors on monocytes and B cells.  These receptors can be blocked with 
human or mouse serum, but the presence of these receptors may have given concern to 
authors of previous studies as to the validity of their findings, if they detected staining of the 
aforementioned PBMC subsets with the LILRB4-Fc reagent.  My data suggests that the 
expression of the LILRB4 ligand or ligands may be considerably more widespread than 
previously thought. 
 
Although these results should be interpreted with a degree of caution, several factors suggest 
that these staining patterns are not likely to be due to non-specific interactions.  Firstly, the 
NK cell PBMC subset does not stain positive with the LILRB4 tetramer and may be a true 
negative population.  Secondly, many of the cell lines tested also did not stain positively.  
Immortalised cell lines tend to undergo high levels of cell death due to apoptosis which can 
often lead to binding in a non-specific fashion, but this was not observed.  Thirdly, initial 
experiments conducted with recombinant monomeric LILRB4 showed very weak staining to 
PBMCs and suggested the need for multimerisation of the receptor to achieve an avidity 
sufficient for detection of the LILRB4 ligand (Garner et al. Prot Exp Pur 2006).  Finally, 
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control experiments showed that LILRB4bt was antibody reactive, monomeric and pure 
suggesting it was likely to retain biological reactivity (Garner et al. Prot Pur Exp 2006).  
These factors lend credence to the notion that the results shown in this section are valid and a 
true indicator of expression of the LILRB4 ligand. 
 
Transformed immortalised cell lines were used to attempt to identify positively and negatively 
staining cells which could then have provided reagents for LILRB4 ligand identification – 
either via the generation of cDNA libraries and expression cloning or through a proteomics 
and mass spectrometry approach.  However, these cell lines did not stain substantially with 
LILRB4 tetramer to a degree which would have given me confidence in attempting these 
methods (which are both time consuming and far from technically trivial to conduct 
successfully).   
 
Why did these cell lines not stain positive for the LILRB4 ligand? One possibility is that the 
expression of the LILRB4 ligand is selected against in long-term culture of immortalised cell 
lines.  This suggestion is consistent with the finding that LILRB4 binding to unidentified 
ligands on T cells inhibits target cell proliferation, suggestive of an inhibitory function for the 
LILRB4 counterstructure.  Furthermore, transformed cell line culture systems are unlikely to 
be the most physiologically relevant biological scenario in which to observe LILRB4 ligand 
expression and investigate LILRB4 function.   
 
LILRB4 is not expressed in the mouse and the closest homologous receptors – the PIR family 
– do not have a corresponding member of the family (being similar instead to Group I LILRs 
which bind to MHC Class I molecules) thus ruling out the use of wild-type mice to study 
LILRB4 and its ligand in an in vivo setting.  Instead, ex vivo clinical studies of patients with 
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cancer or autoimmune diseases could be more revealing of LILRB4 ligand expression and 
function, against the background of the inhibitory tumour microenvironment or dysregulated 
tolerogenic systems.  Indeed a small number of studies have recently been published 
investigating LILRB4 expression and function in such settings (Cortesini J Pancreas 2007, 
Suciu-Foca JI 2007). 
 
Despite the failure of the LILRB4 tetramer to stain transformed cell lines, these studies, which 
focussed on freshly isolated ex vivo human PBMC populations, suggested testable hypotheses 
regarding the identity of the LILRB4 ligand.  In particular, the broad expression of LILRB4 
ligand or ligands on different cellular subsets, combined with the well-established role of 
LILRB4 in tolerance induction and the upregulation of the putative ligand upon cellular 
activation, suggested that members of the B7 and CD28 families of immune costimulatory 
proteins were worthy of investigation as candidate ligands, a concept addressed in subsequent 
sections of this chapter. 
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3.3 Surface Plasmon Resonance Studies of Potential LILRB4 Ligands 
3.3.1 Introduction 
As discussed in my Introduction (Chapter 1 Section 1.2.2), LILRB4 has a well-documented 
role in the induction of tolerance to self-antigens, particularly in the induction of T cell 
tolerance and has been shown to be crucial for the generation of CD4
+ 
CD25
+ 
FoxP3
+
 T 
regulatory cells upon its upregulation on the surface of tolerogenic DCs or transfection into 
model APCs in vitro.  The paper of Kim-Schulze et al. (Kim-Schulze et al. JI 2006) showed 
that recombinant LILRB4-Fc or KG1 cells transfected with a cytoplasmic domain-truncated 
LILRB4 expression construct could also mediate the induction of tolerance in T cells despite 
the absence of the LILRB4 ITIM signalling motifs, suggesting that the ligand for LILRB4 is 
capable of bidirectional signalling both into the T cell and – through LILRB4 engagement – 
into the APC. 
 
In this study I replicated previous findings which established that the ligand for LILRB4 is 
upregulated upon T cell activation but also presented new evidence that the ligand is more 
widely expressed than was previously thought.  These cell staining experiments in addition to 
the work of Chang et al. and Kim-Schulze et al. suggested potential ligands for further 
investigation.  CTLA-4 is one such candidate ligand, being an inhibitory receptor which is 
upregulated upon T cell activation and having a known role in tolerance induction and also T 
regulatory cell effector mechanisms (for a more complete discussion see Chapter 1 and 
Figure 1.1).  However, CTLA-4 expression is restricted to T cells and thus does not fit the 
staining pattern described in the previous section.  
 
CTLA-4 is a member of the CD28 family of costimulatory immunoreceptors, whose counter-
structures belong to the B7 family.  The canonical interaction between these families is the 
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positive costimulatory ‘second signal’ to TCR-pMHC engagement that occurs between CD28 
on T cells and B7.1 or B7.2 on APCs.  As well as having signalling motifs of its own that 
signal directly into the T cell, CTLA-4 acts to downregulate T cell responses by disrupting the 
CD28-B7 interaction as it has a higher affinity for B7 than CD28 thus sterically blocking 
binding.  Members of the CD28 and B7 family are discussed in detail in Section 1.1.4, 
however for reference see Table 3.3 and Table 3.4 (adapted from Greenwald et al. Ann Rev 
Immunol 2005). 
 
Receptor Identity Ligands 
Expression 
Haematopoietic 
Expression 
Other 
B7-1 (CD80) 100% 
CD28, CTLA-
4, PD-L1 
T, DC, B, Mφ  Rare 
B7-2 (CD86) 27% CD28, CTLA-4 T, DC, B, Mφ Rare 
ICOSL (B7-
H2) 
27% ICOS T, DC, B, Mφ 
Fibroblast, 
Endothelial, 
Epithelial 
PD-L1 (B7-H1) 25% PD-1, B7-1 T, DC, B, Mφ 
Endothelial, 
Tissues, 
Tumours 
PD-L2 (B7-
DC) 
23% PD-1 DC, Mφ 
Some B cell 
lymphomas 
B7-H3 29% Unknown T, DC, B, Mφ, NK Bone Marrow 
B7-H4 (B7x, 
B7S1) 
21% Unknown T, DC, B, Mφ 
Lung and 
ovarian 
Tumours 
 
Table 3.3. B7 family members.  Table listing percentage amino acid identity, known 
ligands, and haematopoietic and other tissue distributions of members of the B7 
family of counterstructures for CD28 family receptors. T = T cell, NK = natural killer 
cell, B = B cell, Mφ = macrophage. 
 
 
Collectively the CD28 and B7 family members are widely expressed both on haematopoietic 
and non-haematopoietic cells and are involved in positive and negative costimulation of 
immune responses.  This role in addition to the broad expression pattern of these receptors 
suggested one possibility for LILRB4 ligand recognition, namely that LILRB4 might bind to 
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more than one receptor within a family of structurally related receptors.  This would fit with 
the broad staining pattern of the LILRB4 tetramer utilised in this study.  I chose to address 
this idea by directly testing LILRB4 interaction with CD28 and B7 family members using 
SPR, focussing particularly on those involved in T cell tolerance mechanisms. 
 
Receptor Identity Ligands 
Signal  
Motifs 
Expression Function 
CD28 100% B7-1, B7-2 PI3K, PP2A T 
Naive T cell activation, 
proliferation, 
IL-2 production, 
survival 
CTLA-4 30% B7-1, B7-2 
PI3K, PP2A, 
SHP2 
T 
Inhibition of T cell 
responses 
ICOS 27% ICOS-L PI3K T, NK 
Effector T cell function; 
proliferation; Ig class 
switching; IL-10, IFN-γ,  
IL-4 production 
PD-1 23% 
PD-L1, 
PD-L2 
ITIM, ITSM T, B, Mφ 
Effector T cell 
functions, proliferation; 
IL-10, IFN-γ 
production;  
CTL apoptosis 
Inhibition of T cell 
responses 
BTLA 23% Unknown 2x ITIM T, B 
Inhibition of T and B 
cell responses 
 
Table 3.4. CD28 family members.  Table listing percentage amino acid identity, 
known signalling motifs in the cytoplasmic domain, cellular subset expression and 
proposed function of the members of the CD28 family of costimulatory receptors. 
PI3K = phosphatidyl inositol-3-kinase, PP2A = protein phosphatase 2A, SHP2 = SH2 
domain–containing protein tyrosine phosphatase–2, ITIM = immunoreceptor tyrosine-
based inhibitory motif, ITSM = immunoreceptor tyrosine-based switch motif.  
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3.3.2 CD28-Fc and B7-Fc Fusion Proteins as Potential LILRB4 Ligands 
SPR was used to detect LILRB4 - ligand interactions and conduct affinity analysis utilising a 
BIAcore 3000 SPR machine.  Two main methods were used to immobilise proteins of interest 
to CM5 sensor chips, either immobilisation to streptavidin-coated chips or to chips coated 
with the anti-human-IgG antibody, R10z8e9, for biotinylated or Fc-fusion proteins 
respectively.  Notably, both methods provided orientation of the immobilised ligand, and each 
has been used extensively to study immune receptor/ligand interactions.  For details of the 
SPR methodology used, see Chapter 2: Materials and Methods. 
 
Recombinant biotinylated LILRB4 ectodomain was produced as previously described (Garner 
et al. Prot Pur Exp 2006).  Recombinant biotinylated LILRA5 ectodomain was produced by S. 
Nicholls and used as an additional control.  Recombinant biotinylated HLA-A2 complex, 
containing β2m and a peptide derived from Wilms Tumour antigen 1 (WT1, peptide 
sequence: CYTWNQMNL) had been previously produced in the laboratory and was used as a 
negative control.  In addition one flow cell was left blank (streptavidin only). After activation 
of the CM5 chip with EDC/NHS and immobilisation of streptavidin to all four flow cell 
surfaces, recombinant proteins were injected and immobilisation levels matched as closely as 
possible.   
 
B7 and CD28 family proteins, in the form of commercially available Fc-fusion proteins – 
CTLA4, PD-1 and its ligands PD-L1 and PD-L2, and ICOS and its ligand ICOS-L – were 
then injected serially over all four flow cells to test for binding.  Fc-fusion proteins were all 
injected at 100 µg/ml in HBS-EP.  Results for the six test injections are shown in Figures 
3.13 – 3.15. 
(a) 
FC Streptavidin Ligand Level Total 
1 7835 Blank N/A 7835 
2 7719 LILRB4 D1D2 2264 9983 
3 7308 LILRA5 D1D2 2399 9707 
4 7074 HLA-A2-WT1 2652 9726 
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Figure 3.13. Testing interaction of CTLA4-Fc fusion protein with LILRB4 by 
SPR. (a): Immobilisation levels in Resonance Units (RUs) for streptavidin and 
proteins under test. Total levels are also shown for each flow cell (FC). (b): CTLA4-Fc 
fusion protein (100 μg/ml) was injected over flow cells coated with LILRB4 (FC2, red 
line), LILRA5 (FC3, blue), HLA-A2 (FC4, green), and a blank flow cell (FC1, black).  
■ FC1 Blank 
■ FC2 LILRB4 
■ FC3 LILRA5 
■ FC4 HLA-A2 WT1 
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In Figure 3.13a, levels of immobilised streptavidin and proteins are listed for each flow cell 
and apply to Figures 3.13 – 3.15.  In Figure 3.13b, a SPR sensorgram trace is shown for the 
test injection of CTLA-4-Fc fusion protein over the LILRB4-coated flow cell (FC2) and over 
the control flow cells.  Time is plotted on the x-axis, where t= 0 is the start of the injection of 
the analyte.  The response (in arbitrary resonance units, RUs) is plotted on the y-axis. 
Although an increase in signal is seen after the initial spike post-injection, this increase is 
across all four flow cells.  If an interaction of a reasonable affinity was occurring between 
CTLA-4-Fc and immobilised LILRB4, one would expect to see a higher signal over FC2 than 
over the control surfaces. 
 
In a similar fashion to the data shown in Figure 3.13, Figure 3.14 shows sensorgram traces 
for the injection of PD-1 and its ligands over LILRB4 and control surfaces, and Figure 3.15 
shows sensorgram traces for the injection of ICOS and its ligand ICOS-L over the same 
sensor chip surface.  As is the case with CTLA-4-Fc, these proteins showed no evidence of an 
interaction with LILRB4.  
 
These Fc-fusion reagents are dimeric and would therefore be expected to have an avidity 
which would allow the detection of binding as visualised by an increase in the response over 
surface coated with LILRB4 relative to the control surfaces.  Assuming a monomeric affinity 
one could also expect a slow off rate as both molecules in the dimer would need to disengage 
from the ligand for the dimer to unbind.  The total molecular mass of the Fc reagent is 
considerable, and the immobilisation level for LILRB4 is relatively high and also orientated 
with the LILRB4 molecule projecting from the streptavidin surface, therefore I would expect 
to observe a sizeable response and a slow off rate if any of the Fc reagents were a genuine 
ligand for LILRB4. 
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Figure 3.14 (continued and legend overleaf) 
■ FC1 Blank 
■ FC2 LILRB4 
■ FC3 LILRA5 
■ FC4 HLA-A2 WT1 
■ FC1 Blank 
■ FC2 LILRB4 
■ FC3 LILRA5 
■ FC4 HLA-A2 WT1 
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Figure 3.14. Testing interaction of PD-1 and ligands with LILRB4 by SPR. (a): 
PD1-Fc fusion protein was injected over flow cells coated with LILRB4 (FC2, red 
line), LILRA5 (FC3, blue), HLA-A2 (FC4, green), and a blank flow cell (FC1, black). 
(b): PD-L1-Fc test injection. (c): PD-L2-Fc test injection. Immobilisation levels were 
the same as in Figure 3.13a. All Fc fusion proteins were at a concentration of 100 
μg/ml. 
■ FC1 Blank 
■ FC2 LILRB4 
■ FC3 LILRA5 
■ FC4 HLA-A2 WT1 
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Figure 3.15. Testing interaction of ICOS and ICOS-L with LILRB4 by SPR. (a): 
ICOS-Fc test injection.  (b): ICOS-L-Fc test injection. Flow cells were coated with 
LILRB4 (FC2, red line), LILRA5 (FC3, blue), HLA-A2 (FC4, green), and one flow cell 
was left blank (FC1, black).  Immobilisation levels were the same as in Figure 3.13a. 
The Fc fusion proteins were at a concentration of 100 μg/ml. 
■ FC1 Blank 
■ FC2 LILRB4 
■ FC3 LILRA5 
■ FC4 HLA-A2 WT1 
■ FC1 Blank 
■ FC2 LILRB4 
■ FC3 LILRA5 
■ FC4 HLA-A2 WT1 
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None of the B7/CD28 family member potential ligands tested bound to the LILRB4 coated 
flow cell with any convincing signals over the background.  Control surfaces (Blank, HLA-
A2 and LILRA5) gave practically equivalent signals. PD-1-Fc, PD-L1-Fc and ICOS-Fc 
showed some degree of non-specific sticking across all flow cells, as evidenced by a failure of 
the signal to return to pre-injection levels at the end of the injection, but in each case the 
effects were minimal (< 20 RUs).  This sticking could be due to the presence of a low 
concentration of aggregated protein (although all samples were centrifuged for ten minutes at 
13,000 RPM in a bench top centrifuge prior to use).  CTLA-4-Fc injection also resulted in a 
small artefactual buffer signal at the start of the injection.  Regardless of these experimental 
issues, there was no evidence for binding to LILRB4 (or indeed LILRA5) by any of the B7 
family members tested. 
 
3.3.3 Investigation of LAIR-1 as a Potential LILRB4 Ligand 
An alternative to the hypothesis that the staining pattern of LILRB4 tetramer represented a 
composite pattern resulting from interactions with multiple ligands was the possibility that it 
represented interactions with a single, widely expressed ligand. One such candidate ligand 
was Leukocyte-Associated Ig-like Receptor-1, LAIR-1.  LAIR-1 is a widely expressed 
inhibitory receptor that is known to bind collagen on the surface of target cells (Meyaard et al. 
Immunity 1997, Meyaard et al. JI 1999, Lebbink et al. JEM 2006).  This possibility was 
highlighted to me by Professor Neil Barclay and Dr Lei Jiang (based at the Sir William Dunn 
School of Pathology, University of Oxford), who proposed a direct interaction between 
LILRB4 and LAIR-1. However, analysis of their preliminary results did not provide 
particularly strong evidence for the interaction, as the response was very low (tens of RUs) 
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and immobilisation levels were not adequately controlled, with differing levels of protein 
immobilised on each flow cell (data not shown).   
 
To test the possibility that LILRB4 did recognise LAIR-1, I was provided (by Professor 
Barclay and Dr. Jiang) with recombinant human LAIR-1 fusion protein (hLAIR-1 ectodomain 
fused to Rat CD4 domains 3 and 4 as a linker, incorporating a C-terminal biotinylation tag) 
either biotinylated for streptavidin immobilisation, or non-biotinylated for antibody-mediated 
coupling to the sensor chip via OX68 (mouse anti-Rat-CD4-domains 3 and 4 antibody).  The 
aim was to attempt to reproduce the initial results but instead utilising our recombinant 
soluble LILRB4 ectodomain (the Oxford group used LILRB4 - Rat CD4d3d4 chimeric 
protein) at higher concentrations and with adequately controlled immobilisation levels for 
controls (P. Anton van der Merwe, ‘Protein-ligand Interactions: Hydrodynamics and 
Calorimetry.  Practical Approach series’.  Chapter 6: Surface Plasmon Resonance.  Oxford 
University Press, 2001). 
 
The results for this experiment are shown in Figure 3.16.  Streptavidin immobilisation was 
conducted by standard amine-coupling as previously described and then test proteins – HLA-
A2-WT11 and hLAIR-1-CD4d3d4 at two immobilisation levels – were injected into separate 
flow cells.  Immobilisation levels for this experiment are listed in Figure 3.16a.  LILRB4 
(either D1D2 or D1 domain) was injected over the four flow cells to assess binding.  
 
As can be seen from the sensorgrams in Figures 3.16b-d, injection of LILRB4 over 
immobilised LAIR-1 provided no evidence for specific binding, even at the high 
concentration of LILRB4 attainable in Na citrate buffer.  As expected buffer signals from this 
analyte were higher and there was some evidence for sticking of analyte aggregates to  
(a) 
FC Streptavidin Ligand Level Total 
1 3574 Blank N/A 3574 
2 3423 HLA-A2-WT1 1771 5194 
3 3326 hLAIR1-CD4d3d4 1878 5204 
4 3303 hLAIR1-CD4d3d4 4125 7428 
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Figure 3.16 (continued and legend overleaf) 
■ FC1 Blank 
■ FC2 HLA-A2 WT1 
■ FC3 hLAIR1 1878 RUs 
■ FC4 hLAIR1 4125 RUs 
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Figure 3.16. Testing interaction of human LAIR-1 with LILRB4 by SPR. (a): 
Immobilisation levels in Resonance units (RUs) for streptavidin and proteins under 
test.   Flow cells were coated with HLA-A2 (FC2, red line), two different levels of 
hLAIR-1 (FC3, blue and FC4, green), and one flow cell was left blank (FC1, black). 
(b): Test injection of LILRB4 D1D2 at 307 μM in HBS-EP buffer. (c): Test injection of 
LILRB4 D1D2 at 506 μM in Na citrate buffer. (d): Test injection of LILRB4 D1 at 746 
μM in Na citrate buffer.    
 
■ FC1 Blank 
■ FC2 HLA-A2 WT1 
■ FC3 hLAIR1 1878 RUs 
■ FC4 hLAIR1 4125 RUs 
■ FC1 Blank 
■ FC2 HLA-A2 WT1 
■ FC3 hLAIR1 187  RUs 
■ FC4 hLAIR1 4125 RUs 
LILRB4 D1D2 in Na Citrate 
Test Injection 
LILRB4 D1 in HBS 
Test Injection 
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surfaces as evidenced by the slow return to pre-injection levels of response at the end of the 
injection.  The single distal domain of LILRB4 (LILRB4 D1, produced as described in 
Chapter 4) also gave no specific binding to hLAIR-1 (Figure 3.16d).  In each case, signals 
across the hLAIR-1-coated flow cells were actually lower than across control flow cells 
(Streptavidin-coated alone and also streptavidin-coupled HLA-A2). Although I cannot 
exclude the possibility of an extremely weak interaction with LAIR-1, these data provide no 
evidence of interaction. One noticeable feature of all three experiments was that LILRB4 
injection led to a somewhat greater response over FC3 than FC4, even though FC4 had 
substantially more LAIR-1 immobilised. However, it is possible to rationalise the difference 
in signal between FC3 and FC4 in terms of the total level of protein immobilised on each flow 
cell, as, in the absence of differential binding of the analyte, analyte injections over flow cells 
with greater levels of immobilised protein are known to yield marginally lower response 
signals than over those with less protein immobilised, due to greater proximity of analyte to 
the sensor surface (P. Anton van der Merwe, ‘Protein-ligand Interactions: Hydrodynamics and 
Calorimetry.  Practical Approach series’.  Chapter 6: Surface Plasmon Resonance.  Oxford 
University Press, 2001).  Such differences would be expected to be overcome in the presence 
of a bone fide interaction, with FC4 yielding substantially higher responses.  The fact this was 
not observed provided further indication that no interaction is evident. Furthermore, the 
control flow cell (FC2, HLA-A2) is very well controlled in terms of total protein 
immobilisation level when compared to the test flow cell (FC3, hLAIR-1) – 5194 RUs cf. 
5204 RUs, however in each case, signals over FC2 are marginally higher than FC3, again 
indicative  of lack of interaction at these concentrations of LILRB4.  
 
To exclude the possibility that streptavidin-biotin immobilisation of LAIR-1 prevented 
interaction with LILRB4, I repeated this experiment using an alternative immobilisation 
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method.  For this alternative method, the mouse anti-Rat-CD4-domains 3 and 4-antibody, 
OX68, was amine-coupled to a fresh sensor chip and used to coat a single flow cell (FC2) 
with hLAIR-1-CD4d3d4.  As a negative control, OX68 antibody alone was coupled to FC1.  
The rationale for this experiment was that the increased distance provided by the OX68 
antibody between the surface and the hLAIR-1 domain might reduce any steric hindrance that 
could occur by direct streptavidin coupling of biotinylated hLAIR-1-CD4d3d4 to the surface.  
SPR sensorgram traces for the three test injections are shown in Figure 3.17, with 
immobilisation levels for these experiments listed in Figure 3.17a. As for the previous 
experiment, the analytes tested were LILRB4 D1D2 in HBS-EP buffer, LILRB4 D1D2 at 
higher concentration in Na Citrate buffer, and LILRB4 D1 in Na Citrate buffer. 
 
Signals across the hLAIR-1-OX68 coated surface were slightly but consistently lower than 
across the control surface (OX68 antibody alone), consistent with the higher level of 
immobilised protein.  Although test and control surfaces would ideally have been matched for 
total protein, this experiment provides no evidence for LILRB4/LAIR-1 interaction, 
confirming the results of previous experiments using biotinylated hLAIR-1 immobilised via 
streptavidin. 
  
3.3.4 Investigating Potential Homotypic Interaction of LILRB4 
Additional communications from Dr. Jiang suggested a weak homotypic interaction between 
LILRB4 in solution and immobilised LILRB4 (albeit chimeric LILRB4-CD4d3d4).  To test 
this a third experiment was conducted, involving immobilisation of biotinylated LILRB4 
D1D2 and control HLA-A2 WT1 onto separate streptavidin-coated flow cells. In addition, 
one flow cell was left blank as an extra negative control, and a final flow cell was coated with 
hLAIR-1, providing an additional opportunity to confirm previous results that failed to detect  
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Figure 3.17 (continued and legend overleaf) 
FC OX68 Ab. Ligand Level Total 
1 6846 Blank N/A 6846 
2 6799 hLAIR1-CD4d3d4 1360 8159 
■ FC1 OX68 Control 
■ FC2 OX68 + hLAIR1 
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Figure 3.17. Testing interaction of LILRB4 with hLAIR-1 immobilised via OX68 
antibody. (a): Immobilisation levels in Resonance units (RUs) for OX68 and hLAIR-
1. Flow cells were coated with OX68 alone as a control (FC1, black line) or OX68 
plus hLAIR-1 (FC2, red line). (b): Test injection of LILRB4 D1D2 at 307 μM in HBS-
EP buffer. (c): Test injection of LILRB4 D1D2 at 506 μM in Na citrate buffer. (d): Test 
injection of LILRB4 D1 at 746 μM in HBS-EP buffer. 
 
■ FC1 OX68 Control 
■ FC2 OX68 + hLAIR1 
 
■ FC1 OX68 Contr l 
■ FC2 OX68 + hLAIR1 
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LILRB4/LAIR-1 interaction.  The results are shown in Figure 3.18.  LILRB4 D1D2 at a 
concentration of 179 μM in HBS-EP buffer was injected over all four flow cells at a flow rate 
of 10 µl/min.  The injection was curtailed to 5 μl (30 s contact time) to minimise aggregation.  
As a positive control for binding, LILRB1 D1D2 was also injected over all four flow cells at a 
concentration of 135 μM in HBS-EP buffer.   
 
As in the previous experiments, there was no evidence for LILRB4 D1D2 binding to hLAIR-
1.  However, there was some evidence for homotypic adhesion between soluble LILRB4 and 
immobilised LILRB4, with a specific binding response approximately 400 RUs above the 
streptavidin blank control (Figure 3.18b).  However, these results should be interpreted 
cautiously since there were two indications of non-specific binding.  Firstly there was a weak 
signal across the HLA-A2 control surface (FC2), and secondly, the relatively slow association 
and dissociation phases were suggestive of aggregate binding. Consistent with this, LILRB4 
shows a high propensity to aggregate in solution, particularly in a non-optimised buffer 
system (Garner et al. Prot Exp Pur 2006 and unpublished observations).  In comparison, 
injection of LILRB1 D1D2 resulted in a very clear specific binding response of 
approximately 600 RUs across the HLA-A2 coated flow cell, and a relatively fast association 
and dissociation phase (Figure 3.18c). 
 
Although it was uncertain if this interaction was physiologically relevant, the experimental 
system theoretically allowed an affinity of the postulated LILRB4/LILRB4 homotypic 
interaction to be determined by equilibrium affinity analysis.  Assuming that the 
LILRB4/LILRB4 interaction obeyed simple Michaelis-Menten kinetics and the Langmuir 
(1:1 stoichiometry) binding model, the dissociation constant, Kd, could be calculated by non 
linear curve fitting to the saturation binding plot.  The Michaelis-Menten equation is used to 
(a) 
FC Streptavidin Ligand Level Total 
1 2083 Blank N/A 2083 
2 1872 HLA-A2-WT1 1688 3560 
3 1660 LILRB4 D1D2 1795 3455 
4 1524 hLAIR1-CD4d3d4 1957 3481 
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Figure 3.18 (continued and legend overleaf) 
■ FC1 Blank 
■ FC2 HLA-A2 WT1
■ FC3 LILRB4 
■ FC4 hLAIR1 
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Figure 3.18.  Investigating potential LILRB4 homotypic interaction by SPR. (a): 
Immobilisation levels in Resonance units (RUs) for streptavidin plus flow cells coated 
with HLA-A2 (FC2, red line), LILRB4 (FC3, blue), hLAIR1-CD4d3d4 (FC4, green), 
and a blank flow cell (FC1, black). (b) Test injection of LILRB4 D1D2 at 179 μM in 
HBS-EP buffer. (c): Test injection of LILRB1 D1D2 at 135 μM in HBS-EP buffer 
showing positive control binding to HLA-A2. 
■ FC1 Blank 
■ FC2 HLA-A2 WT1 
■ FC3 LILRB4 
■ FC4 hLAIR1 
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define a hyperbola which predicts the maximum binding response (P1) and the affinity of the 
interaction (P2, equivalent to the concentration of analyte at half maximal binding).  In 
principle, Scatchard analysis could also be carried out; a plot of Bound vs. Bound/Free allows 
calculation of a line of best fit, the negative reciprocal of the slope of which is equal to the 
dissociation constant of the interaction (slope = -1/Kd). 
 
An experiment was conducted to measure the Kd for LILRB4/LILRB4 binding.  Amine-
coupled streptavidin was used to coat flow cells with biotinylated HLA-A2 WT1, LILRB4 
D1D2, or hLAIR-1, and LILRB4 was subsequently injected over all four surfaces.  The 
results are shown in Figure 3.19; Figure 3.19a tabulates the immobilisation levels and the 
serial injections of LILRB4 are shown in Figure 3.19b.  The equilibrium binding response 
curve is shown in Figure 3.19c.  From this curve it can be seen that there is a failure to reach 
saturation of binding as the concentration of LILRB4 is increased.  Scatchard analysis of the 
results, as shown in Figure 3.19d, also proved impossible due to the high number of data 
points that would have to be discarded in order to draw a line of best fit.  I was therefore 
unable to calculate an affinity for the proposed LILRB4/LILRB4 homotypic interaction. 
 
This failure may be due to the assumption of an incorrect binding model.  The proposed 
analysis discussed above assumes that the Langmuir 1:1 binding model is obeyed for the 
molecule analysed in solution binding to the immobilised ligand; however, as the hypothesis 
tested here is that LILRB4 interacts with itself, it follows that some of the LILRB4 in solution 
will interact with other LILRB4 molecules in solution, preventing binding to surface-
immobilised LILRB4.  This effect would lead to a relative decrease in the propensity for 
LILRB4 in solution to interact with immobilised LILRB4 as the concentration of LILRB4 in 
solution increases, which could conceivably prevent saturation of the response as a function 
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of increasing LILRB4 concentration, a hypothesis supported by the result shown in Figure 
3.19c. 
(a) 
FC Streptavidin Ligand Level Total 
1 2587 Blank N/A 2587 
2 2248 HLA-A2-WT1 2764 5012 
3 2020 LILRB4 D1D2 3053 5073 
4 1874 hLAIR1-CD4d3d4 2861 4735 
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Figure 3.19 (continued and legend overleaf) 
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Figure 3.19. Equilibrium affinity analysis of LILRB4 homotypic interaction.  (a): 
Immobilisation levels in Resonance units (RUs) for each flow cell (FC). (b): 
Equilibrium affinity analysis. LILRB4 D1D2 was injected serially over all four flow cells 
in HBS-EP at a concentration of 364 µM and nine 2-fold serial dilutions thereof. For 
each injection, once the association phase was complete, equilibrium responses 
were recorded. (c): Saturation binding plot of the soluble LILRB4 analyte 
concentration plotted against the specific response (i.e. with the response from the 
control blank flow cell subtracted) from the LILRB4 coated flow cell. A non-linear 
curve fit is shown. (d): Attempted Scatchard analysis of LILRB4 - LILRB4 affinity 
data.  
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3.4 Chapter Summary and Discussion 
In this chapter, I have presented data to show the cell surface expression pattern of the 
LILRB4 ligand in freshly isolated human PBMCs.  The expression pattern of the putative 
ligand(s) appears to be relatively broad, as it is present on a variety of cell types, including T 
cells, B cells and monocytes, with low expression on T cells, intermediate expression on B 
cells and high expression on monocytes.  Expression on both CD4
+
 and CD8
+
 T cells can be 
upregulated upon polyclonal activation with the mitogen, PHA.  This potentially composite 
staining pattern led me to investigate members of the B7 and CD28 family of costimulatory 
receptors as potential ligands for LILRB4, utilising recombinant LILRB4 and commercially 
available B7 and CD28 family Fc fusion proteins in a SPR based assay.  I focussed upon 
those members of the B7:CD28 family that are postulated to have critical roles in tolerance 
and negative regulation of immune response, namely CTLA-4, PD-1 and its ligands PD-L1 
and PD-L2, and the inducible costimulator ICOS and its ligand ICOS-L. 
 
CTLA-4 provides inhibitory signals to T cells, curtailing immune responses and limiting 
autoimmune damage (Brunet et al. Nature 1987, Waterhouse et al. Science 1995).  CTLA-4 is 
thought to function in tolerance induction by Tregs (Wing et al. Science 2008), and thus 
might be proposed to be a candidate for engagement by LILRB4 and subsequent delivery of 
the bidirectional inhibitory signal as described earlier (Kim-Schulze et al. JI 2006).  CTLA-4 
is primarily expressed intracellularly and its surface expression is weak and restricted to the 
immunological synapse upon T cell activation (Egen et al. Immunity 2002), which is 
compatible with the upregulation of LILRB4 tetramer staining to T cells upon activation by 
PHA, as described here in Section 3.2.3.  However, CTLA-4 expression is restricted to T 
cells, which does not fit with the LILRB4 tetramer staining of monocytes and B cells 
described in Section 3.2.2, unless LILRB4 is capable of recognising more than one ligand.  
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This hypothesis would explain the widespread distribution of staining to multiple PBMC 
subsets i.e. a composite staining pattern based upon binding to multiple proteins that interact 
with LILRB4.   
 
PD-1 is more broadly expressed than CTLA-4.  It is upregulated upon B and T cell activation 
and acts to inhibit signalling downstream of antigen receptor ligation, and its expression on 
monocytes and DCs could be postulated to contribute to tolerance through the regulation of 
myelomonocytic maturation and/or antigen presentation function (Agata et al. Int Immun 
1996, and for review see Keir Ann Rev Immun 2008). 
 
PD-1 binds to its ligands, PD-L1 and PD-L2.  PD-L1 is expressed on non-haematopoietic 
cells and can be upregulated on T cells, B cells and myeloid cells by interferon treatment.  
PD-L2 expression can be induced on APCs such as mast cells, macrophages and DCs.  There 
is evidence for bidirectional signalling through PD-1/PD-L interactions, with potentially 
tolerogenic outcomes (Kuipers et al. EJI 2006, Dong et al. JCI 2003, Nguyen et al. JEM 
2002), which is suggestive of the functional effects of LILRB4 engagement (Chang et al. Nat 
Immunol 2002, Kim-Schulze et al. JI 2006), and the extensive expression of the PD-1 family 
members on multiple PBMC subsets is in keeping with the pattern of LILRB4 tetramer 
staining (see Section 3.2.2), although it is worth noting that the hypothesis that PD-L1 is a 
ligand for LILRB4 was not supported by my cell-line staining data, which included some 
non-haematopoietic cells (Section 3.2.6 and see Table 3.2). 
 
 
ICOS, in a similar fashion to CTLA-4 and PD-1, is upregulated on T cells after activation 
(Coyle et al. Immunity 2000).  ICOS is also expressed on activated NK cells.  ICOSL is 
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expressed in many tissues and cell types (endothelial/ epithelial cells, B cells, DCs, 
macrophages, some T cells) and  ICOSL engagement has been proposed to be involved in 
tolerance induction through IL-10 mediated mechanisms (Tuettenberg et al. JI 2009).  These 
reported findings are compatible with ICOSL being a potential ligand for LILRB4 and are 
also supported by my cell staining experiments. 
 
The expression patterns and functional roles of these receptors suggested them as potential 
LILRB4 ligands i.e. widely expressed, upregulated upon activation and involved in the 
generation of T cells with suppressive phenotype upon interaction with tolerogenic DCs or 
regulatory T cells.  However, there was no evidence from my SPR binding studies for any 
interaction of these receptors with LILRB4, utilising commercially available Fc-fusion 
proteins.  It is possible that there could be an interaction of low affinity below the threshold 
detectable using this methodology, however I consider it unlikely that such an interaction 
would be functionally relevant unless the avidity of the interaction is substantially increased 
by multimerisation of either LILRB4 or the target ligand (possibly by sequestration within 
lipid microdomains or within the immunological synapse, thus increasing the local 
concentrations of the receptors).  Nevertheless these data are useful in provisionally 
eliminating LILRB4 binding partners.  Although I did not test any such interactions, it could 
be possible that LILRB4 might provide tolerogenic signals to T cells by disrupting binding to 
a positively costimulatory ligand or receptor (e.g. CD28, B7-1, B7-2). 
 
I also attempted to generate data in support of a hypothesis that LAIR-1 binds to LILRB4, as 
proposed by Neil Barclay’s group.  LAIR-1 was first identified by Meyaard et al. in 1997 as a 
cell-surface Ig-family receptor with two cytoplasmic ITIM motifs widely expressed on 
PBMCs, including T cells, B cells, monocytes and NK cells.  The LAIR-1 gene is present 
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within the LRC and shows close homology with the LILRs (32 %).  Using a redirected killing 
assay, this group showed that LAIR-1 cross-linking on human NK cells inhibits target cell 
lysis by resting and activated NK cells and also subsequently showed inhibitory effects upon 
cytotoxic T cells and B cells (Meyaard et al. Immunity 1997, Meyaard et al. JI 1999, van der 
Vuurst de Vries EJI 1999).  LAIR-1 is thought to have a constitutive negative signalling role 
through association with SHP-1 (Sathish et al. JI 2001).  There is evidence that surface 
expression of LAIR-1 is upregulated upon TCR ligation (Maasho et al. Mol Immun 2005). 
 
My data shows no evidence of an interaction between LILRB4 and LAIR-1 by SPR analysis, 
even at high concentrations of LILRB4 and utilising soluble LILRB4 ectodomain rather than 
a LILRB4-Rat CD4 fusion protein, and also utilising two different immobilisation methods 
(antibody coupling and streptavidin-biotin immobilisation).  The initial data from the Barclay 
group were unconvincing and also poorly controlled in terms of protein immobilisation levels 
between control and experimental flow cells, and during my experiments I ensured protein 
immobilisation levels were more closely matched to avoid experimental artefacts.  Despite 
this there was no suggestion from my data that LILRB4 binds to LAIR-1. 
 
Although LAIR-1 could be considered to be a good candidate ligand on the basis of its 
functional role in dampening immune responses and also its widespread expression pattern, it 
is worth noting that flow cytometric analysis of the level of expression on PBMCs first 
presented by the Meyaard group (Meyaard et al. Immunity 1997) does not match with the 
pattern of staining evidenced by the LILRB4 tetramer as used in my flow cytometry studies.  
In particular, this group showed much higher expression levels across various PBMC subsets 
with a distinct population staining positive by flow cytometry analysis as opposed to the more 
diffuse staining patterns that I detected (although it is worth considering that they detected 
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LAIR-1 expression using a monoclonal antibody, which would be expected to have a much 
higher binding affinity than a tetrameric ligand).  In addition, LAIR-1 is highly expressed 
upon NK cells, whereas I found no evidence for LILRB4 tetramer binding to NK cells. 
 
At the time of my experimentation the LILRB4/LAIR-1 data provided by Barclay et al., was 
unpublished but they have since published that LILRB4 interacts with both collagen and 
LAIR-1, albeit with a very low affinity (Jiang and Barclay, EJI 2009).  I would dispute the 
veracity of this conclusion based upon a number of points.  Firstly, the authors suggest that 
the mouse genome contains a homologue to LILRB4, mLilrb4, which they use in a number of 
their assays.  Katz has published a review specifying mLilrb4 (also known as Gp49B1) as 
being the orthologous receptor to human LILRB4 (LILRB4 to use the alternative 
nomenclature).  However, the amino acid identity between Gp49B1 and LILRB4 is relatively 
low (~30 %) and this publication fails to cite a single functional paper discussing human 
LILRB4, suggesting that this assumption may be controversial (Katz Immun Rev 2007).   
 
Jiang and Barclay detect an interaction between collagen or the collagen related peptide, 
(GPO)10 and soluble monomeric mLilrb4 fused to rat CD4 domains 3 and 4, with a Kd of 39 
or 33 μM respectively.  This affinity is low but not outside the range common for Group I 
LILRs for MHC Class I.  Full sensorgram traces for this experiment are not shown and so 
non-specific effects cannot be ruled out.  Further experiments utilising multivalent mLilrb4-
coated beads were used as evidence for an interaction between LAIR-1 and LILRB4, and an 
experiment utilising monomeric soluble LAIR-1-rCD4d3d4 flowing over immobilised 
LILRB4-rCD4d3d4 detected only a very weak interaction with a calculated Kd of >200 μM.  
The authors specify in the publication that this interaction is at the limits of detection for this 
methodology.  I would suggest that the use of multivalent beads in these assays might lead to 
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spurious results due to an innate property of the beads, a possibility that the authors 
themselves discuss.  Artefacts during SPR assays are a common problem and not easily 
controlled for (van der Merwe and Barclay Curr Opin Immun 1996, Karlsson and Fält J 
Immun Methods 1997, P. Anton van der Merwe, ‘Protein-ligand Interactions: Hydrodynamics 
and Calorimetry.  Practical Approach series’.  Chapter 6: Surface Plasmon Resonance.  
Oxford University Press, 2001). 
 
LAIR-1 engagement as conducted in the previously-mentioned functional studies (see 
Meyaard et al. Immunity 1997), whilst being inhibitory for T cell activation, does not seem to 
recapitulate the generation of regulatory T cells as shown by Manavalan et al. (Manavalan et 
al. Trans Immun 2003), although the in vitro stimulations used are different so an argument 
could be made that these results are not directly comparable.  On the basis of the above points 
– the different expression patterns, kinetics and functional outcomes of LAIR-1 engagement, 
plus the lack of evidence for direct binding between LILRB4 and LAIR-1 – I think it unlikely 
that LAIR-1 is a true ligand for LILRB4.  Collagen also seems unlikely as a ligand, although 
its widespread expression in the tissues would fit with a general role for tolerance to self, 
particularly upon tissue damage during wounding or infection.  It is hard to envisage how 
engagement of collagen would lead to tolerogenic signalling into activated T cells and thus I 
find it highly unlikely that collagen is the counterstructure for LILRB4 which is upregulated 
upon T cell activation. 
 
The paper of Jiang and Barclay also suggests that LILRB4 may interact with itself in a 
homotypic fashion, with an estimated Kd greater than 200 μM (Jiang and Barclay EJI 2009).  
This value is relatively high compared to many immune receptor/ligand interactions, which 
typically range between 1-100 µM, and is indicative of a very weak interaction. For 
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comparison within the LILR family, calculated affinities for LILRB1 and LILRB2 for MHC 
Class I are of the order of 10 - 30 µM (Chapman et al. Immunity 2000, Shiroishi et al. PNAS 
2003); these fall within the 1 – 50 µM range of calculated TCR-pMHC interaction affinities 
but are significantly weaker than antibody – antigen interactions, which are usually of the 
order of nM (Davis et al. Nat Immunol 2003).   
 
I investigated the possibility of homotypic LILRB4 interaction by SPR analysis, utilising 
soluble recombinant LILRB4 ectodomain flowed over streptavidin-immobilized biotinylated 
LILRB4bt.  My data do provide some evidence for a homotypic LILRB4/LILRB4 interaction, 
although the calculated equilibrium affinity was unfeasibly low and saturation of binding was 
incomplete even at very high concentrations of LILRB4, suggesting that this interaction might 
be non-specific and possibly due to aggregation of the receptor rather than true binding (P. 
Anton van der Merwe, ‘Protein-ligand Interactions: Hydrodynamics and Calorimetry.  
Practical Approach series’.  Chapter 6: Surface Plasmon Resonance.  Oxford University 
Press, 2001).  Soluble recombinant LILRB4 has a propensity to aggregate at high 
concentrations, especially under non-optimised buffer conditions (e.g. in HBS-EP) and thus I 
would dispute whether this interaction is truly physiological.  Although this interaction could 
explain binding of LILRB4 tetramer to monocytes, LILRB4 is not expressed on T cells or B 
cells but these cell types do stain with the LILRB4 tetramer.  This fact is consistent with the 
hypothesis that LILRB4 could bind more than one ligand but strongly suggests that LILRB4 
homotypic interaction is not responsible for the tolerogenic signalling into activated T cells. 
 
While my studies leave the identity of the physiological ligand or ligands of LILRB4 
unresolved, they do provide a putative ligand expression pattern on freshly-isolated human 
PBMC against which any candidate ligand can be compared.  They also suggest that the 
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CD28 and B7 family receptors CTLA-4, PD-1, PD-L1, PD-L2, ICOS and ICOSL, and the 
IgSF receptor LAIR-1, whilst in principle appear to be attractive candidate ligands for 
LILRB4, do not seem to interact with the LILRB4 receptor.  This evidence suggests that 
LILRB4 effects on tolerance are likely to be mediated via interaction with other as yet 
undefined receptor or receptors. 
 
Potential future approaches to ligand identification for LILRB4 are discussed in Chapter 6.  In 
the next chapter, I will discuss investigations into the structure of LILRB4 using X-ray 
crystallographic methods.   
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CHAPTER 4 - CRYSTALLOGRAPHIC STUDIES OF LILRB4 
4.1 Introduction 
As discussed in Chapter 1, Group I LILRs have been extensively studied both functionally 
and structurally and their initial identification and characterisation suggested their 
involvement in the modulation of myelomonocytic cell functions through their engagement 
with MHC Class I.  The structures of LILRB1, LILRB2, LILRA5 and LILRA2 have been 
elucidated by X-ray crystallography and comprehensively analysed (Chapman et al. Immunity 
2000, Willcox et al. BMC Struc Bio 2002, Willcox et al. Nat Immunol 2003, Shiroishi et al. 
JBC 2006, Chen et al. JMB 2009).  However, the molecular basis of ligand recognition by 
Group II LILRs remains poorly understood.  
 
Numerous reports have highlighted the Group II receptor LILRB4, which is expressed on 
dendritic cells, monocytes and macrophages (Cella et al. JEM 1997), as playing an important 
role in the regulation of immune tolerance (Chang et al. Nat Immunol 2002, and for reviews 
see Suciu-Foca and Cortesini Cell Immunol 2007, Vlad et al. Hum Immunol 2009).  In 
particular, T suppressor cells were found to induce the up-regulation of expression of LILRB4 
and LILRB2 on APCs rendering them tolerogenic to T cells.  In addition, recombinant 
LILRB4-Fc has also been shown to modulate T cell responses via induction of T helper cell 
anergy and differentiation of CD8
+
 T suppressor cells (Kim-Schulze et al. JI 2006), and 
soluble LILRB4 has been detected in the blood of patients with cancer and can promote 
tolerance of tumour grafts in a humanized mouse model (Kim-Schulze et al. JI 2006, Suciu-
Foca JI 2007).  In terms of functional studies LILRB4 is one of the most studied receptors 
within the LILR family, second only to LILRB1. 
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Despite numerous publications, the molecular basis of such effects is unclear, since in contrast 
to LILRB1, both the ligands and structure of LILRB4 have remained elusive. Interestingly, 
LILRB4 is somewhat unusual since whereas most family members contain four Ig-like 
domains in their extracellular region (designated D1, D2, D3 and D4), LILRB4 is one of two 
members that is constitutively expressed as two Ig-like domains (the other one is the closely 
related activating receptor LILRA5 (Borges et al. Blood 2003)).  In addition, a previous study 
found that LILRB4 behaves as an “outlier” in family phylogenetic analysis (Borges et al. JI 
1997, and see below).  These findings suggest that structural analysis of LILRB4 could 
provide some insight into its function and ligand recognition properties.  
 
In order to generate structural data for LILRB4, I carried out recombinant expression of its 
complete extracellular domain with the aim of conducting X-ray crystallographic analysis of 
the receptor.  Due to the refractory nature of the LILRB4 D1D2 protein in crystallisation 
trials, I ultimately solved and analysed a partial structure of the D1 membrane distal domain 
matching the native sequence of LILRB4 in this region. In addition, in a collaboration with 
the group of Professor George Gao (Institute of Microbiology, Chinese Academy of Sciences, 
Beijing, China), I carried out detailed structural analyses of a structure of a mutated form of 
the full LILRB4 ectodomain region that incorporated a non-native disulphide bond to aid in 
protein stabilisation and crystallisation. 
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4.2 Bioinformatic Analysis of LILRB4 
In order to shed light on the distinct structural features of LILRB4, we compared the sequence 
of the LILRB4 ectodomain with that of other LILR receptors.  Sequence alignments were 
conducted by using the ClustalW web resource (Larkin et al. Bioinformatics 2007). 
Phylogenetic trees constructed on the basis of comparison of D1D2 fragment sequences 
highlighted a delineation between Group I receptors and Group II receptors, consistent with 
previous structural results which initially proposed the Group I/II classification based on 
conservation (Group I) or lack of conservation (Group II) of amino acids involved in MHC 
Class I binding (Willcox et al. Nat Immun 2003).  Consistent with its poor conservation of 
residues involved in MHC Class I binding, comparison of the complete LILRB4 ectodomain 
sequence placed it close to other Group II receptors in terms of identity (Figure 4.1a).   
 
Alignment of the D1 domains of LILRB1 and LILRB2 gave a sequence identity of 75 %, with 
24 amino acid substitutions across the domain.  In comparison, the LILRB4 to LILRA5 D1 
alignment gives a sequence identity of 82 %, with 18 amino acid substitutions.  Therefore, 
since LILRA5 possesses the highest sequence identity for LILRB4 within the LILR family it 
was considered to be the best available search model for molecular replacement during 
subsequent structural studies (see below) and suitable for comparative analysis with LILRB4 
(Figure 4.1b).  Comparing the entire LILR family, the D1 domains of Group I LILRs (those 
LILRs with high sequence identity to LILRB1 residues that contact MHC Class I) are more 
conserved than the D1 domains of Group II LILRs (those LILRs thought unlikely to bind 
MHC Class I due to non-conservative substitutions at those amino acid positions, which 
includes LILRB4 and LILRA5) which might suggest that Group II LILRs could bind a 
diverse range of ligands. 
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LILRB4          GPLPKPTLWAEPGSVISWGNSVTIWCQGTLEAREYRLDKEESPAPWDRQNPLEPKNKARF 60 
LILRB1          GHLPKPTLWAEPGSVITQGSPVTLRCQGGQETQEYRLYREKKTAPWITRIPQELVKKGQF 60 
LILRB2          GTIPKPTLWAEPDSVITQGSPVTLSCQGSLEAQEYRLYREKKSASWITRIRPELVKNGQF 60 
LILRB3          GPFPKPTLWAEPGSVISWGSPVTIWCQGSLEAQEYQLDKEGSPEPLDRNNPLEPKNKARF 60 
LILRB5          GTLPKPTLWAEPASVIARGKPVTLWCQGPLETEEYRLDKEGLPWARKRQNPLEPGAKAKF 60 
LILRA1          GTLPKPTLWAEPGSVITQGSPVTLWCQGILETQEYRLYREKKTAPWITRIPQEIVKKGQF 60 
LILRA2          GHLPKPTLWAEPGSVIIQGSPVTLRCQGSLQAEEYHLYRENKSASWVRRI-QEPGKNGQF 59 
LILRA3          GPLPKPTLWAEPGSVITQGSPVTLRCQGSLETQEYHLYREKKTALWITRIPQELVKKGQF 60 
LILRA4          ENLPKPILWAEPGPVITWHNPVTIWCQGTLEAQGYRLDKEGNSMSRHILKTLESENKVKL 60 
LILRA5          GNLSKATLWAEPGSVISRGNSVTIRCQGTLEAQEYRLVKEGSPEPWDTQNPLEPKNKARF 60 
LILRA6          GPFPKPTLWAEPGSVISWGSPVTIWCQGSLEAQEYRLDKEGSPEPWDRNNPLEPKNKARF 60 
                  :.*. ***** .**   ..**: ***  ::. *:* :*  .         *   : :: 
 
LILRB4          SIPSMTEDYAGRYRCYYRS-PVGWSQPSDPLELVMTGAYSKPTLSALPSPLVTSGKSVTL 119 
LILRB1          PIPSITWEHAGRYRCYYGSDTAGRSESSDPLELVVTGAYIKPTLSAQPSPVVNSGGNVTL 120 
LILRB2          HIPSITWEHTGRYGCQYYS-RARWSELSDPLVLVMTGAYPKPTLSAQPSPVVTSGGRVTL 119 
LILRB3          SIPSMTQHHAGRYRCHYYS-SAGWSEPSDPLELVMTGAYSKPTLSALPSPVVASGGNMTL 119 
LILRB5          HIPSTVYDSAGRYRCYYET-PAGWSEPSDPLELVATGFYAEPTLLALPSPVVASGGNVTL 119 
LILRA1          PIPSITWEHTGRYRCFYGSHTAGWSEPSDPLELVVTGAYIKPTLSALPSPVVTSGGNVTL 120 
LILRA2          PIPSITWEHAGRYHCQYYSHNHS-SEYSDPLELVVTGAYSKPTLSALPSPVVTLGGNVTL 118 
LILRA3          PILSITWEHAGRYCCIYGSHTAGLSESSDPLELVVTGAYSKPTLSALPSPVVTSGGNVTI 120 
LILRA4          SIPSMMWEHAGRYHCYYQS-PAGWSEPSDPLELVVT-AYSRPTLSALPSPVVTSGVNVTL 118 
LILRA5          SIPSMTEHHAGRYRCYYYS-PAGWSEPSDPLELVVTGFYNKPTLSALPSPVVTSGENVTL 119 
LILRA6          SIPSITEHHAGRYRCHYYS-SAGWSEPSDALELVMTGAYSKPTLSALPSPVVASGGNMTL 119 
                 * *   . :*** * * :     *: **.* ** *  * .*** * ***:*  *  :*: 
 
LILRB4          LCQSRSPMDTFLLIKERAAHPLLHLRSEHG-AQQHQAEFPMSPVTSVHGGTYRCFSSHGF 178 
LILRB1          QCDSQVAFDGFILCKEGEDEHPQCLNSQPHARGSSRAIFSVGPVSPSRRWWYRCYAYDSN 180 
LILRB2          QCESQVAFGGFILCKEGEDEHPQCLNSQPHARGSSRAIFSVGPVSPNRRWSHRCYGYDLN 179 
LILRB3          RCGSQKRYHHFVLMKEGEHQLPRTLDSQQLHSGGFQALFPVGPVNPSHRWRFTCYYYYMN 179 
LILRB5          QCDTLDGLLTFVLVEE-EQKLPRTLYSQKLPKGPSQALFPVGPVTPSCRWRFRCYYYYRK 178 
LILRA1          HCVSQVAFGSFILCKEGEDEHPQCLNSQPRTHGWSRAIFSVGPVSPSRRWSYRCYAYDSN 180 
LILRA2          QCVSQVAFDGFILCKEGEDEHPQRLNSHSHARGWSWAIFSVGPVSPSRRWSYRCYAYDSN 178 
LILRA3          QCDSQVAFDGFILCKEGEDEHPQCLNSHSHARGSSRAIFSVGPVSPSRRWSYRCYGYDSR 180 
LILRA4          RCASRLGLGRFTLIEEGDHRLSWTLNSHQHNHGKFQALFPMGPLTFSNRGTFRCYGYENN 178 
LILRA5          QCGSRLRFDRFILTEEGDHKLSWTLDSQLTPSGQFQALFPVGPVTPSHRWMLRCYGSRRH 179 
LILRA6          QCGSQKGYHQFVLMKEGEHQLPRTLDSQQLHSGGFQALFPVGPVNPSHRWRFTCYYYYMN 179 
                 * :      * * :*   .    * *.        * *.:.*:.        *:      
 
LILRB4          SHYLLSHPSDPLELIVS 195 
LILRB1          SPYEWSLPSDLLELLVL 197 
LILRB2          SPYVWSSPSDLLELLVP 196 
LILRB3          TPRVWSHPSDPLEILP- 195 
LILRB5          NPQVWSNPSDLLEILVP 195 
LILRA1          SPHVWSLPSDLLELLVL 197 
LILRA2          SPYVWSLPSDLLELLVP 195 
LILRA3          APYVWSLPSDLLGLLVP 197 
LILRA4          TPYVWSEPSDPLQLLVS 195 
LILRA5          ILQVWSEPSDLLEIPV- 195 
LILRA6          TPRVWSHPSDPLEILP- 195 
                     * *** * :   
  
 
Figure 4.1. Phylogenetic analysis of Group I and Group II LILRs. (a): ClustalW 
alignment of LILR family member D1D2 domains.  Percentage identity of LILR family 
members with LILRB4 D1D2 is tabulated, and a phylogram of the alignment is 
depicted.  Red: small, hydrophobic, aromatic, not Y. Blue: acidic. Magenta: basic. 
Green: hydroxyl, amine, amide, basic. Conservation strength is indicated by * > : > .  
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LILRB4          GPLPKPTLWAEPGSVISWGNSVTIWCQGTLEAREYRLDKEESPAPWDRQNPLEPKNKARF 60 
LILRA5          GNLSKATLWAEPGSVISRGNSVTIRCQGTLEAQEYRLVKEGSPEPWDTQNPLEPKNKARF 60 
LILRB3          GPFPKPTLWAEPGSVISWGSPVTIWCQGSLEAQEYQLDKEGSPEPLDRNNPLEPKNKARF 60 
LILRA6          GPFPKPTLWAEPGSVISWGSPVTIWCQGSLEAQEYRLDKEGSPEPWDRNNPLEPKNKARF 60 
LILRB5          GTLPKPTLWAEPASVIARGKPVTLWCQGPLETEEYRLDKEGLPWARKRQNPLEPGAKAKF 60 
LILRB2          GTIPKPTLWAEPDSVITQGSPVTLSCQGSLEAQEYRLYREKKSASWITRIRPELVKNGQF 60 
LILRA2          GHLPKPTLWAEPGSVIIQGSPVTLRCQGSLQAEEYHLYRENKSASWVRRIQ-EPGKNGQF 59 
LILRB1          GHLPKPTLWAEPGSVITQGSPVTLRCQGGQETQEYRLYREKKTAPWITRIPQELVKKGQF 60 
LILRA3          GPLPKPTLWAEPGSVITQGSPVTLRCQGSLETQEYHLYREKKTALWITRIPQELVKKGQF 60 
LILRA1          GTLPKPTLWAEPGSVITQGSPVTLWCQGILETQEYRLYREKKTAPWITRIPQEIVKKGQF 60 
LILRA4          ENLPKPILWAEPGPVITWHNPVTIWCQGTLEAQGYRLDKEGNSMSRHILKTLESENKVKL 60 
                  :.*. ***** .**   ..**: ***  ::. *:* :*  .         *   : :: 
 
LILRB4          SIPSMTEDYAGRYRCYYRSPVG-WSQPSDPLELVMTGAY 98 
LILRA5          SIPSMTEHHAGRYRCYYYSPAG-WSEPSDPLELVVTGFY 98 
LILRB3          SIPSMTQHHAGRYRCHYYSSAG-WSEPSDPLELVMTGAY 98 
LILRA6          SIPSITEHHAGRYRCHYYSSAG-WSEPSDALELVMTGAY 98 
LILRB5          HIPSTVYDSAGRYRCYYETPAG-WSEPSDPLELVATGFY 98 
LILRB2          HIPSITWEHTGRYGCQYYSRAR-WSELSDPLVLVMTGAY 98 
LILRA2          PIPSITWEHAGRYHCQYYSHNH-SSEYSDPLELVVTGAY 97 
LILRB1          PIPSITWEHAGRYRCYYGSDTAGRSESSDPLELVVTGAY 99 
LILRA3          PILSITWEHAGRYCCIYGSHTAGLSESSDPLELVVTGAY 99 
LILRA1          PIPSITWEHTGRYRCFYGSHTAGWSEPSDPLELVVTGAY 99 
LILRA4          SIPSMMWEHAGRYHCYYQSPAG-WSEPSDPLELVVT-AY 97 
                 * *   . :*** * * :     *: **.* ** *  * 
 
 
 
 
 
 
 
Figure 4.1. Phylogenetic analysis of Group I and Group II LILRs, continued:  
(b): ClustalW alignment of LILR family member D1 domains, ordered by alignment 
output.  Percentage identity of LILR family members with LILRB4 D1 is tabulated, 
and a phylogram of the alignment is depicted.  Red: small, hydrophobic, aromatic, 
not Y. Blue: acidic. Magenta: basic. Green: hydroxyl, amine, amide, basic. Gray: 
others. Conservation strength is indicated by * > : > . 
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LILRA2          SKPTLSALPSPVVTLGGNVTLQCVSQVAFDGFILCKEGEDEHPQRLNSHSHARGWSWAIF 60 
LILRA3          SKPTLSALPSPVVTSGGNVTIQCDSQVAFDGFILCKEGEDEHPQCLNSHSHARGSSRAIF 60 
LILRB1          IKPTLSAQPSPVVNSGGNVTLQCDSQVAFDGFILCKEGEDEHPQCLNSQPHARGSSRAIF 60 
LILRB2          PKPTLSAQPSPVVTSGGRVTLQCESQVAFGGFILCKEGEDEHPQCLNSQPHARGSSRAIF 60 
LILRA1          IKPTLSALPSPVVTSGGNVTLHCVSQVAFGSFILCKEGEDEHPQCLNSQPRTHGWSRAIF 60 
LILRB3          SKPTLSALPSPVVASGGNMTLRCGSQKRYHHFVLMKEGEHQLPRTLDSQQLHSGGFQALF 60 
LILRA6          SKPTLSALPSPVVASGGNMTLQCGSQKGYHQFVLMKEGEHQLPRTLDSQQLHSGGFQALF 60 
LILRB5          AEPTLLALPSPVVASGGNVTLQCDTLDGLLTFVLVEE-EQKLPRTLYSQKLPKGPSQALF 59 
LILRA5          NKPTLSALPSPVVTSGENVTLQCGSRLRFDRFILTEEGDHKLSWTLDSQLTPSGQFQALF 60 
LILRA4          SRPTLSALPSPVVTSGVNVTLRCASRLGLGRFTLIEEGDHRLSWTLNSHQHNHGKFQALF 60 
LILRB4          SKPTLSALPSPLVTSGKSVTLLCQSRSPMDTFLLIKERAAHPLLHLRS-EHGAQQHQAEF 59 
                 .*** * ***:*  *  :*: * :      * * :*   .    * *         * * 
 
LILRA2          SVGPVSPSRRWSYRCYAYDSNSPYVWSLPSDLLELLVP 98 
LILRA3          SVGPVSPSRRWSYRCYGYDSRAPYVWSLPSDLLGLLVP 98 
LILRB1          SVGPVSPSRRWWYRCYAYDSNSPYEWSLPSDLLELLVL 98 
LILRB2          SVGPVSPNRRWSHRCYGYDLNSPYVWSSPSDLLELLVP 98 
LILRA1          SVGPVSPSRRWSYRCYAYDSNSPHVWSLPSDLLELLVL 98 
LILRB3          PVGPVNPSHRWRFTCYYYYMNTPRVWSHPSDPLEILP- 97 
LILRA6          PVGPVNPSHRWRFTCYYYYMNTPRVWSHPSDPLEILP- 97 
LILRB5          PVGPVTPSCRWRFRCYYYYRKNPQVWSNPSDLLEILVP 97 
LILRA5          PVGPVTPSHRWMLRCYGSRRHILQVWSEPSDLLEIPV- 97 
LILRA4          PMGPLTFSNRGTFRCYGYENNTPYVWSEPSDPLQLLVS 98 
LILRB4          PMSPVTSVHGGTYRCFSSHGFSHYLLSHPSDPLELIVS 97 
                .:.*:.        *:          * *** * :    
 
 
 
 
 
 
 
Figure 4.1. Phylogenetic analysis of Group I and Group II LILRs, continued:  
(c): ClustalW alignment of LILR family member D2 domains, ordered by alignment 
output.  Note that LILRB4 is bottom of the alignment indicating least conservation 
across the LILR family.  Percentage identity of LILR family members with LILRB4 D2 
is tabulated, and a phylogram of the alignment is depicted.  Red: small, hydrophobic, 
aromatic, not Y. Blue: acidic. Magenta: basic. Green: hydroxyl, amine, amide, basic. 
Gray: others.  Conservation strength is indicated by * > : > .  
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LILRB4          MTGAYSKPTLSALPSPLVTSGKSVTLLCQSRSPMDTFLLIKERAAHPLLHLRSEHGAQQH 60 
LILRB1          AGQFYDRVSLSVQPGPTVASGENVTLLCQSQGWMQTFLLTKEGAADDPWRLRSTYQSQKY 60 
LILRB2          TGQIHGTPFISVQPGPTVASGENVTLLCQSWRQFHTFLLTKAGAADAPLRLRSIHEYPKY 60 
LILRB3          AGQIYDTVSLSAQPGPTVASGENVTLLCQSWWQFDTFLLTKEGAAHPPLRLRSMYGAHKY 60 
LILRB5          AGLIPDIPALSVQPGPKVASGENVTLLCQSWHQIDTFFLTKEGAAHPPLCLKSKYQSYRH 60 
LILRA1          AGQFRGRPFISVHPGPTVASGENVTLLCQSWGPFHTFLLTKAGAADAPLRLRSIHEYPKY 60 
LILRA2          TGQFYDRPSLSVQPVPTVAPGKNVTLLCQSRGQFHTFLLTKEGAGHPPLHLRSEHQAQQN 60 
LILRA3          TGQIRARPFLSVRPGPTVASGENVTLLCQSQGGMHTFLLTKEGAADSPLRLKSKRQSHKY 60 
LILRA4          AGQISDRPSLSVQPGPTVTSGEKVTLLCQSWDPMFTFLLTKEGAAHPPLRLRSMYGAHKY 60 
LILRA6          AGQIYDTVSLSAQPGPTVASGENVTLLCQSRGYFDTFLLTKEGAAHPPLRLRSMYGAHKY 60 
                         :*. * * *:.*:.*******   : **:* *  *..    *:*     :  
 
LILRB4          QAEFPMSPVTSVHGGTYRCFSSHGFSHYLLSHPSDPLELIVS 102 
LILRB1          QAEFPMGPVTSAHAGTYRCYGSQSSKPYLLTHPSDPLELVVS 102 
LILRB2          QAEFPMSPVTSAHAGTYRCYGSLNSDPYLLSHPSEPLELVVS 102 
LILRB3          QAEFPMSPVTSAHAGTYRCYGSYSSNPHLLSFPSEPLELMVS 102 
LILRB5          QAEFSMSPVTSAQGGTYRCYSAIRSYPYLLSSPSYPQELVVS 102 
LILRA1          QAEFPMSPVTSAHSGTYRCYGSLSSNPYLLSHPSDSLELMVS 102 
LILRA2          QAEFRMGPVTSAHVGTYRCYSSLSSNPYLLSLPSDPLELVVS 102 
LILRA3          QAEFPMSPVTSAHAGTYRCYGSLSSNPYLLTHPSDPLELVVS 102 
LILRA4          QAEFPMSPVTSAHAGTYRCYGSRSSNPYLLSHPSEPLELVVS 102 
LILRA6          QAEFPMSPVTSAHAGTYRCYGSYSSNPHLLSFPSEPLELMVS 102 
                **** *.****.: *****:.:     :**: ** . **:** 
 
 
 
 
 
 
 
Figure 4.1. Phylogenetic analysis of Group I and Group II LILRs, continued:  
(d): ClustalW alignment of LILRB4 D2 domain onto LILR family D4 domains.  LILRA5 
is excluded from analysis since it is a two-domain LILR.  Percentage identity of LILR 
family D4 domains with LILRB4 D2 is tabulated, and a phylogram of the alignment is 
depicted.  Note that identity is higher than for D2 alignment as shown in Figure 4.1c.  
Red: small, hydrophobic, aromatic, not Y. Blue: acidic. Magenta: basic. Green: 
hydroxyl, amine, amide, basic. Gray: others.  Conservation strength is indicated by * 
> : > .  
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More detailed analysis of the individual domains of the receptor highlighted that although the 
D1 domain bore similarity to other LILR D1 domains (Figure 4.1b), the LILRB4 D2 domain 
shared highest identity with the D4 domains of other family members, as previously noted 
(Borges et al. JI 1997) (Figure 4.1c-d).  Therefore, LILRB4 is distinguished by an unusual 
domain organization comprising a classical LILR D1 domain, juxtaposed to an Ig domain that 
is most similar to the membrane-proximal D4 domains of other LILR receptors. 
 
4.3 Previous Attempts to Crystallise the Ectodomain of LILRB4  
Attempts to crystallise the two-domain recombinant form of LILRB4, produced as described 
in Chapter Two (and see Garner et al. Prot Exp Pur 2006) were conducted by myself and the 
group‟s protein crystallographer, Dr. Fiyaz Mohammed.  Despite considerable effort these 
attempts were largely unsuccessful.  Microcrystals were grown in two conditions – 1.4M Na / 
K Phosphate pH 6.6 and 1.0M Na / K Phosphate pH 7.2 – with two different crystal 
morphologies – „plates‟ and „bones‟ respectively – at a protein concentration of 8.2 mg/ml 
(Figure 4.2a).  However, SDS-PAGE analysis of the washed crystals showed an apparent 
mass of a single Ig domain (~12 kDa) instead of the expected 25 kDa, and seemed to consist 
of two protein species that formed a close doublet band (Figure 4.2b).   
 
N-terminal amino acid sequencing of the excised doublet protein band was carried out by Dr. 
John Fox (Alta Biosciences, University of Birmingham) and identified both bands as 
consisting of the N-terminal D1 domain of LILRB4.  This result as determined by SDS-
PAGE could be reproduced by incubating refolded LILRB4 for 14 days at room temperature 
(Figure 4.2c).  
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Figure 4.2. Characterisation of LILRB4 D1D2 crystals. (a): Potential LILRB4 D1D2 
crystals exhibit two distinct morphologies, plates (left panel) and bones (right panel). 
(b): SDS-PAGE analysis of the two crystal forms. (c): SDS-PAGE analysis of LILRB4 
degradation products after 14 days incubation at RT. 
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This led us to hypothesise that proteolytic cleavage of the two-domain LILRB4 at the 
interdomain region was occurring in the crystallisation droplets, followed by preferential 
crystallisation of the D1 fragment, probably aided by further proteolytic cleavage and/or 
precipitation of the D2 domain.   
 
This result suggested that, in the absence of successful crystallisation of the complete 
ectodomain of LILRB4, attempts to crystallise just the N-terminal D1 domain of the receptor 
might be more promising and could yield useful structural data.  It could be hypothesised that, 
due to the two-domain nature of LILRB4 (rather than the extended four-domain arrangements 
of LILRB1 or LILRB2), ligand binding regions of the receptor would be more likely to be 
located at the tip of the D1 domain, with the D2 domain acting merely to provide sufficient 
length and/or flexibility for ligand engagement in a „head-to-head‟ fashion on an opposing 
cell surface (rather than the „sideways-on‟ fashion of ligand engagement between the D1D2 
domains of LILRB1 or LILRB2 and the 3 and 2M domains of MHC Class I, which 
involves residues at the interdomain interface of the receptor as well as those at the distal D1 
tip).  Therefore in the absence of crystals of the full LILRB4 ectodomain, attempts to 
crystallise the D1 domain might yield useful structural information. 
 
4.4 Structure Determination of LILRB4 D1 
4.4.1 Production of Recombinant Soluble LILRB4 D1 Domain in E. coli 
In order to produce soluble LILRB4 D1 domain, a stop codon was introduced into the 
previously generated LILRB4-pET23a expression vector (Garner et al. Prot Exp Pur 2006) by 
SDM (Quikchange SDM kit, Stratagene).  Selection of the position for the stop codon was 
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based upon structural analysis of the corresponding interdomain region of LILRB1 (PDB 
code 1G0X; Chapman et al. Immunity 2000) and LILRB2 (PDB code 2GW5; Willcox et al. 
BMC Struc Bio 2002) with the crystallographic software package, COOT (Emsley and 
Cowtan, Acta Cryst D 2004).  Two constructs were generated, LILRB4 D1 GAYstop and 
LILRB4 D1 VMTstop, with stop codons after amino acid positions 99 and 96 respectively.  A 
map of the pET23a expression vector and the DNA sequence for LILRB4 coding for the D1 
domain, along with the corresponding SDM primer sequences is shown in Figure 4.3. 
 
After the SDM PCR reactions utilising the LILRB4-pET23a vector as template, the restriction 
enzyme DpnI was used to degrade the template DNA and the remaining, theoretically 
template-free mutated plasmid solution was transformed into the E. coli strain DH5.  
Following a miniprep plasmid preparation, DNA sequencing (utilising BigDye Terminator 3.0 
reaction and the sequencing service of Functional Genomics, Department of Biosciences, 
University of Birmingham) confirmed that the expected sequence for each LILRB4 D1 
construct was obtained. 
 
Test expression and SDS-PAGE analysis showed clear induction of a protein corresponding 
in size to LILRB4 D1, indicating successful test expression (Figure 4.4a). Subsequently, full-
scale expression of both LILRB4 D1 constructs was conducted in E. coli BL21 (DE3) cells 
and inclusion bodies were purified, solubilised in 8M Guanidine buffer (Figure 4.4b) and 
subjected to standard in vitro refolding conditions (Garboczi et al. PNAS 1992).  Refolds of 
LILRB4 D1 GAYstop (hereafter referred to as LILRB4 D1) were purified by size exclusion 
chromatography (into 20 mM Na Citrate buffer, pH 5.5) providing high yield and purity as  
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(a)
(b) 
 
ATGggTccActTccAaaaccAacTctctgggctgagccaggctctgtgatcagctgggggaactctgtgaccatc 
M  G  P  L  P  K  P  T  L  W  A  E  P  G  S  V  I  S  W  G  N  S  V  T  I   
tggtgtcaggggaccctggaggctcgggagtaccgtctggataaagaggaaagcccagcaccctgggacagacag 
W  C  Q  G  T  L  E  A  R  E  Y  R  L  D  K  E  E  S  P  A  P  W  D  R  Q   
aacccactggagcccaagaacaaggccagattctccatcccatccatgacagaggactatgcagggagataccgc 
N  P  L  E  P  K  N  K  A  R  F  S  I  P  S  M  T  E  D  Y  A  G  R  Y  R   
tgttactatcgcagccctgtaggctggtcacagcccagtgaccccctggagctggtgatgacaggagcctacagt 
C  Y  Y  R  S  P  V  G  W  S  Q  P  S  D  P  L  E  L  V  M  T  G  A  Y  S 
aaacccaccctttcagccctg... 
K  P  T  L  S  A  L  ... 
 
LILRB4 D1 VMT Stop  5’ GGAGCTGGTGATGACATGAGCCTACAGTAAACCC 
Reverse complement  5’ GGGTTTACTGTAGGCTCATGTCATCACCAGCTCC 
 
LILRB4 D1 GAY Stop  5’ GGTGATGACAGGAGCCTACTGAAAACCCACCCTTTC 
Reverse complement  5’ GAAAGGGTGGGTTTTCAGTAGGCTCCTGTCATCACC 
 
Figure 4.3. Generation of LILRB4 D1-pET23a expression vector. (a): Map of the 
pET23a expression vector and MCS.  Reproduced from the Novagen pET23a 
manual. (b): LILRB4 D1 construct sequence showing SDM sites and SDM primers for 
generation of the LILRB4 GAYstop and VMTstop vectors. Bases previously mutated 
from the original LILRB4 sequence for optimal E. coli expression (Garner et al. Prot 
Pur Exp 2006) are in uppercase, and the primer region is underlined. 
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Figure 4.4. Purification and SDS-PAGE analysis of LILRB4 D1. SDS-PAGE 
analysis of (a): test expression and (b): inclusion body preparation of LILRB4 D1. (c): 
size exclusion chromatography elution profile for LILRB4 D1 after FPLC using S200 
column. Fraction positions are marked. (d): SDS-PAGE analysis of FPLC fractions 
under reducing (left panel) and non-reducing (right panel) conditions. (e): light 
microscope image of LILRB4 D1 crystals.  
| | | | | | 
6  7  8  9 10 
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judged by the presence of a single peak on the elution profile (Figure 4.4c) and subsequent 
analysis of peak fractions by SDS-PAGE.  As expected, a single protein band of ~12 kDa was 
visible after concentration of the peak fractions under both reducing and non-reducing 
conditions, consistent with a single, monomeric correctly folded species.  Purity of the protein 
was judged sufficient enough for subsequent crystallisation trials (Figure 4.4d).  Attempts to 
refold LILRB4 D1 VMTstop suffered from much lower yields and were abandoned (data not 
shown). 
 
4.4.2 Crystallisation of LILRB4 D1 
Initial crystallisation trials were set up utilising a Mosquito nanolitre crystallisation robot 
(TTP LabTech), using a hanging drop vapour diffusion approach.  In brief, three 96-well 
plates each consisting of 96 crystallisation conditions, and each corresponding to one of three 
commercial screens (JCSG
+
, Index and PEG/Ion I & II) were set up at 100 μl volume, 
whereby the robot pipetted 100 nl of protein solution at a concentration of 10 mg/ml to 100 nl 
of well solution.  The drops were then sealed and stored in a 23 ˚C crystallisation incubator 
for 72 h before inspection under a light microscope for precipitation and microcrystal 
formation.   
 
Crystallisation was particularly successful in this instance, with 166 of 288 conditions (58 %) 
yielding microcrystals.  Those with the most promising morphologies were selected for scale-
up and optimisation, in order to generate crystals large enough for X-ray data collection.  In 
total 24 conditions were selected (8 from each commercial screen) and placed in a 24-well 
Linbro plate (reservoir volume = 1 ml) and equilibrated against hanging drops consisting of 1 
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μl of protein solution (10 mg/ml) plus 1 μl of well condition.  After a 72 h incubation period, 
the hanging drops were inspected for crystal formation and the results are tabulated in Table 
4.1.  In particular, two conditions stood out as giving rise to large crystals of good 
morphology for data collection:  Index condition 73 (0.2 M Sodium Chloride, 0.1 M Tris pH 
8.5, 25  % w/v PEG 3350) and PEG/Ion Screen I condition 25 (0.2 M Magnesium acetate 
tetrahydrate pH 7.9, 20 % w/v PEG 3350).  Data were collected from crystals grown in Index 
condition 73 (see Figure 4.4e). 
 
4.4.3 Data Collection and Processing 
Prior to data collection LILRB4 D1 crystals were soaked in reservoir buffer supplemented 
with increasing concentrations (5, 10 and 15 %) of ethylene glycol as cryoprotectant, before 
being flash cooled at 100 K in a nitrogen gas stream (Oxford Cryosystems).  X-ray data were 
collected to 1.6 Å resolution (Figure 4.5) under the supervision of Dr Fiyaz Mohammed on 
an in-house MicroMax 007HF rotating anode X-ray generator (Rigaku) using a Saturn CCD 
detector (University of Birmingham Macromolecular X-ray Facility). The crystals belonged to 
the space group P21 with unit cell parameters (a= 41.1 Å, b= 40.7 Å and c= 55 Å; =108.5˚). 
LILRB4 D1 diffraction data set were integrated, scaled and merged using programs of the 
XDS suite (Kabsch Acta Cryst D 2010). The relevant data processing statistics are listed in 
Table 4.2 (overleaf). 
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Figure 4.5. Diffraction pattern for LILRB4 D1 X-ray data.  A 0.5 oscillation image 
of LILRB4 D1 crystal collected at 100 K using the University of Birmingham 
Macromolecular X-ray Facility. The crystal diffracted X-rays to a resolution of 1.6 Å. 
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Space Group P21 
Unit Cell Dimensions 
a=41.1, b=40.7, c=55 (Å) 
α=90, β=108.5, γ=90 (°) 
Resolution (Ǻ) 20-1.6 (1.7-1.6) 
Observed Reflections 138176 (12449) 
Unique Reflections 22154 (3203) 
Multiplicity 6.2 
Completeness (%) 96.4 (84.3) 
Rmerge (%) 4.5 (14.6) 
I/σ(I) 25.1 (8.5) 
 
Table 4.2: Data processing statistics for LILRB4 D1.  Figures in parentheses 
apply to data in the highest resolution shell. Completeness = (number of independent 
reflections/total theoretical number). Rmerge (I) = (Σ|I(i) - <I(h)>|/ΣI(i)), where I(i) is the 
ith observation of the intensity of the hkl reflection and <I> is the mean intensity from 
multiple measurements of the h,k,l reflection. 
  
4.4.4 LILRB4 D1 Structure Solution  
Assuming the LILRB4 D1 crystals possess two LILRB4 D1 molecules within the asymmetric 
unit, a solvent content of 50 % was calculated. Initial phase information for the structure 
determination of LILRB4 D1 was obtained by molecular replacement with CNS (Brünger et 
al. Acta Cryst D Bio Cryst 1998).  The search model consisted of the D1 domain from the 
recently solved LILRA5 D1D2 crystal structure (Shiroishi et al. JBC 2006), with co-ordinates 
for water molecules omitted. Firstly, a cross-rotation function was performed to determine the 
orientation of the search model with respect to the target protein (Table 4.3). The output from 
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the cross rotation function is a list of rotation angles (θ1, θ2 and θ3) with their corresponding 
correlation coefficients (RF-function). The cross rotation function yielded two significant 
solutions (Table 4.3) with RF-functions of 3.2 and 3.0 (with the next peak being at 2.1), 
respectively. These cross rotation function solutions (θ1= 79.99, θ2= 50.87, θ3= 150.24 and 
θ1= 112.11, θ2= 74.35, θ3= 314.21) corresponded to the orientation of the two LILRB4 D1 
molecules within the asymmetric unit and confirmed the solvent content calculations.      
Index θ1 θ2 θ3 RF-function 
1 79.994 50.870 150.238 3.2365 
2 112.105 74.348 314.211 3.0426 
24 194.150 43.043 29.579 2.1783 
25 191.171 54.783 249.776 2.1764 
30 47.119 70.435 40.573 2.1299 
31 158.970 66.522 228.200 2.1276 
32 237.759 23.478 29.338 2.1218 
45 344.172 54.783 0.916 2.0214 
67 231.313 66.522 72.083 1.9271 
68 299.534 62.609 204.024 1.9266 
 
Table 4.3:  Cross Rotation Function. The 10 highest peaks following the cross 
rotation search performed with CNS.  
 
The next stage involved performing a translation function search to determine the position 
(translation vectors x, y and z) of the search model with respect to the target protein (Table 
4.4). The translation function was performed in space group P21 using the orientations 
determined from the cross-rotation function calculations (Table 4.3). Prior to the translation 
function search the orientations were refined using the PC-refinement feature within CNS. 
The translation function produced a list of translation vectors (x, y and z) with their 
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corresponding score function (monitor) and packing value (this being the percentage of the 
unit cell covered by the molecule). Notably, both cross rotation function solutions (θ1= 
79.96, θ2= 52.26, θ3= 149.01 and θ1= 111.98, θ2= 76.66, θ3= 314.91) yielded large 
translation function solutions (x= 6.39, y= 0.63, z= 8.50 and x= 10.39, y= -0.49, z= 3.11) with 
scores of 0.229 (with next score of 0.090), providing further evidence for the existence of 
only two LILRB4 D1 molecules per asymmetric unit (Table 4.4). 
 
 
Table 4.4: Translation Function. The highest translation function peak for each 
cross-rotation solution (see table 4.3) calculated with CNS. 
 
Finally the position of the first LILRB4 D1 molecule was fixed (θ1= 111.98, θ2= 76.66, θ3= 
314.91, x= 10.39, y= -0.49 and z= 3.11) and the translation search was repeated to determine 
R# θ1 θ2 θ3 transX transY transZ monitor packing 
1 79.96 52.26 149.01 6.39 0.63 8.50 0.229 0.3119 
2 111.98 76.66 314.91 10.39 -0.49 3.11 0.229 0.3133 
3 196.67 47.12 30.59 15.42 -2.32 11.09 0.090 0.2921 
4 189.45 52.78 248.22 8.29 -1.01 3.09 0.078 0.2963 
5 47.71 68.97 33.40 -7.10 -2.75 21.34 0.077 0.2750 
6 159.02 64.07 228.04 2.79 -0.53 10.29 0.084 0.3118 
7 238.57 34.04 38.27 8.11 -3.55 23.05 0.091 0.3004 
8 345.24 48.60 3.50 -3.96 -1.11 4.82 0.085 0.3181 
9 233.28 63.14 71.92 2.12 -0.17 9.55 0.081 0.3139 
10 301.13 60.24 207.13 0.93 0.45 13.16 0.066 0.3158 
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the position of the second LILRB4 D1 molecule with respect to the same origin (Table 4.5). 
The translation function provided an unambiguous translation function solution for the second 
LILRB4 D1 molecule (x= 35.51, y= 37.92 and z= -17.85) with a score function of 0.42. In 
addition, the packing value had increased from the previous translation function calculation 
indicating minimal overlap for this solution compared to the others. 
R# θ1 θ2 θ3 transX transY transZ monitor packing 
1 81.03 51.38 148.21 35.51 37.92 -17.85 0.420 0.6212 
2 111.94 76.00 314.03 8.32 0.54 7.93 0.218 0.4168 
3 195.03 47.43 33.19 16.72 13.80 6.02 0.173 0.4236 
4 189.04 53.76 247.68 36.67 9.02 7.21 0.160 0.4168 
5 47.69 68.82 35.95 38.45 27.15 -23.59 0.173 0.4501 
6 160.99 66.01 227.45 24.90 21.82 5.31 0.190 0.4767 
7 239.55 31.73 35.24 8.64 30.75 22.79 0.186 0.4786 
8 343.93 50.43 1.87 26.35 0.45 8.07 0.169 0.5972 
9 233.37 63.24 70.72 2.67 25.39 9.28 0.185 0.5302 
10 301.10 59.79 207.47 40.41 34.76 -23.4 0.191 0.5201 
 
Table 4.5: Translation Function for Second LILRB4 D1 Molecule. The highest 
translation function peaks for each cross rotation solution after fixing the position of 
the first LILRB4 D1 molecule (θ1= 111.98, θ2= 76.66, θ3= 314.91, x= 10.39, y= 
-0.49 and z= 3.11). 
4.4.5 LILRB4 D1 Structure Refinement 
The molecular model was refined with CNS and REFMAC5 (Murshudov et al. Acta Cryst D 
1997).  The progress of refinement was verified by monitoring reduction in the Rfree (Brünger 
Nature 1992) calculated from an independent set of reflections, which were set aside for 
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cross-validation purposes.  The models were subjected to several rounds of alternating 
simulated annealing/positional refinement followed by isotropic B factor refinement.  
Following the initial round of refinement the Rwork and Rfree converged to 32.4 % (reduced 
from 46.4 %) and 33.9 % (reduced from 45.3 %), respectively.  Examination of the resulting 
electron density maps revealed unbiased features in the electron density which corresponded 
to LILRB4 D1 residues (Figure 4.6) and confirmed the validity of the molecular replacement 
solution. 
 
All model manipulations were performed using COOT.  Once the R-factors had dropped 
below 30 %, water molecules were included in the models if they appeared in Fo-Fc maps 
contoured at > 3 and were within hydrogen bonding distance to chemically acceptable 
groups.  These water molecules were added in successive steps and were included in the 
subsequent refinement cycles.  After further cycles of refinement interspersed with model 
building, the Rwork and Rfree converged to 20.3 and 23.9 %, respectively for all data between 
20 Å and 1.6 Å. The final model consists of two LILRB4 D1 molecules (designated subunit A 
(residues 3-93) and subunit B (residues 3-95)), 3 ethylene glycol molecules and 130 solvent 
molecules. The quality of the final refined model was verified using PROCHECK (Laskowski 
et al. J App Cryst 1993) which demonstrated that non-glycine residues were absent from the 
disallowed regions of the Ramachandran plot (Figure 4.7).  The majority of the residues are 
well defined with the exception of a few solvent exposed side chains, which are likely to be 
flexible.  Hydrogen bonding and van der Waals contacts were analysed using CONTACT 
(Collaborative Computational Project Number 4, Acta Cryst D 1994).  The final refinement 
statistics are summarised in Table 4.6 (overleaf). 
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(a) (b)
(c) (d)
Figure 4.6. Unique electron density features used to validate molecular 
replacement of LILRB4 D1 structure.  (a): Part of the LILRB4 electron density map 
after first rebuild, showing LILRA5 model residues L37, V38 and K39 in ball-and-stick 
representation.  Note that V38 does not fit the observed electron density. (b): The 
same region after final structural solution, this time with LILRB4 residues L37, D38 
and K39 in ball-and-stick representation.  (c): Electron density map after first rebuild 
for another region, this time showing LILRA5 model residues H68 and H69 in ball-
and-stick representation. (d): The same region after final structural solution showing 
how LILRB4 residues D68 and Y69 fit the observed electron density. The Fo-Fc map 
(depicted in red) is contoured at the 2 level, whereas the 2Fo-Fc map (depicted in 
cyan) is contoured at the 1 level.  
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Figure 4.7. Ramachandran plot for LILRB4 D1.  The Phi and Psi dihedral angles 
for the peptide bond of each amino acid residue in the LILRB4 D1 structure are 
plotted as squares. The regions of the Ramachandran plot are categorized as most 
favoured (red), addionally allowed (yellow), generously allowed (cream) and 
disallowed (white). Glycine residues exhibit additional flexibility and are depicted as 
triangles.  
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Resolution (Å) 19.5-1.6 
Reflections in working set 19991 
Reflections in test set 1081 
Rwork (%) 20.3 
Rfree (%) 23.9 
Number of protein atoms 1510 
Average B-factor (Å2) 
 
Subunit A 
Subunit B 
 
 
9.6 
9.5 
 
Number of water molecules 130 
 
Table 4.6: Refinement Statistics for LILRB4 D1 structure.  
Rwork (F) = Σh||Fobs(h)| - |Fcalc(h)||/Σh|Fobs(h)| and |Fcalc(h)| are the observed and 
calculated structure factor amplitudes for the h, k, l reflection. Rfree is calculated over 
reflections in a test set not included in atomic refinement. 
 
4.4.6 Overall Structure of LILRB4 D1 Domain 
Structural analysis of LILRB4 D1 and comparisons with LILRB1, LILRB2 and LILRA5 D1 
structures were performed with COOT and the CCP4 software suite (Collaborative 
Computational Project Number 4, Acta Cryst D 1994).  All main-chain superpositions 
between the D1 domains of LILRB4 and LILRA5, LILRB1 and LILRB2 were conducted 
using LSQMAN (Kleywegt Acta Cryst D 1996).  All molecular graphic figures were 
generated with MOLSCRIPT (Kraulis J App Cryst 1991) and rendered using POVRAY 
(http:// www.povray.org). 
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The two molecules of LILRB4 D1 in the asymmetric unit were designated A and B.  
Superposition of LILRB4 D1-A onto LILRB4 D1-B gave a very low Root Mean Square 
Deviation (RMSD) value of 0.16 Å, indicating that both molecules in the unit cell are 
essentially identical.  Subsequent analysis of LILRB4 D1 was conducted using molecule A. 
 
As expected the superposition of LILRB4 D1 onto LILRA5 D1 shows that the main chains of 
both proteins are structurally very similar (Figure 4.8a) and this is reflected in the low RMSD 
value of 1 Å.  This raises questions as to whether LILRB4 and LILRA5 bind ligands that are 
structurally related. In contrast, superposition of LILRB4 D1 onto LILRB1 D1 (Figure 4.8b) 
revealed substantial differences in the main chain particularly in the C-C‟ loop and at the 
distal D1 tip, with a RMSD value of 3.5 Å, highlighting structural differences between Group 
I and Group II LILRs. Interestingly, the superposition of LILRB1 D1 onto LILRB2 D1 
(Figure 4.8c) resulted in a relatively high RMSD value (3.1 Å) demonstrating that as a subset, 
Group I LILR proteins also exhibit large differences in their backbone topology.  One of  the 
most significant differences between LILRB1 D1 and LILRB2 D1 is at the loop at the distal 
tip of the D1 domain which conceivably contributes to the differences in affinity between 
LILRB1 and LILRB2 in binding to MHC Class I ligands and UL18 (Willcox et al. BMC 
Struc Bio 2002, Willcox et al. Nat Immun 2003).  However, despite these differences the 
LILRB1 and LILRB2 membrane distal domains have similar overall secondary structure and 
bind the same MHC Class I ligands, thus an important caveat is that it is hard to extrapolate 
the similarity in backbone structure between LILRB4 and LILRA5 into a propensity to bind 
similar ligands (which are currently unknown). 
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Figure 4.8. Main-chain superposition of LILRB4 D1 domain.  LILRB4 superposed 
onto (a): LILRA5 (b): LILRB1. (c):LILRB1 superposed onto LILRB2 for comparison. 
(d): For orientation purposes the LILRB1 D1D2/HLA-A2 complex is shown.  In panels 
(a), (b) and (c) the domain is orientated at the same angle as the D1 domain of 
LILRB1 as shown in (d), in which the MHC Class I binding face is pointing left and 
the distal tip of the D1 domain is at the bottom of the figure. 
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4.4.7 Secondary Structure Analysis of D1 Domains of Group I and Group II LILRs 
The secondary structure of LILRB4 D1 was analysed using the CCP4 program PROCHECK 
and compared to LILRB1, LILRB2 and LILRA5 D1 secondary structures.  The output from 
PROCHECK and the overall topology of the LILRB4 D1 domain are shown in graphical form 
in Figure 4.9. 
 
The overall secondary structure topology of LILRB4 D1 is very similar to LILRA5 D1, with 
the standard C2-Ig type domain as conserved across the LILR family, comprising two anti-
parallel β-sheets formed by the ABE and the CFG β-strands respectively, separated by a short 
310 helix region and with the G strand interrupted by a Polyproline Type II Helix motif.  As in 
the other LILRs, the C strand is interrupted either by a loop region (LILRA5) or a helix 
(LILRB1 and LILRB2) resulting in the formation of a C and a C‟ strand.  In LILRB4 D1 the 
A strand is defined as being much shorter by PROCHECK as the lack of electron density for 
residues at the C-terminal end of the G strand (due to disorder at the end of the D1 domain) 
causes some hydrogen bonding with A‟ to be disrupted, although the appearance of the A‟ 
strand on COOT is of that of an extended strand in a similar manner to the other LILRs.   
 
The secondary structures of LILRB1, LILRB2, LILRB4 and LILRA5 D1 are shown in 
graphical form in Figure 4.10.  By comparison with the known D1 domain structures of the 
Group I LILRs LILRB1 and LILRB2, the D1 domains of the Group II LILRs, LILRB4 and 
LILRA5, have fewer helical regions (lacking helices following the C strand) and have the 
distal D1 loop orientated in a more similar position to LILRB2 than to LILRB1. 
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Figure 4.9. PROCHECK secondary structure assignment for LILRB4 D1.  The 
output from PROCHECK is shown in two graphical forms, as an alignment of the 
primary sequence of LILR D1 structures with secondary structures indicated 
underneath (top panel) and as a topological map of the LILRB4 D1 domain (bottom 
panel).  Interacting strands are adjacent to each other and helices are shown. 
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Figure 4.10. Comparison of tertiary structures of LILR D1 domains.  LILRB4 D1 
is shown alongside LILRA5 D1 (top panels).  The D1 domains of the Group I LILRs, 
LILRB1 and LILRB2, are shown underneath for comparison.  Images were generated 
using MOLSCRIPT and POVray. β-strands are shown as arrows and labelled with 
their strand designation; -helices are shown in red and polyproline helices are in 
green. Disordered loops are shown as dotted lines.  Orientation of each molecule is 
as in Figure 4.8. 
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4.4.8 Rationalisation for Non-binding of LILRB4 D1 to MHC Class I 
Although the LILRB4 D1 structure is just a single domain, as opposed to the known 
structures of the binding domains of LILRB1 and LILRB2 which are the distal D1D2 
domains, comparison of the structure and residue substitutions in this domain allowed the 
development of hypotheses for why LILRB4 does not bind to MHC Class I.  Alignment of the 
primary amino acid sequences of LILRB1 D1 and LILRB4 D1 identified eight amino acid 
substitutions (Figure 4.11) that are located at the LILRB1/HLA-A2 binding interface 
(Willcox et al. Nat Immun 2003).  Of these, only two are conservative substitutions (E68D 
and R39K) and the remaining are non-conservative changes that either involve charged 
(W67E, K41E, K42S and Y38D) or hydrophobic residues (Q18W and T43P).  The net change 
in charge introduced by such substitutions is -5; thus the surface electrostatic potential at the 
CFG face, a region corresponding to the LILRB1-D1/HLA-A2 binding interface, is 
substantially more negatively charged.  Notably, the substitution of Q18W and W67E may be 
compensatory, in order to maintain a hydrophobic tryptophan residue at the interdomain 
interface. 
These non-conservative substitutions, which result in predominantly charge-related changes 
in comparison to LILRB1 D1, may disrupt LILRB4 D1 binding to the α3 and β2m domains of 
MHC Class I, particularly as the α3 domain contacted by LILRB1/2 D1 domain is itself 
negatively charged (see below).  In addition, the superposition of LILRB4 D1 onto the 
LILRB1/HLA-A2 complex structure shows that the conformation of the LILRB4 D1 C-C‟ 
loop encompassing residues 41-46 is substantially shifted, such that the A44 side chain could 
sterically clash with the backbone carbonyl of V194 of the α3 domain of MHC Class I and 
thus impair binding.  Interestingly, the LILRB2 D1 helical region between the C and C‟ 
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Figure 4.11. Amino acid substitutions between LILRB1 D1 and LILRB4 D1 
located at the LILRB1 D1/HLA-A2 binding interface. Images were generated using 
MOLSCRIPT and POVray. β-strands are shown as arrows; -helices are shown in 
red and polyproline helices are in green. Amino acid side-chains for substituted 
residues are shown in ball-and-stick representation. Orientation of each molecule is 
as in Figure 4.8. 
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 strands has been implicated in binding to HLA-G (Shiroishi et al. PNAS 2006) and the lack 
of such a helix in LILRB4 D1 provides further evidence for its failure to bind MHC Class I. 
This helix is also absent in LILRA5, which is known not to bind to MHC Class I.  Mapping of 
the LILRA5 substitutions on the LILRB1/HLA-A2 binding interface also suggest that binding 
to MHC class I would be unlikely (Willcox et al. Nat Immun 2003, Shiroishi et al. JBC 2006).  
The structural elements of LILRB4 D1D2 which make it unsuited to MHC Class I recognition 
are discussed extensively in Section 4.5.4. 
 
4.4.9 Comparison of LILRB4 D1 with LILRA5 D1  
LILRA5 has the closest primary sequence comparison to LILRB4 across the whole LILR 
family, with 83 % identity across the D1 domain.  Based on sequence alignments of the 
LILRA5 D1 and LILRB4 D1 domains it has been possible to map the substituted residues 
onto the corresponding tertiary structures.  Of the 18 amino acid substitutions found between 
LILRA5 D1 and LILRB4 D1, ten substitutions involve charge changes which comprise 
R18W, R25W, Q33R, V38D, G41E, E44A, T48R, M68D, Y78R, and E85Q.  In particular, 
this analysis has revealed significant changes in charge distribution between LILRA5 and 
LILRB4 from electronegative to electropositive residues (E44A, T48R, E85Q, Y78R and 
Q33R), particularly at the CFG face and D1 distal tip (which is important for LILRB1 and 
LILRB2 binding to MHC Class I).  This is illustrated in Figure 4.12. 
 
The large difference in surface charges between LILRB4 D1 and LILRA5 D1 across the CFG 
face is clearly visible when calculating the electrostatic potential for each residue and 
generating the electrostatic surface for each receptor using GRASP (Nicholls et al. Proteins: 
169 
 
Struc Func Genet 1991), as illustrated in Figure 4.13.  I would hypothesise that this could 
have implications for ligand binding between the two Group II receptors.  The broad 
difference in the electrostatic surface between LILRB4 D1 and LILRA5 D1 could suggest that 
the ligands for LILRB4 and LILRA5 are different, despite the overall structural similarity.  
Further investigation into the structures of other Group II LILRs is warranted and may indeed 
delineate the LILR family into additional sub-groups. 
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Figure 4.12. Amino acid substitutions between LILRA5 D1 and LILRB4 D1. 
Images were generated using MOLSCRIPT and POVray. β-strands are shown as 
arrows; -helices are shown in red and polyproline helices are in green. Amino acid 
side-chains for substituted residues are shown in ball-and-stick representation. 
Orientation of each molecule is as in Figure 4.8. 
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Figure 4.13. Electrostatic surface potential of LILRB4 D1 compared to LILRA5. 
LILRB4 D1 and LILRA5 D1 molecular surface depicted using GRASP with 
electropositive residues shown in blue and electronegative residues in red.  The 
molecule is oriented with the CFG face – which corresponds to the MHC Class I 
binding surface in LILRB1/LILRB2 - towards the observer.  Selected residues have 
been labelled. 
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4.5 Structural Analysis of LILRB4 D1D2 Incorporating a Non-native Disulphide Bond 
Recently, we were approached by Professor George Gao (Chinese Academy of Sciences, 
Beijing, China) who contacted the Willcox group with the news that his group had 
successfully determined the crystal structure of the full ectodomain (D1D2) of LILRB4.  A 
collaboration was established whereby my role was to comprehensively analyse the LILRB4 
D1D2 structure, compare it with my LILRB4 D1 structure, and determine the implications of 
each for LILRB4 ligand recognition. 
 
4.5.1 Generation, Crystallisation, and Structure Solution of LILRB4 D1D2 
As described above, crystallisation of the wild-type D1D2 ectodomain of LILRB4 had proven 
problematic, both for myself and for the Gao group.  To overcome intransigent crystallisation 
LILRB4 was engineered to include a non-native disulphide bond, based on the observation 
that LILRB1 and LILRB2, which both crystallised readily, contained an additional disulphide 
bond in the D2 domain, close to the C-C‟ flexible loop region. By introducing mutations to 
comparable positions in LILRB4 (I133C and H143C), it was hoped to stabilise the D2 C-C‟ 
flexible loop region, which was hypothesised to affect protein stability and crystallisation.  
This strategy had previously been employed to facilitate the structural determination of 
LILRA2 (Chen et al. JMB 2007).  Mutated LILRB4 D1D2 was found to have higher stability 
and could be concentrated to substantially higher levels than the wild-type protein, displaying 
considerably less precipitation during concentration steps.   
 
The mutated LILRB4 protein was subsequently successfully refolded by standard Garboczi 
methods (Garboczi et al. PNAS 1992); analysis of the mutated protein was carried out by the 
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Gao group by size exclusion chromatography, analytical ultracentrifugation (AUC) and SDS-
PAGE and the protein was judged to be correctly folded and pure enough for crystallisation 
trials.  In addition, their AUC data showed a narrower molar mass distribution peak 
suggesting reduced flexibility of the protein with the engineered disulphide bond as compared 
to wild-type LILRB4 (data not shown).  In contrast to wild type LILRB4, the mutated 
LILRB4 D1D2 protein was crystallized to data-collection quality at 4 °C in hanging drops 
equilibrated against a reservoir solution containing 0.2 M sodium sulfate heptahydrate, 20 % 
w/v PEG 3350.  The crystal diffracted X-rays to a resolution of 1.8 Å resolution and belongs 
to the tetragonal space group P41212, (unit cell constants: a= b= 61.92 Å, c= 115.87 Å, α= β= 
γ= 90°), with one LILRB4 molecule per asymmetric unit.  
 
The LILRB4 D1D2 structure was determined by molecular replacement using LILRA5 D1D2 
as the search model with MOLREP (Vagin and Teplyakov Acta Cryst D Bio Cryst 2010) and 
PHASER (McCoy Acta Cryst D Bio Cryst 2007).   Refinement of the molecular model was 
carried out in CNS and REFMAC5, interspersed with iterative manual rebuilding with the 
program COOT. Subsequent 2Fo-Fc and annealed omit electron density maps allowed for the 
placement of all LILRB4 residues. After further cycles of refinement the Rwork and Rfree 
converged to 18.7 % and 22.1 %, respectively for all data between 50 Å and 1.8 Å (Chen et 
al, manuscript in preparation). 
 
Superposition of my LILRB4 D1 structure onto the LILRB4 ectodomain structure showed a 
high degree of correlation between the two structures, with RMSD values of 0.71 Å and 0.72 
Å for the A and B subunits, respectively, onto the D1 domain of the ectodomain structure, 
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indicating the D1 conformation of each structure was essentially identical.  This lends a high 
degree of confidence about the validity of both structures. 
 
4.5.2 Overall Structure of LILRB4 D1D2 
The LILRB4 D1D2 structure is comprised of two C2-type Ig-like domains arranged at a ~ 90° 
angle, and defined as D1 (residues 2-95) and D2 (residues 96-195). The disulphide bonds 
formed between C26 and C75 in D1, C121 and C172 in D2, in addition to the artificial 
disulphide introduced between C133 and C143, collectively stabilize the arrangement of six 
β-strands into two anti-parallel β-sheets per domain, as observed in other members of the 
LILR family. The most notable difference with LILRB1 and LILRB2 include the lack of the 
helical region following the C strand in D1, which is consistent with the LILRB4 D1 structure 
(see Section 4.4.6).  In addition,  LILRB4 displays two novel 310 helical regions not 
previously observed in other LILR receptors, one located between the C-C‟ strands, and 
another between the E-F strands (Figure 4.14a).  The divergence in the D2 domain of 
LILRB4 is consistent with the finding that its primary sequence has higher identity with the 
D4 domains of the other LILR family members and has been noted before in an early LILR 
publication (Borges et al. JI 1997) and discussed here in Section 4.2. However, arguably the 
most striking feature of the structure was the interdomain angle. In contrast to previous LILR 
structures, where the D1-D2 interdomain angles are ~84 - 90° in their ligand-free forms, the 
LILRB4 structure displayed an obtuse D1-D2 interdomain angle, of 107° (Figure 4.14b). 
 
The topology of the LILRB4 domains was similar to that of other LILRs, but with some 
distinctive features (Figure 4.14c).  In the D1 domain, LILRB4 displays some topological 
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differences compared to LILRB1 and LILRB2.  In these Group I receptors, the region 
between the C and E strands, which in many Ig domains forms a strand termed D, instead 
includes helical secondary structural elements (Chapman et al. Immunity 2000, Willcox et al. 
BMC Struc Bio 2002).  In contrast, in LILRB4 D1, the corresponding region is replaced by a 
β-strand termed C‟ that pairs with strand C, as in the KIR receptors (Figure 4.14c), and also 
observed in the LILRB4 single domain D1 structure. Interestingly, recent studies have shown 
that the 310 helix region between the C-E strands in LILRB2 D1 is directly involved in the 
recognition of the α3 domain of HLA-G (Shiroishi et al. PNAS 2006), and the corresponding 
region of LILRB1 also forms interactions with the α3 domain of HLA-A2 (Willcox et al. Nat 
Immun 2003).  Alterations in this region of LILRB4 relative to LILRB1/LILRB2 could 
therefore affect LILRB4 ligand interactions. Notably, the C‟ strand observed in LILRB4 has 
previously been noted in LILRA2 and LILRA5, suggesting this topological feature can be 
present in both Group I and Group II receptors and in Group II is not restricted to LILRA5.  
In contrast to the loss of helical elements in the C-E region in LILRB4, the 310 helix observed 
between E and F strands in LILRB1, LILRB2 and LILRA5 is preserved in LILRB4.  These 
findings were entirely consistent with our previous analysis of the LILRB4 D1 domain 
structure. 
 
In D2, LILRB4 displays two novel 310 helical regions not previously observed in other LILR 
receptors, one located between the C-C‟ strands, and another between the E-F strands (Figure 
4.14c).  For the C-C‟ helix, the possibility cannot be excluded that introduction of the 
additional disulphide bond into this region affects that propensity for 310 helix formation. 
However, notably LILRB1 and LILRB2 contain this additional disulphide in their native 
form, and do not have a helix in this region, suggesting instead the divergent sequence of  
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Figure 4.14. Overall LILRB4 D1D2 structure.  (a): Tertiary structure of LILRB4 
D1D2 generated using MOLSCRIPT and POVray.  β-strands are shown as arrows 
with their strand designation, helices are shown in green for 310 helix and red for 
polyproline Type II helix, and disulphide bonds are shown in yellow. (b): Comparison 
of the interdomain angles of LILR family members using DomAngle software.  Protein 
backbones are shown, with LILRB4 in cyan, LILRA5 in green and LILRB2 in blue. 
The more obtuse angle of LILRB4 is readily apparent. (c): Topological map of the 
secondary structure of LILRB4 D1D2 as calculated using PROCHECK, showing 
strands as arrows and helices as cylinders (note 310 helices are in green and 
polyproline helices are in red).  The stalk region, transmembrane domain and 
cytoplasmic domain are shown as a dotted line. 
 
 
(a) 
(b) 
(c) 
177 
 
LILRB4 in this region relative to other LILRs may underlie this novel structural feature.  
Finally, in addition to 310 helical regions, LILRB4 also contains a region of polyproline II 
helix in the F-G loop of each domain, and this is also present in LILRB1, LILRB2 and 
LILRA5 as well as other LRC receptors  such as KIRs (Saulquin et al. JEM 2003) and NKp46 
(Foster et al. JBC 2003). 
 
4.5.3 Structural Features at the LILRB4 D1D2 Interface 
Analysis of the LILRB4 D1-D2 interdomain interface using the program CONTACT 
indicated a buried surface area of 878 Å
2
, intermediate between that of LILRB1 (946 Å
2
) and 
LILRB2 (776 Å
2
) and comparable with LILRA5 (843 Å
2
).  Consistent with a broadly similar 
interdomain interface, some of the hydrogen bonding interactions present at the D1-D2 
interface in LILRB1, LILRB2 and LILRA5 were conserved in LILRB4.  These interactions 
are located from the D1 F strand (R72) to the short strand bearing Y183 in LILRB1 
(equivalent to Y181 in LILRB4) as shown in Figure 4.15a.   
 
However, several other hydrophobic interactions were altered.  Firstly, the hydrophobic 
interactions between W67 and E184 in LILRB1 are lost as the residues are replaced in 
LILRB4 by E67 and L182 (Figure 4.15a-b).  This decreases interdomain interactions as E67 
loses all contacts to L182.  Although LILRA5 also has E67, this mediates compensatory 
interactions with F97, whereas this is not the case in LILRB4 as the interaction with the side-
chain of F97 is replaced with the shorter side-chain of A97.    
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Figure 4.15. Analysis of the LILRB4 interdomain interface. (a): Sequence 
alignment of known LILR structures and NKp46. * indicates interface stabilizing 
residues. Conserved residues are boxed/shaded red. Disulfide bond cysteines are 
shaded yellow. LILRB4 secondary structure is shown with 310 helices in green and 
polyproline type II helices in red (b): LILRB4 and LILRB1 D1-D2 interfaces compared.  
Key residues are shown in ball-and-stick representation. Top and bottom panels 
show slightly different orientations, for clarity. 
(a) 
(b) 
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A second alteration is the substitution of Y175 in LILRB1 (also conserved at the equivalent 
position in LILRB2 and LILRA5) with a phenylalanine residue at the corresponding position 
(F173) in LILRB4 (Figure 4.15b) which makes substantially fewer contacts.  Finally, 
arguably the most significant alteration at the LILRB4 D1-D2 interface is substitution of 
W185 (present in LILRB1, LILRB2 and at the equivalent W184 in LILRA5) to the less bulky 
leucine residue at the equivalent position in LILRB4 (L183) (Figure 4.15b).  The shorter size 
of the L183 side-chain in LILRB4 results in reduced contacts to V15 and V93 as compared 
with the extensive contacts between W185 and these residues in LILRB1, LILRB2 and 
LILRA5.  Strikingly, L183 of LILRB4 only makes 22 contacts to neighbouring atoms (<4.00 
Å), whereas the equivalent W184 in LILRA5 forms 44 contacts.  These observations indicate 
that the LILRB4 D1-D2 interface, although of a similar size to that of other LILR family 
members, involves considerably fewer stabilizing hydrophobic interactions. 
 
4.5.4 LILRB4 D1D2 is Conformationally and Electrostatically Unsuited for Recognition 
of MHC Class I 
The crystal structures of LILRB1/HLA-A2 (Willcox et al. Nat Immunol 2003) and 
LILRB2/HLA-G complexes (Shiroishi et al. PNAS 2006) showed that the ligand binding 
portion of LILRB1/2 comprises residues located in two distinct surface patches, firstly a 
membrane distal portion of the D1 domain that forms contacts to the HLA α3 domain, and 
secondly in the inter-domain D1-D2 hinge region, which contacts the β2m domain. These 
interacting residues are highly conserved among Group I LILRs, but extremely poorly 
conserved in Group II LILRs including LILRB4 and LILRA5.  Determination of the LILRB4 
structure allowed the conformation and electrostatic properties of these potential interaction 
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surfaces to be examined, as well as alterations in the LILRB4 interdomain orientation relative 
to MHC Class I-bound forms of LILRB1 and LILRB2 to be assessed.  
 
Preliminary analysis of the LILRB4 D1D2 structure particularly in regions analogous to the 
MHC Class I-binding surfaces of LILRB1 and LILRB2 (i.e. the distal D1 tip and the D1D2 
hinge region), did not reveal gross structural changes in these regions, despite the low amino 
acid conservation at these two sites.  However, superposition of the LILRB4 D1 and D2 
domains onto the previously determined LILRB1/HLA-A2 complex structure (Willcox et al. 
Nat Immunol 2003) provided a clear rationale for why this mode of MHC Class I recognition 
could not be feasible for LILRB4.  
 
In terms of contacts with the α3 domain, in LILRB1, residues within strand C and the loop 
following strand C (including Y38, K41 and T42) as well as Y76 in the F strand, form 
hydrophobic and van der Waals contacts to residues V194, S195, D196, T200 and V248 of 
the α3 domain of HLA-A2.  Although no drastic steric clashes are evident in the 
LILRB4/HLA-A2 superposition at this region, non-conservative amino acid substitutions are 
prevalent and there are secondary structural rearrangements, with the 310
 
helix present in 
LILRB1 replaced by the C‟ strand in LILRB4.  Consequently the potential molecular contacts 
at the LILRB1/α3 interface are likely to be lost in LILRB4. 
 
With regards to the β2m domain, the substitution of Q18 (LILRB1) with W18 (LILRB4) 
creates substantial steric clashes with Q89 of β2m (Figure 4.16) and results in the loss of 
hydrogen bonding between these two residues.  The loss of LILRB1 W67 (replaced with E67 
in LILRB4) reduces a significant number of hydrogen bonding, van der Waals and 
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Figure 4.16. Conformational incompatibility at the LILRB4/MHC Class I 
interface. (a): Analysis of the LILRB1/HLA-A2/β2m interaction (far left), and 
expanded views of LILRB1 contacts with the β2m moiety (centre), and of critical 
changes at the hypothetical LILRB4/β2m interface (right, with steric clashes indicated 
by red circles). The β2m moiety is shown in green, with LILRB1 in red, and LILRB4 in 
cyan. (b): Analysis of the LILRB2/HLA-G/β2m interaction (far left), with expanded 
views of LILRB2 contacts with the β2m moiety (top centre), and of critical changes at 
the LILRB4/β2m interface (top right) The lower expanded panels show LILRB2 
contacts at the HLA-G α3 domain (centre), and relevant alterations at the 
hypothetical LILRB4/HLA-Gα3 interface (right). The HLA-G heavy chain is shown in 
grey, β2m in green, and LILRB2 and LILRB4 in yellow and cyan, respectively. As for 
(a), likely steric clashes are indicated by red circles. 
(a) 
(b) 
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 hydrophobic interactions with K91, I92 and V93 of the HLA-A2 β2m domain and would thus 
be energetically unfavourable, in addition to changing the electrostatic properties in this 
region.  Conservation of electrostatic charge via the LILRB1 E68 to LILRB4 D68 is apparent 
however the shorter D68 side-chain is unable to maintain the bidentate salt bridge to K94 of 
the β2m domain which is present in the LILRB1/HLA-A2 complex. 
 
Finally, substitution of Q125 (LILRB1) with R124 (LILRB4) results in the loss of a side-
chain hydrogen bond and creates a steric clash with the side-chain of residue Q2 (β2m), 
contributing to many of the  disallowed contacts between the LILRB4 D2 domain and the β2m 
domain of HLA-A2.  Furthermore, minor clashes are observed between residue H153 
(LILRB4) and residue I1 (β2m) (Figure 4.16a). Therefore, amino acid changes at the 
LILR/β2m interface would be predicted to result in both steric clashes and loss of individual 
contacts. 
 
Superposition of the LILRB4 D1 and D2 domains onto the LILRB2/HLA-G complex also 
highlighted a combination of steric clashes, loss of contacts, and electrostatic repulsion effects 
at the interaction surfaces, which also strongly suggest that LILRB4/MHC Class I binding is 
unlikely.  In terms of the α3 domain residues of HLA-G, a number of steric clashes occur with 
the LILRB4 C-C‟ loop and C‟ strand (R36, P43, A44, P45 and R48).  The salt bridge between 
K41 (LILRB2) and D227 (HLA-G) is lost by the substitution to E41 in LILRB4 and replaced 
with electrostatic repulsion of similar charges.  In a similar fashion, the bidentate salt bridge 
between K42 (LILRB2) and E229 (HLA-G) is disrupted by the replacement to the uncharged 
residue S42 in LILRB4 (Figure 4.16b). In addition, secondary structure changes resulting 
from the substitution of S43 (LILRB2) to P43 (LILRB4) introduces steric clashes with the 
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side chain of V248 (HLA-G) and loss of interactions with T200 in the α3 domain.  The 
substitution of I47 and T48 (LILRB2) with D47 and R48 (LILRB4) results in the loss of 
interface stability due to impaired hydrophobic contacts with F195 (HLA-G) and a steric clash 
with R48 (LILRB4), in addition to greatly changing the electrostatic properties at this 
interaction surface. 
 
In terms of LILR interaction with the HLA-G β2m domain, hydrogen bonding between A126 
(LILRB2) and Q2 of β2m is eliminated by the change to P126 (LILRB4) and furthermore 
causes a steric clash between these two residues.  The Q18 (LILRB2) to W18 (LILRB4) 
substitution also creates a steric clash with Q89 of β2m in a similar fashion to the 
LILRB4/HLA-A2 superposition.  Finally, substitution of D177 (LILRB2) to H177 (LILRB4) 
results in the disruption of a salt bridge to β2m residue K6 and loss of a hydrogen bonding 
interaction to T4, thereby reducing the favourable interactions necessary for LILR binding to 
MHC Class I (Figure 4.16b). 
 
As well as the specific electrostatic charge changes and loss of salt bridges discussed in detail 
above, comparison of the electrostatic surfaces of the LILRB1/HLA-A2 complex and 
LILRB2/HLA-G complex with LILRB4 also suggested LILRB4 was unsuited for the 
recognition of MHC Class I.  Figure 4.17a shows an overview of the LILRB1/HLA-A2 
complex colored by electrostatic potential. Notably, the α3 region of the MHC Class I heavy 
chain for both HLA-A2 and HLA-G contacted by the LILRs is predominantly negatively 
charged and features numerous acidic residues. The α3-interacting surface on both LILRB1 
and LILRB2 is relatively positively charged (Figure 4.17a-b), and several interacting 
residues are basic, including R39 and K41 (on LILRB1) and R36, K41 and K42 (on LILRB2), 
suggesting substantial electrostatic complementarity between the interacting surfaces.   
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Figure 4.17. Electrostatic incompatibility at the LILRB4/MHC Class I interface. 
(a): Electrostatic surface representations of HLA-A2 (left), LILRB1 (centre) and 
LILRB4 (right), with the LILR receptors rotated to show the interaction surface. 
Residues involved in LILRB1- β2m interaction are indicated in black, and those 
involved in LILRB1-α3 interaction in green. Equivalent residues on LILRB4 are all 
shown in black. (b): Electrostatic surface representations of HLA-G/β2m (left), LILRB2 
(centre) and LILRB4 (right). Interacting residues are colour-coded as in (a).
(b) 
(a) 
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However, the comparable LILRB4 surface that would contact the α3 domain residues is 
considerably less positively charged than that of LILRB1 and LILRB2 (Figure 4.17a-b, right 
panels).  Furthermore, within this surface, there is a K41E change that reverses charge and 
would introduce electrostatic repulsion at the interface with MHC Class I.  In addition, 
whereas in the LILRB2/HLA-G interaction hydrophobic interactions with the aromatic 
residue F195 on HLA-G are mediated by I47 and T48 on LILRB2, in LILRB4 these are 
changed to D47 and R48, respectively, resulting in a highly charged surface in proximity to 
the hydrophobic HLA-G residue (Figure 4.17b).  Furthermore, D177 on LILRB2 forms salt 
bridges to K6 on HLA-G (β2m), whereas in LILRB4 this residue is altered to H176, 
eliminating this charged residue and the interactions it mediates.  Therefore, the electrostatic 
properties of LILRB4 are unsuitable for recognition of MHC Class I in comparison to the 
MHC Class I-recognising receptors LILRB1 and LILRB2. 
 
These findings collectively suggest that the region of LILRB4 equivalent to the ligand 
binding surface of LILRB1 and LILRB2 is unsuited for MHC class I interaction, both in 
terms of conformation and also the chemical nature of the surface.  Consistent with these 
differences, neither LILRB4 nor the related Group II receptor LILRA5 have shown any 
significant binding to MHC Class I molecules (Shiroishi et al. JBC 2006, Garner et al. Prot 
Exp Pur 2006). 
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4.6 Implications of LILRB4 D1 and LILRB4 D1D2 Structures for Ligand Recognition 
Although the ligands of LILRB4 are unknown, analysis of the LILRB4 structure was 
conducted to try to identify components of an interaction surface or surfaces for ligand 
binding. Firstly, manual inspection of the surface of the D1 domain structure using COOT 
highlighted a group of residues on the ABE face of the domain, consisting of two exposed 
hydrophobic residues (W9 and W25), with three charged groups in close proximity (E11, K57 
and R59). The residues contributing to this putative binding site are conserved across Group 
II LILRs with the exception of W25 in LILRA5 (substituted by R25) and R59 (it is 
substituted conservatively to K59 in LILRB5 and LILRA2).  The two solvent-exposed 
tryptophan side-chains would constitute a hydrophobic patch at the ABE face opposing the 
CFG face which is involved in contacting MHC Class I in LILRB1 and LILRB2 (Figure 
4.18a).  Closely-grouped hydrophobic residues at the surface of a receptor are often indicative 
of a potential binding site.  Intriguingly, in the LILRB4 ectodomain structure this region 
interacts with a sulphate anion (Figure 4.18b). While this observation is suggestive of 
potential as an interaction surface, it is highly unlikely to reflect physiological ligand 
interaction.  
 
Secondly, automated analysis of the LILRB4 ectodomain crystal structure was conducted 
using the SPPIDER web server (Solvent accessibility based Protein-Protein Interface 
iDEntification and Recognition) which utilises an artificial neural network for prediction of 
protein-protein binding sites.  The SPPIDER protein interface recognition server can be used 
to predict residues to be at the putative protein interface(s) by considering a single protein 
chain with resolved 3D structure.  SPPIDER uses Relative Solvent Accessibility-based 
methods for prediction of protein-protein binding sites, based on discrepancies between  
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Figure 4.18. Proposed ligand binding site on the LILRB4 D1 structure. (a): The 
LILRB4 D1 molecular surface is depicted using GRASP with electropositive residues 
shown in blue and electronegative residues in red.  The molecule is oriented with the 
ABE face – which opposes the MHC Class I binding surface in LILRB1/LILRB2 - 
towards the observer.  Selected conserved residues have been labelled.  (b): 
Position of the sulphate anion in the LILRB4 D1 structure. The secondary structure is 
depicted as a ribbon diagram with strands shown as arrows, and the conserved 
residues contributing to the proposed binding site displayed in ball-and-stick 
representation.  The sulphate anion is shown in yellow. 
(b) (a) 
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predicted and observed (in an unbound protein structure) surface exposure of amino acid 
residues (Porollo and Meller, Proteins: Struc Func Bioinformatics 2007). 
 
Output from the SPPIDER web server is in the form of a modified PDB file, with the values 
for B-factor for each residue replaced by a percentage probability score, reflecting the 
likelihood that a particular residue is involved in protein-protein interactions.  The output for 
the submitted LILRB4 ectodomain structure is visualised in Figure 4.19.   From this figure, 
which shows the molecular surface of the LILRB4 ectodomain colour-coded according to the 
SPPIDER output, it can be seen that there are three main regions of potential protein-protein 
interaction site, as predicted by SPPIDER: residues 2-5, 80-82 and 85 at the D1 tip of the 
receptor (particularly P2, V81 and Q85); residues 11-15 and 138-142 at the D1D2 interface 
(noting P12 and L142 as having probability greater than 75 %); and a larger number of 
residues - principally 102-116, 158-165 and 189-195 - with higher probability scores at the 
D2 tip (noting L110, S113, G114, S160, P161 and S164 as having probability 95 % or 
higher). 
 
Both the D1 tip of LILRB1/LILRB2 and the D1D2 interface of these two MHC Class I-
binding receptors are involved in ligand recognition.  This could suggest that the ligand 
binding surfaces of Group II receptors such as LILRB4 share features with Group I LILRs 
that recognize MHC Class I.  The D2 tip region in LILRB4 may be falsely recognised as a 
protein-protein interaction site due to its proximity to the plasma membrane, as LILRB4 has 
only a short stalk region connecting the transmembrane domain to D2. 
189 
 
 
>97
64-84
85-91
92-97
48-63
41-47
11-40
0-10
P2
Q85
P80 V81
G82
A97
Y98
K100
H153
E156L106
P107
S108
P109
L110
K115
P2
L3
P4
K5
P80
V81
T7
E11
P12
V15A138
H139L142
R136
E135P161
T163 S164
V165
G168T169
R171
E191
P189
I193
V194
S195
L110
S113
 
Figure 4.19. SPPIDER prediction of protein-protein interaction sites in LILRB4.  
The LILRB4 D1D2 PDB file was submitted to the SPPIDER web server and the 
output is depicted as a bar chart of probability of interaction against amino acid 
residue (top panel).  Each bar is colour coded as per the lower panels.  The lower 
panel shows the molecular surface of LILRB4, generated using Swiss PDB Viewer 
and colour coded according to probability.  Two views are shown, towards the CFG 
face (lower left panel) or towards the ABE face (lower right panel).  Residues of 
interest above the 50% probability limit are labelled. 
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Finally, although SPPIDER predictions failed to match the surface highlighted by manual 
inspection, the D1D2 hinge region site predicted by SPPIDER also included E11, and 
therefore overlapped minimally with this surface. Nevertheless one could consider the 
presence of a hydrophobic patch at the ABE face of the receptor to be indicative of a potential 
ligand binding site and this possibility cannot be easily discounted. 
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4.7 Chapter Summary and Discussion 
In previous work to conduct structural and ligand identification studies on LILRB4, the 
extracellular domain of wild type LILRB4 D1D2 was produced using E. coli expression and 
in vitro refolding methodologies.  Although pure, antibody-reactive material was produced to 
high levels (Garner et al. Prot Exp Pur 2006), its limited in vitro stability and propensity for 
precipitation during concentration steps proved problematic and crystallization trials only 
produced microcrystals of insufficient quality for X-ray diffraction data collection.   
 
In order to progress LILRB4 structural analyses, I adopted an alternative strategy to obtain 
diffraction-quality crystals, i.e. production of the single D1 domain form of the receptor, on 
the basis that partial structural information was better than no information at all, and in 
concert with the hypothesis that the D1 domain would be more likely to constitute the ligand-
binding portion of the receptor, due to the two-domain arrangement of LILRB4 (as opposed 
to the four-domain composition of most of the other LILR molecules).  The phylogenetic 
analysis of the LILR family provided some support for this hypothesis, as the D2 domain of 
LILRB4 has more identity with the D4 domains of the other LILRs, which has been shown 
not to be involved in ligand recognition (for those LILRs where the ligand and binding sites 
are known). 
 
This approach proved particularly successful, both in terms of solving stability and protein 
precipitation obstacles and also in terms of crystallisation.  The isolated D1 domain of 
LILRB4 readily crystallised and these crystallisation conditions were rapidly optimised to 
produce crystals capable of X-ray diffraction to a resolution of 1.6 Å.  Use of the previously-
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published LILRA5 structure as a model for molecular replacement – again on the basis of 
phylogenetic analysis of the LILR family – was also highly successful and resulted in high-
resolution structural data with publishable refinement statistics (see Table 4.2 and Table 4.6, 
and also Figure 4.6 and Figure 4.7).  This allowed for analysis of structural elements of the 
LILRB4 D1 domain, namely secondary structure assignment and tertiary structural 
arrangement, rationalisation for non-binding to MHC Class I on the basis of steric and 
electrostatic clashes by comparison with LILRB1/HLA-A2 and LILRB2/HLA-G, and 
comparison with its closest LILR family member, LILRA5.  It also allowed me to formulate a 
hypothesis regarding a potential ligand-binding site on the ABE face of the domain. 
  
Nevertheless, despite these successes more complete structural information was desirable.  An 
alternative strategy to overcome problems with the LILRB4 ectodomain was undertaken by 
Prof. Gao‟s group, namely the production of a mutated form of the receptor introducing a 
non-native disulphide bond into the D2 domain in order to reduce flexibility in the molecule 
and thus minimize precipitation and promote crystallisation.  This approach had previously 
been utilised and had resulted in the successful crystallisation and structure determination of 
LILRA2 (Chen et al. JMB 2007). 
 
Analysis of the interdomain interface of the LILRB4 ectodomain revealed that the more 
obtuse D1-D2 interdomain angle of LILRB4 is shifted out by approximately 20° relative to 
the other LILR family members.  This is accompanied by a marginally reduced buried solvent 
accessible area at the interdomain region (846 Å
2
 for LILRB4 compared to 957 Å
2
 for 
LILRB1) and the substitution of a key bulky hydrophobic residue resulting in the loss of 
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contacts to neighboring residues.  LILRB4 is therefore unique in terms of its more obtuse 
interdomain angle, and this may have profound implications for ligand recognition by 
LILRB4 and supports the hypothesis that LILRB4 may interact with its ligand in a „head-on‟ 
fashion, primarily through the D1 domain, with the D2 domain serving to orientate the ligand-
binding D1 domain towards its target or targets.  However, one caveat with respect to this 
issue is that the presence of the engineered disulphide could affect the topology of the 
LILRB4 D2 C-C‟ loop such that it artificially contributes to stabilization of this particular 
interdomain angle, due to the involvement of residues from the unique LILRB4 C-C‟ 310 helix 
(Figure 4.15b) and in particular P140, which are absent in LILRB1/LILRB2/LILRA5, in 
interdomain interactions.  In the absence of this disulphide bond, it seems highly likely that 
the native form of LILRB4 would exhibit a high degree of flexibility at the D1D2 hinge 
region and therefore have the capacity to adopt a range of interdomain angles, which is 
consistent with the high degree of proteolytic cleavage observed between the D1 and D2 
domains of the native receptor. 
 
The introduction of the artificial disulphide into the C-C‟ loop of LILRB4 D2 may affect the 
overall structure in two ways; firstly, it may affect the propensity of this region to form a 
helical structure (residues 139-143) and secondly it may affect the interdomain interface, 
since the resulting loop lies in close proximity to the first domain and effectively „blocks‟ the 
hinge region.  It is therefore possible introduction of the non-native disulphide may account 
for the more obtuse interdomain angle, which is calculated to be 107˚ (DomAngle software 
program, Su et al. Science 1998), in contrast to the ~90˚ angle adopted by the other LILR 
receptors which have been crystallised.  Figure 4.15 illustrates that this arrangement can 
provide a region of close proximity between D2 C-C‟ loop residues and D1 residues.  The 
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interdomain interface contacts thus introduced could stabilize this interdomain angle and 
reduce interdomain flexibility, thereby favouring crystallization of the receptor.  It is tempting 
to speculate that the native disulphide in this region in LILRB1 and LILRB2, which 
corresponds to the artificial disulphide introduced into LILRA2 and LILRB4 and allowed 
crystallization of these receptors, contributes to the propensity of LILRB1 and LILRB2 to 
crystallize by reducing flexibility in this region.  However, notably the D2 C-C‟ loop adjacent 
to the disulphide is not involved in contacting D1 in either LILRB1 or LILRB2, and an 
alternative possibility is that the naturally more extensive D1-D2 interdomain interface 
interactions in LILRB1 and LILRB2 result in less flexibility at the D1-D2 hinge region and 
instead underlie their greater propensity to crystallise.  
 
Structural analyses of LILRB4 identified strong rationalisation for its non-binding to MHC 
Class I.  Analysis of the D1 structure alone identified key amino-acid substitutions with 
LILRB1 at the known MHC binding sites.  In addition, the LILRB4 D1D2 ectodomain 
structure was superimposed on the LILRB1/HLA-A2 and LILRB2/HLA-G complex 
structures and revealed a number of steric clashes, loss of hydrogen bonding networks and 
disruption of salt bridges which would make LILRB4/MHC Class I binding unlikely (see 
Figure 4.16).  Further evidence to support this hypothesis comes from analysis of the 
electrostatic surface of LILRB4, which shows major changes in electrostatic charge – both in 
terms of polarity and in loss/gain of charges – in comparison to LILRB1 and LILRB2 at the 
known MHC Class I binding sites (see Figure 4.17). 
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Analysis of potential non-MHC ligand-binding sites in the LILRB4 D1 structure by visual 
inspection and also in the LILRB4 D1D2 ectodomain structure by an automated 
computational method, SPPIDER, suggested a number of possibilities for protein-protein 
interaction sites at the receptor surface.  In addition, the ABE surface of the D1 domain of 
LILRB4 has a close grouping of residues that are mostly conserved across the Group II LILRs 
and this includes charged residues and two solvent-exposed hydrophobic tryptophan residues 
in close proximity.  Although SPPIDER failed to detect most of these residues as being highly 
probable for protein-protein interaction, some additional evidence for this hypothesis is 
provided by the presence of a sulphate anion bound to this ABE face site in the LILRB4 
D1D2 ectodomain structure.   
 
The SPPIDER analysis detected probable ligand interaction sites at the D1 tip, the D1D2 
interdomain region, and at the D2 tip of LILRB4.  These first two sites are reminiscent of the 
binding sites for MHC Class I on LILRB1 and LILRB2, although the balance of evidence 
suggests that MHC Class I is not the ligand for LILRB4.  However, the possibility remains 
that LILRB4 uses regions analogous to those on LILRB1/2 involved in MHC Class I binding, 
for recognizing different ligand interaction sites.  In keeping with this concept, KIRs and 
FcαR use regions analogous to those used by LILRB1/2 for binding to distinct ligand sites on 
either MHC Class I (the α1α2 platform, for KIRs) or IgA (for FcαR)  (Willcox et al. Nat 
Immun 2003).  Another possibility which is supported by the more obtuse domain angle of 
LILRB4 and the arrangement of its two domains is that the receptor engages such a ligand in 
a „head-on‟ fashion as discussed earlier. 
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Further studies of LILRB4 are thus necessary to solve the puzzle of its ligand and the high-
resolution structural data presented herein may contribute to the search for this elusive 
binding partner.  In an attempt to glean further information about the Group II LILRs, which 
could conceivably shed light on the nature of the LILRB4 ligand I attempted structural studies 
on the other members of this group, and I will present these data in the following chapter. 
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CHAPTER 5 - STRUCTURAL STUDIES OF OTHER GROUP II 
LILRS 
5.1 Introduction 
Following the successful crystallisation and X-ray structural analysis of the D1 domain of 
LILRB4, I decided to attempt a similar strategy to obtain structural information for other 
Group II LILRs.  Previous attempts at in vitro refolding of other LILR family members had 
been largely unsuccessful, hypothetically as a result of flexibility of the two-domain 
recombinant proteins and/or incorrect disulphide bond formation leading to instability in 
solution and concomitant precipitation during the refolding process.  Although this strategy 
would yield structural data for only one of the domains it was reasoned that obtaining limited 
structural information across the Group II LILRs would still be valuable.  The high yield of 
inclusion bodies from E. coli transformed with the LILRB4 D1 pET23a vector and the high 
yield and purity of correctly refolded LILRB4 D1 obtained gave me confidence that such a 
strategy would be fruitful for generation of crystals of other Group II LILRs for X-ray data 
collection.  Since the crystal structure of the LILRA5 ectodomain had previously been 
elucidated by Maenaka et al. in 2006, we focussed on the remaining Group II LILRs, 
LILRB3, LILRB5 and LILRA4.  LILRA6 was ignored as its amino acid sequence is identical 
to LILRB3 in the D1 domain. 
 
The published literature on LILRB3 and LILRB5 is sparse and relatively little is known about 
these two receptors functionally or structurally.  Both are predicted to have four Ig domains in 
the extracellular region and ITIM motifs in the cytoplasmic domain (Borges et al. JI 1997).  
LILRB3 is expressed on cells of the myeloid lineage, with upregulation of its expression on 
monocytes and granulocytes as the cells undergo maturation (Sloane et al. Blood 2004).  
LILRB3 is also expressed on human cord-blood derived progenitor mast cells, but not on 
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mature mast cells, further suggesting a role in maturation and differentiation of myeloid cells 
(Tedla et al. J Leuk Bio 2008).  Abnormal expression of LILRB3 has been detected in 
rheumatoid arthritis patients, with upregulation of the receptor on synovial fluid mast cells 
(Tedla et al. Am J Pathol 2002, Huynh et al. Rheumatology 2007).  LILRB3 may therefore 
have involvement in autoimmune pathologies. 
 
The expression levels of both LILRB3 and LILRB5 are elevated in skin samples from patients 
with lepromatous leprosy (Bleharski et al. Science 2003).  LILRB5 expression at the mRNA 
level was first described in a restricted subset of NK cells only (Borges et al. JI 1997) but 
protein expression remained undetected until recently, when it was described as being in the 
granules of mature cord-blood derived mast cells: intracellular LILRB5 colocalizes with 
tryptases in mast cell granules, is mobilized to the surface and also released as a soluble form 
upon FcεRI cross-linking, suggesting that the function of the soluble protein is as a decoy 
receptor (Tedla et al. J Leuk Bio 2008).  Thus, one could speculate that LILRB5 may function 
to regulate inflammation in the skin. 
 
LILRA4 (also termed ILT7) is selectively expressed on plasmacytoid dendritic cells (pDCs), 
has four extracellular Ig domains and associates with the FcεRIγ adaptor protein (Rissoan et 
al. Blood 2002).  LILRA4 engagement would thus be expected to signal in an activatory 
fashion; however, TLR stimulation of primary pDCs in the presence of cross-linking 
antibodies to LILRA4 inhibits the production of type I IFNs (Cao et al. JEM 2006, Cho et al. 
Int Immun 2007).  The ligand for LILRA4 was recently identified as being BST2 (Cao et al. 
JEM 2009), also known in the retroviral field as Tetherin and identified as being a host-
encoded viral restriction element that prevents virus budding in certain cell lines (Neil et al. 
Nature 2008).  As IFN-α upregulates BST2 expression, the LILRA4/BST2 interaction may 
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function during infection as a feedback inhibition loop to downregulate the antiviral responses 
of pDCs when type I IFN responses are sufficient (Blasius et al. JI 2006). 
 
5.2 Attempted Crystallisation of Other Group II LILR D1 Domains 
5.2.1 Cloning of Recombinant Group II LILR D1's  
A construct for expression of the D1D2 domains of LILRA4 in E. coli was generated by 
cloning from the full-length LILRA4 gene in the plasmid pCMV-Flag (a kind gift from Dr. 
Rachel Allen).  In brief, a PCR was conducted using primers to introduce a start codon and 
optimised codons for E. coli expression at the N-terminus and a premature stop codon at the 
C-terminal D2-D3 boundary, as estimated by primary amino acid sequence alignment with the 
other LILR family members (see Figure 4.1a).  The nucleotide and amino acid sequence of 
LILRA4 D1D2 are shown in Figure 5.1a.  These primers incorporated an NdeI restriction site 
(including an ATG codon for the initiating methionine) in the 5’ primer and a HinDIII 
restriction site in the 3’ primer (Figure 5.1b) in order to allow cloning into the MCS of 
pET23a.   
 
After PCR generated a product of the expected mass (c. 600 bp, see Figure 5.1c), the PCR 
product was then digested with NdeI and HinDIII, gel purified and ligated into cut and gel 
purified pET23a vector.  This ligation product was used to transform E. coli DH5α cells. 
Colonies were selected for plasmid miniprep and test digests with NdeI-HinDIII and agarose 
gel electrophoresis showed that a fragment of the expected size was generated (Figure 5.1d, 
arrowed).  Subsequent DNA sequence analysis confirmed successful cloning of the LILRA4 
D1D2 sequence into the pET23a vector.  (Functional Genomics, Department of Biosciences, 
University of Birmingham). 
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(a) 
   1 ctacgggcac cgtggccaca cctgcctgca cagccagggc caggaggagg agatgccatg 
  61 accctcattc tcacaagcct gctcttcttt gggctgagcc tgggccccag gacccgggtg 
 121 caggcagaaa acctacccaa acccatcctg tgggccgagc caggtcccgt gatcacctgg 
 181 cataaccccg tgaccatctg gtgtcagggc accctggagg cccaggggta ccgtctggat 
 241 aaagagggaa actcaatgtc gaggcacata ttaaaaacac tggagtctga aaacaaggtc 
 301 aaactctcca tcccatccat gatgtgggaa catgcagggc gatatcactg ttactatcag 
 361 agccctgcag gctggtcaga gcccagcgac cccctggagc tggtggtgac agcctacagc 
 421 agacccaccc tgtccgcact gccaagccct gtggtgacct caggagtgaa cgtgaccctc 
 481 cggtgtgcct cacggctggg actgggcagg ttcactctga ttgaggaagg agaccacagg 
 541 ctctcctgga ccctgaactc acaccaacac aaccatggaa agttccaggc cctgttcccc 
 601 atgggccccc tgaccttcag caacaggggt acattcagat gctacggcta tgaaaacaac 
 661 accccatacg tgtggtcgga acccagtgac cccctgcagc tactggtgtc aggcgtgtct 
 
MTLILTSLLFFGLSLGPRTRVQAENLPKPILWAEPGPVITWHNPVTIWCQGTLEAQG
YRLDKEGNSMSRHILKTLESENKVKLSIPSMMWEHAGRYHCYYQSPAGWSEPSDP
LELVVTAYSRPTLSALPSPVVTSGVNVTLRCASRLGLGRFTLIEEGDHRLSWTLNSH
QHNHGKFQALFPMGPLTFSNRGTFRCYGYENNTPYVWSEPSDPLQLLVS                                          
 
(b) 
5’: GGAATTC CATATG GAAAACCTGCCGAAACCGATCCTGTGGGCTGAACCG 
3’ Primer: CCCCTGCAGCTACTGGTGTCATGA GGATCC GCG 
3’ Reverse Complement: CGC GGATCC TCATGACACCAGTAGCTGCAGGGG 
 
500 bp
1 kb
1 kb
100 bp
ladder
100 bp
ladder PCR Cut Cut CutUncut Uncut Uncut
Clone 1 Clone 2 Clone 3
500 bp
(c) (d)
 
Figure 5.1. Cloning of LILRA4 D1D2 into pET23a vector. (a): Nucleotide sequence 
for LILRA4 D1D2.  The boundaries of the coding sequence for the domain are 
underlined and in bold. The translation of the sequence is shown underneath with the 
signal peptide in italics and the D1D2 boundaries in bold. (b): Primer design for 
LILRA4 D1D2-pET23a construct showing insertion of the overhang and NdeI site into 
the 5’ primer in bold (incorporating the ATG codon for the initiating methionine) and 
mutations to optimise codon usage underlined. The overhang, HinDIII site and stop 
codon are also highlighted in the 3’ primer. (c): Agarose gel electrophoresis of the 
LILRA4 D1D2 PCR product and (d): test digests of three clones from minipreps of the 
LILRA4 D1D2 PCR product ligated into the pET23a vector. 
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Although expression of LILRA4 D1D2 as E. coli inclusion bodies was successful, attempts to 
chemically refold the protein were not, in common with previous attempts to generate 
correctly refolded LILRB3 and LILRB5 (data not shown).  LILRB3 and LILRB5 two-domain 
constructs in pET23a vectors had previously been generated in the laboratory.  Due to the 
success of the LILRB4 D1 strategy for generating high yields of correctly folded protein and 
data-quality grade crystals for X-ray diffraction studies, I decided to generate LILR D1-
pET23a constructs for LILRA4, LILRB3 and LILRB5. 
 
LILRB3 D1, LILRB5 D1 and LILRA4 D1 constructs were generated by SDM of the relevant 
two-domain pET23a plasmids.  Primers were designed to introduce a premature stop codon at 
the D1-D2 boundary, at the residues corresponding to ...GAY of the LILRB4 D1 construct.  
After dpnI digestion to remove template plasmid, these new D1 plasmids were used to 
transform  E. coli DH5α cells for plasmid miniprep and DNA sequencing to confirm the 
correct sequence.  The cloning strategy and primer sequences are shown in Figure 5.2. 
 
 
5.2.2 Protein Expression in E. coli and in vitro Refolding of Group II LILR D1 Domains 
LILRB3 D1 pET23a, LILRB5 D1 pET23a and LILRA4 D1 pET23a plasmids were used to 
transform E. coli BL21(DE3) cells for test expression and subsequent analysis by SDS-PAGE 
(Figure 5.3a).  Test expression was judged to be successful with significant upregulation of a 
single protein band of the expected apparent mass for each construct after IPTG induction.  
Bulk expression was then carried out for each construct, and after harvesting and washing of 
inclusion bodies, the protein was solubilised overnight at 4 ºC in Guanidine solubilisation 
buffer. Yields at this stage were high (typically 50 mg/L of solubilised denatured protein). 
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(a) 
 
LILRA4 
... 
361 agccctgcag gctggtcaga gcccagcgac cccctggagc tggtggtgac agcctacagc 
421 agacccaccc tgtccgcact gccaagccct gtggtgacct caggagtgaa cgtgaccctc 
... 
LILRB3 
... 
421 gcaggctggt cagagcccag cgaccccctg gagctggtga tgacaggagc ctacagcaaa 
481 cccaccctct cagccctgcc cagccctgtg gtggcctcag gggggaatat gaccctccga  
... 
LILRB5 
... 
361 tgctactatg agacccctgc aggctggtca gagcccagtg accccctgga gctggtggcg 
421 acaggattct atgcagaacc cactctttta gccctgccga gtcctgtggt ggcctcagga 
... 
 
(b) 
 
LILRA4 ...ELVVTAYSRPTLSALP... 
LILRB3 ...LVMTGAYSKPTLSALP... 
LILRB5 ... LVATGFYAEPTLLALP... 
 
(c) 
 
LILRA4    GAGCTGGTGGTGACAGCCTACAGCAGACCCACCCTGTCCGCACTGCCA 
LILRB3    CTGGTGATGACAGGAGCCTACAGCAAACCCACCCTCTCAGCCCTGCCC 
LILRB5    CTGGTGGCGACAGGATTCTATGCAGAACCCACTCTTTTAGCCCTGCCG 
 
(d) 
 
LILRA4    5’ GAGCTGGTGGTGACAGCCTACTAATAACCCACCCTGTCCGCACTGCC 
      3’ GGCAGTGCGGACAGGGTGGGTTATTAGTAGGCTGTCACCACCAGCTC 
 
LILRB3    5’ CTGGTGATGACAGGAGCCTACAGCAAACCCACCCTCTCAGCCCTGCC 
      3’ GGCAGGGCTGAGAGGGTGGGTTTGCTGTAGGCTCCTGTCATCACCAG 
 
LILRB5    5’ CTGGTGGCGACAGGATTCTATGCAGAACCCACTCTTTTAGCCCTGCCG 
      3’ CGGCAGGGCTAAAAGAGTGGGTTCTGCATAGAATCCTGTCGCCACCAG 
 
 
Figure 5.2. SDM primer design for LILRA4, LILRB3 and LILRB5 D1 constructs. 
(a): Nucleotide sequence corresponding to the D1D2 junction for each LILR. 
Nucleotide sequence selected for primer design is underlined and in bold. (b): 
Corresponding peptide translation of the underlined nucleotides. The terminal three 
D1 residues are in bold. (c): Target nucleotide sequences for each protein, with the 
codons to be mutated to stop residues underlined. (d): Final SDM primer designs for 
each construct. 
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In vitro refolding of inclusion bodies was conducted by the standard Garboczi method (PNAS 
1992), and followed by purification by size exclusion chromatography into a buffer 
containing 50 mM NaCl 20 mM Tris pH 8.0.  Single peaks corresponding to monomeric 
protein were detected at an elution volume of approximately 260 ml – in the expected range 
for a single Ig domain of 12 kDa – for each protein, with minimal aggregate peaks at earlier 
elution points (Figure 5.3b).  Absorbance at 280 nm of these peaks was typically between 
400-500 mAU indicating a high yield.  Subsequent concentration of the peak fractions (using 
stirred cell (Amicon) and centrifugal filter devices (Microcon)) allowed protein 
concentrations of ~10 mg/ml to be achieved with an estimated final yield of 15 % per refold. 
 
Protein samples were analysed by SDS-PAGE to ensure correct refolding and verify apparent 
molecular mass.  As can be seen from Figure 5.3c, a single band corresponding to monomeric 
protein with an apparent mass of c. 12 kDa was visible for each protein after coomassie 
staining of the gel.  In addition, a single band was detected under non-reducing conditions, 
suggestive of correct disulphide bond formation.  The high yield and purity of the proteins 
was considered to be promising for successful crystallisation trials. 
 
 
5.2.3 Crystallisation Screening of LILRB3 D1 and LILRB5 D1 
Crystallisation screens were set up on a small scale using a Mosquito crystallisation robot, in 
a 100 nl plus 100 nl hanging drop format in 96-well plates, with 100 μl of reservoir solution in 
each well.  Commercially available screens used were JCSG
+
, Structure Screens I and II, and 
PACT (Molecular Dimensions Ltd.), PEG/Ion I and II, Index Screen (Hampton Research) and 
Wizard Screens I and II (Emerald Biosystems).  Each of the six screens utilised one 96-well 
plate.
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Figure 5.3. Purification and SDS-PAGE analysis of Group II LILR D1 proteins. 
(a): SDS-PAGE analysis of test expression samples of Group II LILR D1 domains. 
(b): size exclusion chromatography profiles for Group II LILR D1 proteins after FPLC 
using S200 column. (c): SDS-PAGE analysis of refolded, concentrated proteins under 
reducing and non-reducing conditions. 
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Initial attempts to crystallise LILRB3 D1 utilised protein primarily at 10 mg/ml, with some 
screens set up between 11-16 mg/ml (with one outlier at high concentration, 38 mg/ml).  The 
protein buffer was varied between 50 mM Na Cl 20 mM Tris pH 8.0, and a buffer used for 
optimal stability with LILRB4, namely 50 mM Na citrate pH 5.5.  Drops were inspected 
visually using a Leica light microscope at 3 days and at weekly intervals thereafter for a 
maximum of 2 months.  Although a large number of the drops had visible precipitate 
(especially at the higher concentrations), no microcrystals were observed with the exception 
of JCSG
+
 condition number 22 (0.2 M magnesium chloride, 0.1 M Na cacodylate pH 6.5, 50 
% v/v PEG 200) which yielded small poor quality crystals.  However, attempts to repeat this 
hit both on the small and the large scale (1 μl plus 1 μl drops, 1 ml reservoir solution in a 24-
well Limbro plate) were unsuccessful.  
 
Due to the high levels of precipitation, a second round of crystallisation trials were screened 
at the lower concentration of 5 mg/ml and in 50 mM Na citrate pH 5.5 buffer.  These drops 
were primarily clear and yielded no microcrystals.  Further optimizations were attempted by 
varying the protein concentration, with screens set up at 20 mg/ml, but again no microcrystals 
were observed.  As further strategies to promote crystallisation, sitting-drop crystal screens 
were attempted on the small scale utilising protein at 14 mg/ml, and each of the six screens 
were set up at 4 ºC also on the small scale but at lower protein concentration (5 mg/ml).  None 
of these strategies produced any visible microcrystals.  
 
In parallel, LILRB5 D1 screens were generated by the same methodology.  An initial round of 
screening utilising all six commercial screens with LILRB5 D1 protein at a concentration of 
10 mg/ml and in 50 mM Na citrate pH 5.5 buffer also produced no hits.  A further round of 
screening was conducted at a concentration of 20 mg/ml and in 50 mM NaCl 20 mM Tris pH 
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8.0.  This also failed to produce microcrystals.   
 
In order to progress with crystallisation, thermal shift screening was conducted on LILRB3 
D1 and LILRB5 D1 protein, to try to optimise protein solubility and stability, which might 
influence nucleation and subsequent formation of microcrystals (for review, see Macpherson 
et al. Methods 2004).  This thermal stability screening process was conducted in collaboration 
with Dr. Timothy Knowles (Overduin Group, Cancer Sciences, University of Birmingham) 
and utilised Sypro Orange dye in combination with a thermal cycler and RT-PCR analysis 
software.  Sypro Orange binds to exposed hydrophobic patches on denatured proteins and its 
fluorescence profile can thus be used as a measure of correct protein folding.  A thermal 
cycler is used to analyse buffer conditions and protein in a 96-well format, with a stepwise 1 
ºC increment in temperature from 25 ºC to 95 ºC.  As the protein is exposed to increasing 
temperature, it undergoes unfolding and denaturation which leads to the exposure of 
hydrophobic core residues and an increase in Sypro Orange dye binding which can be 
detected spectroscopically.  The melting temperature – Tm – of the protein is the point at 
which this binding is half maximal and is a measure of the protein stability and solubility in 
that specific buffer condition. 
 
A plot of temperature versus fluorescence yielded the melting curve for that particular 
protein/buffer combination.  A plot of temperature versus the first derivative of fluorescence 
(Rn (T)) generated a dissociation curve, the inflection point of which is the Tm for that protein 
in that buffer condition.  Buffer optimisation is then a case of identifying which buffers 
increase the Tm.  For LILRB3 D1, the buffer was optimised to 50 mM Bis-Tris propane pH 
6.0.  For LILRB5 D1, the optimal buffer was determined to be 150 mM NaCl, 50 mM Bis-
Tris propane pH 6.0. 
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One final round of crystal screening was conducted using LILRB3 D1 and LILRB5 D1 at 20 
mg/ml in optimised buffers.  Hanging drops were set up on the small scale utilising all six 
commercial screens; however, no microcrystals were detectable at 3 days or weekly up to 2 
months after setup.  A list of screens and conditions for all three proteins (including LILRA4 
D1, discussed below) is shown in Table 5.1 (overleaf). 
 
5.2.4 Crystallisation Screening and Optimisation for LILRA4 D1 
Crystallisation screening for LILRA4 D1 was more successful.  Although initial screens on 
the small scale (100 nl plus 100 nl hanging drops, 100 μl reservoir in 96-well plates) at 10 
mg/ml in 50 mM Na Cl 20 mM Tris pH 8.0 buffer yielded no hits, further screens at 20 mg/ml 
in the same buffer yielded 23 hits across all six screens.  The principle crystal morphology of 
these hits was long, thin needles.  The screens and conditions which yielded microcrystals are 
shown in Table 5.2 (overleaf). 
 
To ensure crystals were protein and not crystallisation condition components, and to optimise 
crystal morphology, each of the 23 conditions was set up on the small scale with protein at a 
concentration of 0, 15, 20 or 25 mg/ml.  After 3 days, all control drops were clear.  
Furthermore, although hanging drops set up at 15 mg/ml primarily contained precipitate only, 
all drops at 20 mg/ml and above contained microcrystals as before.  Index Screen condition 
35 was observed as generating the best morphology microcrystals for optimisation (1.0 M 
ammonium sulphate, 0.1 M HEPES pH 7.0, 0.5 % w/v PEG 8000), namely long thin needles 
but the thickest of those observed across all 23 conditions.  Protein concentration was judged 
to be optimal at 20 mg/ml although the presence of multiple nucleation sites suggested that 
reducing protein concentration might lead to increased crystal size on the larger scale. 
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LILRB3 
Screen [Protein]  mg/ml Buffer 
JCSG+ 5, 10, 20, 37.8 50 mM Na Citrate pH5.5 
SS I&II 5, 10, 20 “ 
Wizard I & II “ “ 
PACT “ “ 
PEG-Ion I&II “ “ 
Index “ " 
JCSG+ 15.6 50 mM NaCl 20mM Tris pH8.0 
SS I&II 14, 11 “ 
Wizard I & II 14, 10 “ 
PACT “ “ 
PEG-Ion I&II 14, 11 “ 
Index “ “ 
LILRB5 
Screen [Protein]  Buffer 
JCSG+ 10 50 mM Na citrate pH 5.5 
SS I&II “ “ 
Wizard I & II “ “ 
PACT “ “ 
PEG-Ion I&II “ “ 
Index “ " 
JCSG+ 20 50 mM NaCl 20 mM Tris pH 8.0 
SS I&II “ “ 
Wizard I & II “ “ 
PACT “ “ 
PEG-Ion I&II “ “ 
Index “ “ 
JCSG+ 20 150 mM NaCl 50mM Bis-Tris propane pH 6.0 
SS I&II “ “ 
Wizard I & II “ “ 
PACT “ “ 
PEG-Ion I&II “ “ 
Index “ “ 
LILRA4 
Screen [Protein]  Buffer 
Wizard I & II 10 50 mM NaC l 20 mM Tris pH 8.0 
SS I&II “ “ 
JCSG-plus 20 “ 
SS I&II “ “ 
Wizard I & II “ “ 
PACT “ “ 
PEG-Ion I&II “ “ 
Index “ “ 
 
Table 5.1. Initial screens and conditions for Group II LILR D1 crystallisation 
trials. 
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Four conditions were selected as giving rise to the best morphologies and used as a base 
condition to screen for optimal buffer pH, which can affect crystal growth and morphology 
(McPherson J Appl Cryst 1995).  These conditions were: PEG-Ion Screen I condition 6 (0.2 
M Na Cl, pH 6.9, 20 % PEG 3350), PEG-Ion Screen I condition 25 (0.2 M magnesium acetate 
tetrahydrate, pH 7.9, 20 % PEG 3350), Index Screen condition 26 (1.1 M ammonium tartrate 
dibasic pH 7.0) and Index Screen condition 35 (1.0 M ammonium sulphate, 0.1 M HEPES pH 
7.0, 0.5 % w/v PEG 8000).  A small-scale hanging-drop screen was set up for each condition 
utilising the StockOptions pH Buffer Kit (Hampton Research), varying the pH of the added 
buffer from pH 2.2 to pH 11.0 in steps of 0.4 pH units.  Protein concentration was kept fixed 
at 20 mg/ml.  After 3 days incubation, the best morphology crystals were observed in the 
following conditions:  1.0 M ammonium sulphate, 0.1 M HEPES pH 6.8, 0.5 % w/v PEG 
8000 and 1.0 M ammonium sulphate, 0.1 M Tris pH 9.0, 0.5 % w/v PEG 8000.  These 
microcrystals were thicker, more oblate needles, but still of insufficient size for X-ray data 
collection. 
 
The two optimised conditions were then repeated on the larger scale (1 μl + 1 μl hanging 
drops, 1 ml reservoir solution in a 24-well Limbro plate).  Needle-shaped crystals were 
observed after 3 days incubation at 25 °C and were of the dimensions of approximately 500 x 
25 x 25 μm.  Unfortunately this was judged to be too small for X-ray data collection; attempts 
to loop these crystals were made by Dr. Mohammed but the crystals were too small and 
fragile for successful looping prior to flash-cooling. 
 
Additional rounds of optimisation were conducted using the Mosquito robot.  Varying 
concentrations, from 0.25 M to 1.5 M of NaCl, ammonium sulphate, ammonium chloride or 
ammonium acetate were used in combination with 0.1 M HEPES pH 7.0 and 0.5 % w/v PEG 
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8000.  Protein concentration was varied at 5, 10, 15 or 20 mg/ml for each condition.  No 
discernible improvement in crystal size or morphology was obtained.  A commercially-
available additive screen (Additive Screen, Hampton Research) was employed using the base 
condition (1 M ammonium sulphate, 0.1 M HEPES pH 7.8, 0.5 % PEG 8000), with protein 
concentration fixed at 20 mg/ml (protein buffer was 50 mM NaCl 20 mM Tris pH 8.0 as 
before).  This screen includes a range of divalent cations, some of which have been noted to 
have favourable effects upon protein crystallization (Trakhanov and Quiocho Protein Science 
1995).  Numerous hits were obtained after 3 days and the conditions are tabulated in Table 
5.3 below. 
 
Well Additive 
A6 0.1 M Magnesium chloride hexahydrate 
A7 0.1 M Manganese(II) chloride tetrahydrate 
A8 0.1 M Strontium chloride hexahydrate 
B2 0.1 M Praseodymium(III) acetate hydrate 
B3 1.0 M Ammonium sulphate 
B4 1.0 M Potassium chloride 
B5 1.0 M Lithium chloride 
B7 0.5 M Sodium fluoride 
C1 1.0 M Sodium malonate pH 7.0 
C5 0.1 M Sodium bromide 
C12 0.1 M Taurine 
D1 0.1 M Betaine hydrochloride 
D6 0.1 M Trimethylamine hydrochloride 
D10 0.1 M Adenosine-5’-triphosphate disodium salt hydrate 
D11 0.1 M TCEP hydrochloride 
 
Table 5.3. LILRA4 D1 Hampton Research Additive Screen for crystallisation.  
Highlighted additives were used for scale-up screening.  
 
From this screen, six additives were selected as giving rise to the most favourable 
morphologies, and were used in a larger scale screen (1 μl plus 1 μl hanging drops, 1 ml 
reservoir solution in a 24-well Limbro plate) utilising essentially the same conditions as the 
small-scale additive screen.  These additives are highlighted in Table 5.3.  A final condition 
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was selected (1 M ammonium sulphate, 0.1 M HEPES pH 7.8, 0.5 % PEG 8000, 10 mM 
manganese chloride tetrahydrate) and replica drops were set up on the larger scale at varying 
protein concentrations from 10 mg/ml to 20 mg/ml in 2 mg/ml steps.  Crystals were visible in 
these drops after just 3 h incubation and were thick oblate/needle shaped crystals but with 
multiple nucleation sites in each drop.  Reducing protein concentration only partly correlated 
with the number of crystals in each drop and the dimensions of the crystals were still not 
improved (i.e. the crystals were of sufficient length but insufficient depth and width to be 
viable for X-ray data collection). 
 
Additional optimisations on the large scale were conducted.  These included omitting the PEG 
8000 (which appeared to have no effect), varying the well solution volume to attempt to 
change the rate of equilibration between the drop and the well solution, varying the drop size 
(using 2 μl plus 2 μl and 3 μl plus 3 μl size drops) and attempting sitting drops (1 μl plus 1 μl 
and 2 μl plus 2 μl in sitting-drop bridges).  No improvements in terms of a reduction in the 
number of nucleations or an increase in the dimensions of the crystals were obtained.  Using 
three-quarters and half-strength conditions (down to 0.5 M ammonium sulphate, 50 mM 
HEPES pH 7.8, 5 mM manganese chloride tetrahydrate) resulted in reduced numbers of 
nucleations but also slightly smaller, thinner needle crystals and thus offered no progress. 
 
Streak seeding has previously been used to optimise crystal generation for LILRB2 (Willcox 
et al. 2002).  In this process, whole microcrystals are touched with a fine hair or fibre and 
used to transfer nucleation sites to a sitting drop that has been pre-equilibrated overnight with 
half-strength condition and at a low protein concentration that is capable of supporting crystal 
growth but insufficient for de novo nucleation.  Drops are streaked in a serial fashion to 
reduce the number of nucleation sites in each successive drop and thus encourage the growth 
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of single crystals of larger dimensions.  For LILRA4 D1, large scale drops (1 μl plus 1 μl) 
were equilibrated against reservoir solution at half strength (0.5 M ammonium sulphate, 50 
mM HEPES pH 7.8, 5 mM manganese chloride tetrahydrate) and protein concentration was 
varied between 1-4 mg/ml at 1 mg/ml steps with six repetitions.  After overnight equilibration, 
previously grown microcrystals were touched with a clean cat whisker, and the streak-seeding 
drops were then opened and streaked serially with the whisker.  Drops were then re-sealed and 
incubated at 25 ºC.  Inspection was conducted using a light microscope after 3 days and 
weekly for five weeks but only small amounts of precipitate were visible; no crystals grew. 
 
An alternative additive screen was then utilised on the larger scale (Molecular Dimensions 
Ltd., Additive Screen 1).  1 μl of protein solution at 16 mg/ml was mixed with 0.8 μl of 
condition at 1.25 x strength (i.e. 1.25 M ammonium sulphate, 125 mM HEPES pH 7.8, 12.5 
mM manganese chloride tetrahydrate) and 0.2 μl of each of 24 additives, one for each well.  
After one week of incubation at 23 ºC, a heavy precipitate was visible in most drops.  Those 
drops which gave microcrystals, the additive used and the morphologies are listed below in 
Table 5.4 (overleaf). 
 
Although seven of the additives yielded microcrystals, only slight improvements in crystal 
dimensions and morphologies were visible in two of the drops, one containing 5 mM DTT as 
an additive and the other containing 10 mM magnesium chloride.  It was felt that this 
approach was not productive enough to pursue and that a more broad variation in condition 
was necessary. 
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Tube # Compound Type Concentration Observed Crystals 
2 Glutamine Amino acid 50 mM Thick needles 
3 
Spermine tetra 
hydrochloride 
Polyamine 10 mM Bones/brush-forms 
4 Spermidine Polyamine 10 mM Multiple needles 
6 Dithiothreitol 
Reducing 
agent 
5 mM Thick bone-forms 
16 Ethylenediamine* Amine* 5 mM Multiple needles 
19 
Magnesium 
chloride 
Divalent 
cation 
10 mM Thick needles/bones 
23 2-propanol* Organic* 3 % 
Multiple 
needles/brushes 
 
Table 5.4. LILRA4 D1 Molecular Dimensions Additive Screen for crystallisation.  
Highlighted additives produced marginally improved morphology microcrystals.  
Compounds marked with an asterisk are volatile and were added to the well solution 
at 1/10th volume as well as the drop, as per the screen instructions. 
 
 
Three final rounds of optimisation were attempted on the small scale.  A screen was produced 
which varied pH against percentage (w/v) of the precipitant, PEG 8000.  The pH was varied 
between 6.8 and 9.0 units in 0.2 unit steps and the percentage of PEG 8000 was varied 
between 0.1 % and 0.8 % in steps of 0.1 %.  LILRA4 D1 protein concentration remained 
fixed at 20 mg/ml in 50 mM Na Cl 20 mM Tris pH 8.0 buffer.  In a separate screen, the 
protein concentration was varied from 20-8 mg/ml against a percentage of glycerol from 0 to 
5.5 % in 0.5 % steps.  Finally, the glycerol screen was repeated at 4 ºC.  Despite this broad 
range of conditions, no improvement in crystal size was observed. 
 
Figure 5.4 shows light microscope images of the LILRA4 crystals that were observed at 
various stages of the optimisation process. 
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(a)      (b)    
 
(c) 
 
Figure 5.4. Light micrograph images of LILRA4 crystals. (a): Initial screen crystal 
hit at 20 mg/ml in Index condition #35 (1.0 M ammonium sulphate, 0.1 M HEPES pH 
7, 0.5 % w/v PEG 8000).  (b): scale-up of the condition described in (a), but at 25 
mg/ml. (c): best morphology crystals of LILRA4 obtained.  Protein is at 16 mg/ml in 
1.0 M ammonium sulphate, 0.1 M HEPES pH 7.8, 0.5 % w/v PEG 8000, with 10 mM 
manganese chloride tetrahydrate as an additive.  Dimensions (length, width) are 
marked in µm. 
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5.3 Nuclear Magnetic Resonance studies of LILRA4 D1 
The unsuccessful attempts at crystallisation of LILRA4 D1 proved too problematic to 
overcome and an alternative structural strategy was adopted. NMR was an attractive 
alternative, since it provides detailed information about both the structures and dynamics of 
proteins but involves studying the target protein in solution, with no requirement for 
crystallisation.  In addition, the D1 domains of the Group II LILRs that I generated refolded in 
high yields that were adequate for NMR methods.  Furthermore, although NMR spectroscopy 
is limited by the size of the protein under study (typically under 50 kDa, although the 
technique is rapidly developing) and is not well suited to large macromolecular complexes, 
single Ig domains would theoretically be suitable for NMR analysis.  An in-depth explanation 
of the underlying theory of NMR is beyond the scope of this thesis; however a brief outline of 
the principles involved has been presented in my Materials and Methods, Chapter 2.  This 
work was conducted in collaboration with Dr. Timothy Knowles (Overduin NMR Group, 
Institute for Cancer Sciences, University of Birmingham). 
 
5.3.1 NMR Analysis of Unlabelled LILRA4 D1 
To determine the suitability of LILRA4 D1 for NMR analysis, an initial experiment was 
conducted with unlabelled LILRA4 D1 protein, produced as described in Section 5.2.2.  A 
refolded protein sample was concentrated to approximately 1 mM in 50 mM Na Cl 20 mM 
Tris pH 8.0 buffer, [90 % H2O / 10 % D2O] and analysed using a Varian Inova 800 MHz 
NMR spectrometer equipped with an HCN 5 mm z-PFG cryogenic probe with enhanced 
13
C 
and 
1
H sensitivity (HWB-NMR, University of Birmingham).  The resulting 
1
H NMR 
spectrum is displayed in Figure 5.5.  The presence of sharply-defined peaks is indicative that 
the protein is folded; sharp, dispersed peaks below 1.5 ppm to 0 and below indicate the 
presence of methyl groups, and those between 6-11 ppm represent amides and aromatics. 
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The presence of sharp signals below 0 ppm is also indicative of a folded protein.  The strong 
peak at 4.7 ppm is H2O, and other strong peaks at 3.5 ppm and 3.0 ppm are buffer 
components.  These results were indicative that LILRA4 D1 was suitable for further analysis 
by NMR. 
 
5.3.2 3D HSQC NMR Analysis of 
13
C 
15
N-labelled LILRA4 D1 
The structural determination of a protein by NMR requires the assignment of all H/C/N 
residues within the protein.  NMR assignment experiments tend to be lengthy and require a 
protein to be stable at RT for several days.  Using thermal shift screening as discussed 
previously, 50 mM Na Cl 50 mM potassium phosphate pH 7.0 was chosen for its increased 
stability compared to the previously used Tris based buffer.  A test aliquot of the refolded 
LILRA4 D1 protein was buffer exchanged with a PD-10 column, concentrated to 1 mM and 
left at room temperature for seven days to observe protein stability.  No evidence for protein 
precipitation was visible and spectrophotometric analysis at 280 nm (following high-speed 
centrifugation at 13,000 g to pellet precipitates) showed no reduction in absorbance, 
suggesting that the protein was stable at room temperature in the new buffer for long periods 
of time. 
 
For assignment to be performed isotope labelling of carbon and nitrogen residues by 
13
C and 
15
N is required.  
12
C and 
14
N are not NMR active and as such cannot be used for study.  
13
C/
15
N LILRA4 D1 was produced by expression in E. coli BL21(DE3) cells transfected with 
the LILRA4 D1-pET23a plasmid and grown in M9 minimal media supplemented with 
13
C-
labelled glucose and 
15
N-labelled ammonium chloride.  Induction, inclusion body purification 
and chemical refolding were as previously described.  The final purification step by SEC 
utilised the new phosphate buffer.  The protein was concentrated to 1 mM prior to analysis by 
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3D NMR spectroscopy.  Backbone assignment spectra were recorded on LILRA4 using a 
Varian Inova 800 MHz spectrometer equipped with an HCN 5 mm z-PFG cryogenic probe 
with enhanced 
13
C and 
1
H sensitivity: HNCA, HNCACB, HNCO, HNCACO and 
CBCA(CO)NH (described more fully in Chapter 2 Section 2.6).  Initial data processing was 
conducted using the NMRPipe program (Delaglio et al. J Biomol NMR 1995).  Protein 
backbone assignments were conducted using the program SPARKY 3 (Goddard and Kneller, 
University of California, San Francisco).  The backbone 
1
H, 
15
N, CO, Cα and Cβ chemical 
shift values for each resonance – where assignable – are listed in Table 5.5 (overleaf).  A 
number of residues were un-assignable due to weak resonance signals from these residues, 
most likely due to dynamic/flexible regions within the protein.  The final 
1
H-
15
N HSQC 
contour plot for LILRA4 D1 highlighting its backbone assignments is shown in Figure 5.6.  
Figure 5.7a shows which residues of LILRA4 D1 were successfully assigned or otherwise 
un-assignable. 
 
5.3.3 TALOS Prediction of LILRA4 D1 Secondary Structure 
The recorded assignments were submitted to the NMR structural web server, TALOS 
(Cornilescu et al. J Biomol NMR 1999).  TALOS calculates the protein backbone dihedral 
angles, phi (ϕ) and psi (ψ), and can also be used to predict the secondary structure of the 
protein.  The phi and psi angles for LILRA4 D1 are shown in Table 5.6 and plotted in Figure 
5.7b.   The secondary structure prediction from TALOS is shown in graphical form in Figure 
5.7c.
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Residue 
Chemical Shift Values (ppm) 
H N CA CB CO 
E1 - - 56.611 30.285 175.799 
N2 8.496 119.103 53.258 38.722 174.412 
L3 8.193 123.629 52.866 41.694 174.842 
P4 - - 62.571 32.206 177.489 
K5 8.542 124.883 55.012 32.732 175.022 
I7 - - 54.851 35.227 173.332 
L8 9.029 125.906 53.349 45.604 174.531 
W9 8.77 129.305 54.552 29.823 174.744 
A10 8.525 119.965 52.877 48.6 - 
P12 - - 64.365 33.858 175.871 
G13 7.169 110.082 45.16 - - 
P14 - - 63.529 32.223 173.868 
V15 7.159 119.054 61.381 31.688 175.576 
I16 8.776 130.454 57.901 41.293 174.8 
T17 8.217 123.872 62.903 68.978 173.791 
R18 8.299 126.017 58.016 29.855 175.728 
H19 9.608 116.961 57.324 27.384 174.935 
N20 8.187 120.838 51.31 38.292 173.136 
P21 - - 62.355 33 176.147 
V22 8.285 115.751 60.777 35.237 172.478 
T23 8.456 122.48 61.566 70.447 172.13 
I24 8.575 127.879 60.211 38.952 173.149 
W25 8.574 126.601 54.924 30.375 174.057 
C26 8.345 117.123 52.804 44.143 171.898 
Q27 9.826 127.71 54.802 33.165 174.996 
G28 8.526 119.359 45.662 - - 
T29 - - 53.762 44.888 174.785 
L30 8.547 121.919 57.713 63.027 173.516 
E31 8.546 128.777 57.068 38.157 176.392 
A32 7.207 122.262 53.041 18.942 177.58 
Q33 8.983 119.729 55.674 - - 
G34 - - 56.126 - 174.676 
Y35 8.599 115.311 59.007 35.204 172.552 
R36 7.652 115.508 52.43 34.649 174.244 
L37 8.77 129.305 62.851 32.697 175.436 
D38 8.581 120.414 60.751 40.433 173.48 
K39 8.918 130.085 53.788 47.075 175.289 
E40 9.338 127.655 57.566 32.132 0 
G41 9.097 119.317 58.029 - 175.712 
N42 9.608 116.969 57.324 27.384 174.935 
S43 8.548 121.905 58.392 65.456 174.043 
M44 8.071 117.776 55.396 29.298 174.043 
S45 8.071 117.777 55.396 29.298 174.056 
H47 - - 62.851 32.697 175.437 
I48 8.581 120.404 60.751 40.433 173.48 
L49 8.918 130.085 53.788 47.075 175.289 
K50 9.338 127.655 57.579 32.138 170.7 
 
Table 5.5. Chemical shift values for LILRA4 D1 NMR data (continued overleaf). 
For each residue in LILRA4, the 15N, 1H, and 13Cα/β/o chemical shifts are listed, where 
determined.
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Table 5.5. Chemical shift values for LILRA4 D1 NMR data (continued) 
Residue 
Chemical Shift Values (ppm) 
H N CA CB CO 
T51 8.796 120.706 49.579 22.911 176.036 
L52 9.107 119.422 52.87 32.601 - 
S54 - - 62.173 30.604 177.901 
E55 8.224 112.441 58.179 65.848 174.851 
N56 8.91 121.037 52.917 43.13 174.694 
K57 8.733 124.275 54.544 35.372 176.119 
V58 7.994 124.702 64.525 33.546 173.777 
K59 7.745 121.547 61.838 31.54 175.576 
L60 8.796 120.706 53.762 44.888 174.785 
S61 8.547 121.919 57.713 63.027 173.52 
I62 8.547 128.776 58.404 55.532 174.241 
P63 - - 64.328 32.167 176.019 
S64 6.76 109.193 55.786 62.802 173.731 
M65 8.59 128.36 56.828 32.649 175.686 
W67 - - 60.722 - 179.611 
E68 9.042 115.068 58.557 28.834 176.498 
H69 7.658 117.186 58.368 33.368 177.09 
A70 7.476 122.495 52.831 19.609 176.478 
G71 8.557 108.764 44.258 - 170.859 
R72 8.211 119.836 55.633 32.19 174.581 
Y73 - - 56.504 42.236 174.639 
H74 8.671 114.106 56.593 34.256 173.305 
C75 8.524 119.96 52.877 48.6 - 
Y76 - - 56.256 43.787 174.669 
Y77 8.6 115.314 55.888 41.018 172.332 
Q78 8.324 121.52 54.141 29.298 174.282 
S79 8.492 126.121 56.77 65.085 173.052 
P80 - - 65.527 31.333 176.513 
A81 7.658 116.837 52.102 19.6 176.861 
G82 7.621 107.176 43.975 - 173.348 
W83 8.558 121.489 57.866 30.515 176.938 
S84 9.12 117.736 58.407 65.457 174.039 
E85 8.071 117.777 55.396 29.298 - 
P86 - - 62.173 30.604 177.901 
S87 8.224 112.441 58.179 65.848 174.858 
D88 8.91 121.036 54.713 38.591 175.706 
P89 - - 62.402 31.759 176.168 
L90 8.625 123.905 53.349 45.722 174.543 
E91 - - 54.61 - 174.751 
L92 8.888 125.516 53.727 43.32 177.227 
V93 9.122 127.335 61.437 35.607 173.459 
V94 7.994 124.702 58.947 33.546 175.537 
T95 8.262 118.658 59.64 70.095 173.72 
A96 8.67 123.995 53.334 19.632 176.456 
Y97 7.215 120.317 58.091 39.364 179.82 
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Residue Phi, ϕ Psi, ψ  Residue Phi, ϕ Psi, ψ 
3 -94.7 126.1  49 -118 127.3 
4 -67.9 146.4  50 -101.1 122.6 
5 -88.8 131.4  51 -132.6 150.8 
6 -67.5 146.8  55 -93.7 0.8 
7 -111.9 144.9  56 -129.5 140.6 
8 -105 121.6  57 -126.1 142.8 
9 -120.5 138.5  60 -118.9 130.8 
10 -123.7 148  61 -100 122.8 
11 -95.1 118.7  62 -108.2 128.2 
12 -63.5 149.7  63 -58 -27 
13 -119.9 147.6  64 -121.6 124.8 
15 -95.7 127.2  68 -64.2 -27.4 
16 -122.6 138.5  69 -92.1 -16.9 
17 -82.8 137.5  70 -86.8 151.9 
20 -80.1 136  71 -162.5 162.4 
21 -69.7 149.2  72 -108.2 136.2 
22 -132.8 140.3  73 -118.9 154.9 
23 -118.7 125.5  74 -142.5 142.9 
24 -115.1 130.4  75 -117.5 139.6 
25 -124.5 141.7  76 -127.7 149.4 
26 -125.8 140.1  77 -147.2 154.6 
27 -125.1 126.7  78 -97.8 120.6 
28 -130.4 137.8  79 -100.9 141 
29 -132.8 151.9  80 -54.9 -33.3 
30 -87.2 125.5  81 -90.6 -1.8 
32 -86.1 139.7  82 -104.4 158.8 
35 56.8 40.4  83 -89 123.5 
36 -122.1 141.9  85 -98 132.5 
38 -93.8 130.6  88 -66.9 147.4 
39 -111.5 125.7  89 -64.2 148.9 
40 -115.9 118.9  90 -121 139 
43 -104.8 -27.7  91 -125.8 135.8 
44 -146.7 172.2  92 -109.3 125.9 
45 -109 150.6  93 -125.9 139.5 
46 -76.7 143.1  94 -114.2 123 
47 -87.5 -34.4  95 -116 151.9 
48 -137 132.2     
 
Table 5.6. TALOS output for LILRA4 D1 NMR data. Phi, Psi (ϕ,ψ) main-chain 
dihedral angles are tabulated for each residue with assigned resonance. 
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ENLPKPILWA EPGPVITRHN PVTIWCQGTL EAQGYRLDKE GNSMSRHILK
TLESENKVKL SIPSMMWEHA GRYHCYYQSP AGWSEPSDPL ELVVTAY
(b)
ENLPKPILWAEPGPVITRHNPVTIWCQGTLEAQGYRLDKEGNSMSRHILK 
LLLLLLEEELLLLLEEELLLLEEEEEEELLLLLLLEELLEELLLLLLEEE 
06899627558897275689749999740257886648562788873787
TLESENKVKLSIPSMMWEHAGRYHCYYQSPAGWSEPSDPLELVVTAY
LXXXLEEELLELLLLXXHHLLEEEEEEELLLLLLLLLLLEEEEEELL
20003584415589700746517887767898789999758998130
0 1 2 3 4 5 6 7 8 9
(c)
Confidence β-strand (E) α-helix (H) coil (L)
KEY:
1 50
51 97
Sequence
Prediction
Confidence
Structure
Sequence
Prediction
Confidence
Structure
 
Figure 5.7. TALOS secondary structure prediction for LILRA4 D1. (a): Primary 
amino acid sequence of LILRA4 D1.  Residues lacking 1H, 15N assignments are in 
red. (b): Output from TALOS showing Phi, Psi (ϕ,ψ) protein backbone dihedral angles 
for LILRA4 D1. (c): TALOS secondary structure prediction. The TALOS prediction is 
listed below the LILRA4 D1 primary sequence, showing β-strand (E), α-helix (H) and 
coil (L) regions. Confidence for each residue prediction is colour-coded red to green. 
The secondary structure prediction is also shown in diagrammatic form. 
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TALOS predicts the presence of ten β-strands and one α-helix in those regions of LILRA4 D1 
for which we had assignable NMR resonances.  By comparison with the known Group II 
LILR secondary structures, I would designate these strands AA’BCC’EFG as per standard C2-
type Ig fold terminology (Figure 5.8).  Disrupted strands are evident but may be a result of 
missing assignments and the resulting lower confidence of the predictions made by TALOS.  
Structural elucidation would be necessary for more precise analysis of the secondary structure 
of the LILRA4 D1 domain; however, the predictions are highly analogous to that of the other 
Group II LILRs that have structural solutions, i.e. LILRB4 and LILRA5.  The single alpha-
helical region in the D1 domain between the E and F strands is evident, and although TALOS 
is unable to predict the presence of the polyproline helix, the primary amino acid sequence is 
almost identical to LILRB4 and LILRA5 in this region. 
 
The TALOS output file was submitted to the web server, CS-ROSETTA (Shen et al. J Biomol 
NMR 2009).  CS-ROSETTA uses distributed computing power to predict the tertiary structure 
of proteins from backbone assignment (chemical shift) data.  Unfortunately however, due to 
the missing assignments in the LILRA4 D1 NMR spectrum, CS-ROSETTA was unable to 
calculate a final structural solution.  The absence of strong, assignable NMR resonances for 
many residues in the LILRA4 D1 protein could be attributable to flexibility within the 
molecule at these residues.  This hypothesis fits with the observed intransigence of LILRA4 
D1 to crystallisation, and is reflective of a common theme within the LILR receptors which 
may explain the refractoriness to chemical refolding and crystallisation exhibited by some 
members of the LILR family. 
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ENLPKPILWAEPGPVITRHNPVTIWCQGTLEAQGYRLDKEGNSMSRHILK
GPLPKPTLWAEPGSVISWGNSVTIWCQGTLEAREYRLDKEESPAPWDRQN
GNLSKATLWAEPGSVISRGNSVTIRCQGTLEAQEYRLVKEGSPEPWDTQN
A A’ B C C’
TLESENKVKLSIPSMMWEHAGRYHCYYQSPAGWSEPSDPLELVVT-AY
PLEPKNKARFSIPSMTEDYAGRYRCYYRSPVGWSQPSDPLELVMTGAY
PLEPKNKARFSIPSMTEHHAGRYRCYYYSPAGWSEPSDPLELVVTGFY
E F G
LILRA4
LILRB4
LILRA5
LILRA4
LILRB4
LILRA5
LILRA4
LILRB4
LILRA5
LILRA4
LILRB4
LILRA5
1 50
51 97
β-strand α-helix coil 
KEY:
PP-helix 
 
Figure 5.8. Comparison of secondary structures of Group II LILR D1 domains. 
TALOS secondary structure prediction for the LILRA4 D1 NMR data is shown 
alongside the PROCHECK secondary structure designation for the known Group II 
LILR D1 structures, LILRB4 D1 (from the LILRB4 ectodomain structure) and LILRA5 
D1 (from Maenaka et al. 2006). Primary amino acid sequence for each molecule is 
listed with the secondary structures shown in diagrammatic form below. Strand 
designations are from LILRB4 and LILRA5, which have essentially identical 
secondary structures in the D1 domain. 
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5.4 Investigating LILRA4-Ligand Interactions 
5.4.1 Introduction 
While the molecular properties of Group I LILR/ligand interactions have been studied 
extensively, those of Group II LILRs have not, mainly due to a lack of ligands identified for 
this subset.  Recently, the group of Professor Wei Cao (MD Anderson Cancer Centre, 
University of Texas) identified the ligand for LILRA4 as being BST2 (also known as Tetherin, 
CD317 or HM1.24), by an expression cloning approach (Cao et al, JEM 2009). 
BST2/Tetherin has also been the subject of a recent publication by Neil et al, who identified it 
as the host innate immune defence factor which inhibits the budding of enveloped viruses 
including HIV-1 from infected cells (Neil et al. Nature 2008 and see Introduction Section 1.2).  
While data described by Cao et al showed evidence for direct LILRA4/BST2 interaction, the 
approaches involved, namely a plate-bound ELISA and also SPR using LILRA4-Fc fusion 
protein injected over amine-immobilized BST2-Fc (Cao et al. JEM 2009), provided little 
information regarding the monomeric LILRA4/BST2 binding properties. We therefore 
established a collaboration with Professor Wei Cao to use SPR to investigate the molecular 
properties of the monomeric interaction by using monomeric LILRA4, either in 2-domain or 
full 4 ectodomain forms, in order to try to investigate the affinities and kinetics of 
LILRA4/BST2 recognition. 
 
5.4.2 Production of Recombinant LILRA4 D1D2 in the Drosophila Expression System 
Attempts to produce refolded LILRA4 – both two-domain and four-domain constructs – by 
chemical refolding from E. coli inclusion bodies were unsuccessful, as the protein proved to 
be refractory to standard Garboczi chemical refolding methods.  Instead, I adopted a strategy 
utilising expression of the receptor in an insect cell expression system, using Drosophila 
melanogaster S2 cells.  The coding region of the gene for the full-length LILRA4 ectodomain 
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was cloned into the pMT/BiP/V5-His expression vector, which includes a signal peptide for 
efficient export of soluble protein into the cell culture medium and an N-terminal His-tag 
(comprising six consecutive histidine residues) for purification by Ni-NTA column.  Protein 
expression in this system is inducible by the addition of CuSO4, under the control of the 
metallothionein promoter.  The cloning process is outlined in Figure 5.9. 
 
I designed primers to introduce a BglII restriction site into the 5’ end of the LILRA4 gene and 
an AgeI restriction site into the 3’ end of the coding region for the LILRA4 D2 domain, to 
allow cloning into pMT/BiP/V5-His.  The 3’ primer lacked a stop codon to allow read-
through of this region and subsequent expression of the His tag encoded by the vector.  The 
LILRA4-pCMV-FLAG construct provided by Dr. Allen was used as a template.  Initial 
attempts at the PCR using pfu polymerase were unsuccessful, but PCR using expand enzyme 
was successful.  The PCR product and the pMT/BiP/V5-His plasmid were digested with BglII 
and AgeI and gel purified then ligated overnight with T4 DNA ligase.  The ligation product 
was used to transform E. coli DH5α cells and colonies were picked for plasmid miniprep and 
test digests.  Successful test digests generated a fragment of the expected molecular weight (c. 
600bp) as visualised by agarose gel electrophoresis.  Correct LILRA4 D1D2-pMT/BiP/V5-
His sequence was confirmed by DNA sequencing (Functional Genomics, University of 
Birmingham). 
 
I decided to generate a full-length LILRA4-pMT/BiP/V5-His expression construct in order to 
try to express full-length LILRA4 (LILRA4 F).  For LILRA4 F cloning, it was necessary to 
perform a SDM reaction to remove an internal BglII site within the LILRA4 gene.  
Confirmation of successful SDM was carried out by test digest of the LILRA4-pCMV-FLAG 
plasmid with BglII.  I then designed a primer to the 3’ end of the LILRA4 ectodomain coding 
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(a)  
   1 ctacgggcac cgtggccaca cctgcctgca cagccagggc caggaggagg agatgccatg 
  61 accctcattc tcacaagcct gctcttcttt gggctgagcc tgggccccag gacccgggtg 
 121 caggcagaaa acctacccaa acccatcctg tgggccgagc caggtcccgt gatcacctgg 
 181 cataaccccg tgaccatctg gtgtcagggc accctggagg cccaggggta ccgtctggat 
 241 aaagagggaa actcaatgtc gaggcacata ttaaaaacac tggagtctga aaacaaggtc 
 301 aaactctcca tcccatccat gatgtgggaa catgcagggc gatatcactg ttactatcag 
 361 agccctgcag gctggtcaga gcccagcgac cccctggagc tggtggtgac agcctacagc 
 421 agacccaccc tgtccgcact gccaagccct gtggtgacct caggagtgaa cgtgaccctc 
 481 cggtgtgcct cacggctggg actgggcagg ttcactctga ttgaggaagg agaccacagg 
 541 ctctcctgga ccctgaactc acaccaacac aaccatggaa agttccaggc cctgttcccc 
 601 atgggccccc tgaccttcag caacaggggt acattcagat gctacggcta tgaaaacaac 
 661 accccatacg tgtggtcgga acccagtgac cccctgcagc tactggtgtc aggcgtgtct 
 721 aggaagccct ccctcctgac cctgcagggc cctgtcgtga cccccggaga gaatctgacc 
 781 ctccagtgtg gctctgatgt cggctacatc agatacactc tgtacaagga gggggccgat 
 841 ggcctccccc agcgccctgg ccggcagccc caggctgggc tctcccaggc caacttcacc 
 901 ctgagccctg tgagccgctc ctacgggggc cagtacagat gctacggcgc acacaacgtc 
 961 tcctccgagt ggtcggcccc cagtgacccc ctggacatcc tgatcgcagg acagatctct 
1021 gacagaccct ccctctcagt gcagccgggc cccacggtga cctcaggaga gaaggtgacc 
1081 ctgctgtgtc agtcatggga cccgatgttc actttccttc tgaccaagga gggggcagcc 
1141 catcccccgt tgcgtctgag atcaatgtac ggagctcata agtaccaggc tgaattcccc 
1201 atgagtcctg tgacctcagc ccacgcgggg acctacaggt gctacggctc acgcagctcc 
1261 aacccctacc tgctgtctca ccccagtgag cccctggagc tcgtggtctc aggagcaact 
 
MTLILTSLLFFGLSLGPRTRVQAENLPKPILWAEPGPVITWHNPVTIWCQGTLEAQGY
RLDKEGNSMSRHILKTLESENKVKLSIPSMMWEHAGRYHCYYQSPAGWSEPSDPL
ELVVTAYSRPTLSALPSPVVTSGVNVTLRCASRLGLGRFTLIEEGDHRLSWTLNSHQ
HNHGKFQALFPMGPLTFSNRGTFRCYGYENNTPYVWSEPSDPLQLLVSGVSRKPS
LLTLQGPVVTPGENLTLQCGSDVGYIRYTLYKEGADGLPQRPGRQPQAGLSQANFT
LSPVSRSYGGQYRCYGAHNVSSEWSAPSDPLDILIAGQISDRPSLSVQPGPTVTSG
EKVTLLCQSWDPMFTFLLTKEGAAHPPLRLRSMYGAHKYQAEFPMSPVTSAHAGT
YRCYGSRSSNPYLLSHPSEPLELVVS 
 
(b) 
 
LILRA4 D1D2  
5’ Primer: GGAATTC AGATCT GAAAACCTGCCGAAACCGATC 
3’ Primer: CCCCTGCAGCTACTGGTGTCA ACCGGT GGAATTC 
3’ Reverse Complement: GAATTCC ACCGGT TGACACCAGTAGCTGCAGGGG 
 
LILRA4 F  
3’ Primer: CCCCTGGAGCTCGTGGTCTCA ACCGGT GGAATTC 
3’ Reverse Complement: GAATTCC ACCGGT TGAGACCACGAGCTCCAGGGG 
 
Figure 5.9. Cloning of LILRA4 into pMT/BiP/V5-His for S2 cell expression 
(continued overleaf). (a): Gene sequence for LILRA4 up to the end of the fourth Ig 
domain.  The amino acid translation is listed below the nucleotide sequence, with the 
leader peptide in italics and the N terminus of the D1 domain, the D2D3 boundary, 
and the C terminus of the D4 domain in bold.  (b): Primer design for LILRA4 D1D2-
pMT/BiP/V5-His and LILRA4 F-pMT/BiP/V5-His cloning. 
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(c)
 
500 bp
1 kb
1 kb
100 bp
ladder
100 bp
ladder PCR Cut Cut CutUncut Uncut Uncut
Clone 1 Clone 2 Clone 3
500 bp
(d) (e)
 
Figure 5.9. (continued). (c): Map of the pMT/BiP/V5-His vector, with the MCS 
expanded to show restriction sites and features such as the metallothionine promoter 
(PMT), the Drosophila BiP signal sequence and the histidine tag (6xHis) highlighted. 
(from the Invitrogen pMT/BiP/V5-His manual). (d): Agarose gel electrophoresis of the 
LILRA4 D1D2 PCR product and (e): test digests of three clones from minipreps of the 
LILRA4 D1D2 PCR product ligated into the pMT/BiP/V5-His vector. 
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 region, incorporating an AgeI restriction site, and used this primer in combination with the 5’ 
primer described above to carry out PCR using the mutagenised LILRA4-pCMV-FLAG 
plasmid as a template.  The PCR product was then digested with BglII and AgeI, gel purified 
and ligated into similarly digested pMT/BiP/V5-His expression vector.  After transformation 
of E. coli DH5α, plasmid miniprep and successful test digests, the DNA sequence was 
verified (Functional Genomics, University of Birmingham). 
 
The LILRA4 D1D2-pMT/Bip/V5-His and LILRA4 F-pMT/Bip/V5-His vectors were then 
plasmid maxiprepped and used to transfect D. melanogaster S2 cells by calcium phosphate 
transfection.  Transient transfections and test expressions were conducted to show that the 
protein was correctly expressed; western blotting using an anti-His-tag antibody was 
performed to attempt to verify the presence of correctly-folded LILRA4 protein.  As can be 
seen from Figure 5.10a, LILRA4 D1D2 is detectable under both reducing and non-reducing 
SDS-PAGE conditions at both 3 days and 4 days post-transfection, with a small shift in the 
apparent molecular mass between reducing and non-reducing conditions, indicative of correct 
disulphide bond formation.  The apparent mass of the two-domain protein is much higher than 
the expected mass of 22 kDa, which is likely due to glycosylation.  A previous publication had 
reported that LILRA4 is heavily glycosylated upon expression in 293T cells, as evidenced by 
a reduction in its apparent mass upon N-glycosidase treatment (Cho et al. Int Immun 2008), 
and that its apparent mass is heterogenous in this system.  The SDS-PAGE analysis in Figure 
5.10a also shows the presence of a doublet band, which is suggestive of differential 
glycosylation, in accordance with these published observations. 
 
Unexpectedly, this analysis showed that LILRA4 F was undetectable under non-reducing 
conditions, which suggests the fully-folded full length protein may be masking the His tag.  
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Figure 5.10. Test expression and WB detection of LILRA4 proteins from 
Drosophila. (a): Western blot detection of test expressions of LILRA4 D1D2 and 
LILRA4F, under reducing and non-reducing conditions, at 72 h and 96 h post-
induction, using anti-His antibody. (b): Western blot of samples from bulk expression 
of the same constructs under reducing (R) and non-reducing (NR) conditions. (c): 
size exclusion chromatography elution profile for LILRA4 post-Ni-NTA purification 
using S200 column. Peak positions are indicated. (d): SDS-PAGE analysis of 
fractions constituting Peak 3 from the SEC elution profile, compared with a sample 
directly from Ni-NTA elution, under reducing and non-reducing conditions. 
 
234 
 
 
 Since this would render purification of the full-length protein difficult, expression of LILRA4 
F was abandoned in favour of LILRA4 D1D2. 
 
Co-transfection with the pCoHygro plasmid, which includes the Hygromycin resistance gene, 
allowed the generation of a stable S2 cell line containing the LILRA4 D1D2-pMT/Bip/V5-
His plasmid by selection with Hygromycin.  Bulk expression of the protein was conducted by 
growing the cells in 1 L volumes of Schneider’s medium and inducing expression when the 
cells reached log phase of growth (2-4 x 10
6
 cells/ml) by the addition of 500 µM CuSO4.  The 
cells were then removed by low-speed centrifugation (to avoid lysis), and the supernatant 
retained.  The supernatant was then analysed again by western blotting to verify expression of 
the LILRA4 protein (Figure 5.10b).  The supernatant was then dialysed overnight into 150 
mM NaCl 20 mM HEPES pH 7.0, a buffer suitable for purification by Ni-NTA column.  500 
ml of dialysed supernatant was applied to the column overnight at 4 ºC, and then the column 
was washed with 10 mM Imidazole to remove unbound proteins.  Elution was carried out 
with 250 mM Imidazole.  To prevent precipitation of the eluted protein, which was of high 
concentration (approximately 250 μg/ml), the protein fractions were stored on ice. 
 
Following Ni-NTA column purification, the protein sample was subjected to SEC using a 
Superdex S200 column, both to remove Imidazole and to increase purity.  Figure 5.10c shows 
the SEC profile, and it can be seen from this figure that the yield was very low (only 10 mAU 
absorbance of the highest peak) and that multiple species exist as evidenced by the three 
peaks.  SDS-PAGE analysis of fractions from the first two peaks showed high levels of 
contaminants but the third peak contained a protein species of the expected mass for two-
domain LILRA4.  Fractions from the third peak were pooled and concentrated by 
centrifugation filter device.  Figure 5.10d shows the SDS-PAGE analysis of the purified and 
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concentrated protein, as well as a sample of the protein prior to SEC purification.  As can be 
seen from Figure 5.10d, the resulting protein sample was not particularly pure, even after 
purification by SEC, however despite repeat attempts at bulk expression this was the best 
level of purity attained and so I therefore decided to conduct SPR experiments with this 
protein sample.  I also retained a separate protein sample post Ni-NTA column elution but 
without purification by SEC.  Instead this sample was buffer-exchanged by PD-10 column 
into 150 mM NaCl 20 mM HEPES pH 7.0. 
 
5.4.3 SPR Analysis of LILRA4 D1D2/BST2 Interaction 
Professor Cao kindly provided me with a construct for expression of the BST2-Fc fusion 
protein in 293T cells.  BST2 expression was conducted by the Willcox group’s technician, 
Sarah Nicholls.  Purification was by Protein A column and SEC.  Refolded soluble BST2-Fc 
was generated at high concentration and purity as assessed by SDS-PAGE (not shown). 
 
BST2-Fc was immobilized on a CM5 sensor chip using the R10z8e9 anti-human Fc antibody, 
which was amine-coupled to the surface.  As a negative control, a commercially available 
CTLA4-Fc fusion protein was immobilized to the surface of another flow cell by the same 
method.  Two test injections were then conducted, each of 10 μl volume at a flow rate of 10 
μl/min.  The first test injection was with Ni-NTA and SEC-purified LILRA4 D1D2 at a 
concentration of 750 μg/ml; the second test injection was with non-SEC-purified LILRA4 
D1D2 at a concentration of 357 μg/ml.  Sensorgram traces for this experiment are shown in 
Figure 5.11, along with the immobilisation levels for the R10z8e9 antibody, the BST2-Fc 
fusion protein and the CTLA4-Fc control protein indicated. 
 
236 
(a) 
FC R10z8e9 Ligand Level Total 
1 9390 CTLA4-Fc 2219 11609 
2 9540 BST2-Fc 2062 11602 
(b)  
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Figure 5.11. SPR analysis of LILRA4/BST2 interaction. (a): Immobilisation levels 
in resonance units (RUs) for R10z8e9 and proteins under test. (b): Test injection of 
LILRA4 D1D2 post S200 purification, at 750 μg/ml.  (c): Test injection of LILRA4 
D1D2 after Ni-NTA column elution, at 357 μg/ml. Flow cells were coated with CTLA4-
Fc (FC1, black line) or BST2-Fc (FC2, red line). 
 
■ FC1 CTLA4-F  
■ FC2 BST2-Fc 
■ FC1 CTLA4-Fc 
■ FC2 BST2-Fc 
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From Figure 5.11 it can be seen that there is no evidence for an interaction between the 
recombinant monomeric LILRA4 D1D2 protein that I produced, and R10z8e9-immobilised 
BST2-Fc. More specifically, injection of LILRA4 D1-D2 resulted in similar signals over 
BST2-Fc and control surfaces, thereby providing no evidence of specific interaction.  In order 
to clarify this result I conducted a second SPR experiment using LILRA4 D1D2 after SEC 
purification, this time concentrated to 1.28 mg/ml.  Immobilisation levels for this experiment 
are shown in Figure 5.12a, and the sensorgram is shown in Figure 5.12b.  Although the total 
protein immobilisation levels are lower compared with the first experiment, (due to the 
reduced amine-coupling of R10z8e9 antibody in this experiment), the amount of potential 
ligand and control proteins immobilised are still at levels sufficient to see an interaction.  In 
addition, the immobilisation levels were well controlled in these experiments; each flow cell 
had a roughly equivalent amount of total protein immobilised. 
 
Nevertheless, there is no evidence from the sensorgram trace in Figure 5.12b of an interaction 
between soluble LILRA4 D1D2 and immobilised BST2-Fc.  What is clear from these results 
is that binding of the recombinant soluble LILRA4 D1D2 to BST2-Fc is not detected in these 
experiments. 
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(a) 
FC R10z8e9 Ligand Level Total 
1 4109 CTLA4-Fc 1231 5340 
2 3958 BST2-Fc 1216 5174 
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Figure 5.12. SPR analysis of LILRA4/BST2 interaction at higher concentration. 
(a): Immobilisation levels in resonance units (RUs) for R10z8e9 and proteins under 
test. (b): Test injection of LILRA4 D1D2 post S200 purification, at 1.28 mg/ml. Flow 
cells were coated with R10z8e9 alone as a blank (FC1, black line), or R10z8e9 plus 
CTLA4-Fc (FC2, red line) or BST2-Fc (FC3, blue line). 
 
 
■ FC1 CTLA4-Fc 
■ FC2 BST2-Fc 
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5.5 Chapter Summary and Discussion 
In this chapter, I attempted a structural analysis of the Group II LILR family focussed on the 
membrane distal D1 domains of each receptor, in the hope of providing limited structural 
information across the whole Group II subfamily.  However, crystallographic approaches 
proved very problematic, with LILRB3 and LILRB5 failing to crystallise in initial screens. 
LILRA4 was promising in that it yielded microcrystals in numerous conditions, but the 
morphology and size of these (i.e. thin needles) rendered them unsuitable for X-ray data 
collection and despite considerable attempts to overcome these problems data collection 
quality grade crystals were not generated.  
 
In spite of problems with protein crystallisation, the high yields of the Group II D1 domains 
generated indicated that NMR methods were a feasible alternative to X-ray crystallographic 
approaches.  LILRA4 was prioritised for these studies as recent studies have highlighted 
BST2 as a ligand (Cao et al. JEM 2009), the first such identification of a ligand for a Group II 
LILR.  Using standard NMR-based approaches, I managed to produce labelled LILRA4 D1 in 
sufficient yields for partial assignment of the primary backbone of the protein by 3D NMR 
spectroscopy, and calculation of the chemical shifts allowed an NMR-based secondary 
structure prediction of the protein to be conducted using the program TALOS.  This analysis, 
which represents the first structural information about this receptor, indicated the secondary 
structure of the LILRA4 D1 domain is likely to share many features with other Group II 
LILRs, and revealed areas of likely high flexibility that could explain the intransigence of this 
protein to formation of usable crystals.  
 
A second aim was to study the molecular properties of the LILRA4/BST2 interaction, since 
previous studies have not provided information on the affinity or kinetics of this recognition 
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event.  Such data would be of considerable interest since it would represent the first such 
analysis of a Group II LILR/ligand interaction. Although I was able to generate a recombinant 
form of the LILRA4 receptor comprising the membrane distal two domains (D1-D2), a 
second construct comprising the entire ectodomain (D1-D4) was not produced in a usable 
form, as a C-terminal His tag was obscured, precluding purification.  SPR experiments 
involving the LILRA4 D1D2 protein failed to demonstrate binding of recombinant protein to 
immobilised BST2-Fc.   
 
Several explanations for this could be envisaged.  Firstly, since the LILRA4 protein utilised 
comprised only the membrane distal two domains, it is possible that the D3 and D4 domains, 
or the D2-D3 junction, are crucial for this interaction.   If so, this would distinguish LILRA4 
from the Group I LILRs, where the D1-D2 domains seem to dominate ligand interactions.  A 
second possibility was that the affinity of the interaction was very low, such that monomeric 
interactions were undetectable.  This remains an attractive possibility, since LILRA4 is, 
structurally at least, an “activatory” receptor on the basis of its short cytoplasmic tail and 
association with FcRγ, and both activatory Group I LILRs and activatory KIRs are thought to 
recognise MHC Class I with considerably lower affinities relative to their inhibitory 
counterparts.  In addition, the Cao et al study on LILRA4/BST2 interaction found LILRA4-Fc 
protein bound GST-immobilised BST2 with an apparent affinity in the µM range, suggesting 
the monomeric interaction may indeed be extremely weak.  A third possibility was that 
differences in Drosophila-expressed protein (e.g. in the glycosylation pattern) were 
responsible for lack of detectable binding in the SPR experiments.  Heterogenous 
glycosylation is evident from the western blotting, SEC profile and SDS-PAGE analysis 
presented earlier.  The post-translational modification of the expressed LILRA4 with large 
sugar moieties may mask the binding site for BST2 or otherwise disrupt the conformation of 
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the receptor such that it is unable to bind.  If correct, this hypothesis would suggest that 
glycosylation plays a much more important role in LILRA4/BST2 interaction than in Group I 
LILR/ligand interactions analysed to date.  Fourthly, the low purity of the protein that I 
generated may be responsible for inhibiting binding to immobilized BST2-Fc (see Figure 
5.9d).  Unfortunately, the low yield of expression of LILRA4 in the Drosophila system 
precluded extensive purification steps which might correct this.  Finally, the BST2-Fc protein 
itself may be in a conformation unsuited to binding by LILRA4.  There is some evidence from 
recent publications that BST2 may form a heterodimer at the cell surface (Ohtomo et al. 
BBRC 1999), and this dimerization may be necessary for its recognition by LILRA4. 
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CHAPTER 6 – CONCLUSION 
 
 
The LILR receptor family is a relatively evolutionarily ancient family of immune receptors 
which most likely play diverse roles in immune regulation and tolerance.  Although certain 
family members are expressed on lymphocytes such as T, B and NK cells, the predominant 
expression of most LILRs on monocytes, macrophages and dendritic cells suggests potentially 
important functions in the regulation of myeloid cell and antigen presenting cell function. 
Indeed, a growing body of evidence suggests engagement of LILRs on APC cells has major 
effects on maturation, functional efficacy in antigen presentation, and ability to initiate 
downstream tolerance mechanisms.  Examples of effects on tolerance include implication of 
LILRs in the control of DC maturation, and differentiation of DCs to a tolerogenic phenotype 
capable of inducing T cell anergy and influencing generation of T regulatory cells.  Such 
studies suggest that LILR expression or functions may be altered in pathogenic scenarios, and 
consistent with this, LILRs have been implicated in both autoimmune conditions such as 
rheumatoid arthritis, and also in cancer, where they may be involved in mediating suppressive 
effects of the tumour microenvironment via myeloid suppressor cells.  Collectively, these 
studies highlight the potential clinical relevance of LILR immune function. Furthermore, they 
stress the importance of a comprehensive understanding of LILR immune biology, and raise 
the possibility that such an understanding would lead to novel LILR-focussed strategies to 
manipulate dendritic cell function to enhance suppressive effects in autoimmune conditions 
and decrease them in the context of cancer.  
 
A more comprehensive understanding of LILR/ligand recognition events is likely to be key if   
we are to fully understand LILR function in the regulation of immune tolerance.  Arguably 
the two LILRs most strongly implicated in the regulation of myeloid cell function are 
LILRB2 and LILRB4.  Early work on the LILR family showed that the Group I receptor 
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LILRB2 (as well as the more broadly expressed LILRB1) bound to MHC molecules, and 
subsequent studies confirmed that LILRB2 interactions with MHC Class I molecules may 
underlie its tolerogenic effects on DC subsets.  However, implication of the Group II receptor 
LILRB4 in such studies strongly suggests that ligands other than MHC Class I likely play 
important roles in LILR-mediated regulation of tolerogenic DC.  The identity of such novel 
ligands is of considerable interest (particularly for LILRB4 as published data suggest an 
inhibitory signalling role for its ligand on T cells), and this issue was addressed in Chapter 3.  
Briefly, tetramers of the LILRB4 ectodomain were used to stain target cells to assess the 
pattern of ligand expression.  While my T cell staining data were essentially analogous to 
those published by Saverino et al and similarly highlighted increases in staining on activated 
T cells, my dataset was novel in that it showed LILRB4 staining to B cells and monocytes.  
Based on this staining pattern, as well as the proposed inhibitory function for the LILRB4 
ligand, and the finding that it was upregulated on T cell activation, I went on to test direct 
interaction between LILRB4 and various candidate ligands with roles in regulation of 
tolerance, predominantly belonging to the B7 family of costimulatory/inhibitory molecules.  
No interactions with LILRB4 were observed.  Although key caveats should be mentioned 
with respect to my LILRB4 tetramer staining experiments – most notably the fact that such 
experiments are inherently difficult to control, and lack of staining to any in vitro cell lines 
tested – my staining dataset is potentially important since it implies LILRB4 may have 
immunosuppressive modulatory effects on multiple downstream effector populations rather 
than just T cells, and as such it further increases interest in the identity of its ligand(s). 
 
These data raise the important question of how future studies could best determine the ligand 
or ligands of LILRB4.  An important step forward would be if the ectodomain region of 
LILRB4 could be shown to confer binding or reactivity to specific target cells but not others. 
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While in principle this could be achieved using a staining reagent consisting of a multimeric 
form of the LILRB4 ectodomain to stain target cells, given my failure to stain in vitro cell 
lines with LILRB4 tetramers, an alternative approach would be to use a cell surface-expressed 
LILRB4 reporter construct such as an NFAT-GFP-linked construct.  Irrespective of the 
strategy used, differential LILRB4-mediated binding or recognition of target cells would 
enable several downstream options to identify the ligand.  One possibility would be a 
microarray comparison of the transcriptional profile in recognised vs non-recognised cells. 
While this has the potential to identify a relatively large number of differentially expressed 
genes, it is possible that the functional data on LILRB4 in immune tolerance, as well as the 
suggestion that its ligand has an inhibitory signalling function, would help prioritise attractive 
candidate ligands for further investigation.  Alternatively, proteomics-based SILAC (stable 
isotope labelling by amino acids in cell culture) methods potentially provide a parallel 
methodology to identify in a comparable manner differentially expressed proteins enhanced in 
ligand-positive versus ligand-negative cell lines.  A second strategy once ligand-positive and 
ligand-negative target cell lines are identified would be to adopt an expression cloning 
approach, involving transfection of cDNA derived from ligand-positive cells to ligand-
negative cells in order to confer LILRB4 reactivity/binding.  Finally, generation of antibodies 
against ligand-positive target cells that block LILRB4-dependent reactivity or binding 
remains a powerful approach, since such antibodies could potentially either be used to directly 
immunoprecipitate the LILRB4 ligand or conceivably as a tool to facilitate efficient selection 
of ligand-positive cells in expression cloning approaches.  Recently, the group of Cao et al 
identified the ligand for LILRA4, an activatory receptor exclusively present on plasmacytoid 
dendritic cells, by combining several of these steps, using an ILT7-NFAT GFP reporter 
system to identify ligand-positive target cells, followed by generation of a blocking antibody 
that was used to select cDNA species that conferred reactivity to LILRA4-NFAT recognition.  
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While such ligand identification efforts remain speculative in nature, they are likely to prove 
seminal to our understanding of LILR receptor biology. 
 
In Chapter 4, I addressed the related question of the structure of the LILRB4 receptor.  After 
extensive attempts to crystallise the native D1D2 ectodomain failed, I chose to focus on the 
membrane distal D1 domain and successfully crystallised, solved, and analysed its structure 
using X-ray crystallography.  In a collaboration with the group of Professor Gao, I also 
extensively analysed a structure of a D1D2 fragment of the LILRB4 ectodomain bearing a 
non-native disulphide bond to enhance protein stability.  Collectively, these studies provide 
the first structural information on this important regulator of myeloid cell function.  Arguably 
four key points emerged from these studies.  Firstly, although broadly similar in structure to 
other LILRs, in comparison to other family members, LILRB4 has reduced hydrophobic 
contacts at the interdomain interface and an unusual obtuse interdomain angle, strongly 
suggestive of substantial flexibility between the LILRB4 D1 and D2 domains.  Secondly, 
analysis of the LILRB4 structure in relation to structures of both LILRB1/B2 in complex with 
ligand confirms that LILRB4 is highly unsuited to binding MHC Class I, both in terms of 
conformation and the biophysical properties of its surface, confirming its status as a Group II 
LILR.  Thirdly, the structure of the LILRB4 D1 domain is extremely similar to that of another 
Group II receptor, LILRA5, raising the question of whether they interact with structurally 
related ligands.  Finally, analysis of the LILRB4 molecular surface for potential ligand 
binding sites identified several patches of interest.  One, identified by manual inspection, was 
noted to bind to a sulphate ion in the crystal structure, whereas two others, identified by 
automated analysis, corresponded approximately to the D1 tip and D1-D2 hinge region sites 
on LILRB1 uses for binding MHC Class I.  These data suggest there may be structural 
parallels between LILRB4 ligand recognition and that of LILRB1/B2, and they also highlight 
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putative binding sites on LILRB4 that can be analysed further once definitive ligands are 
identified.  In addition, in principle the involvement of each site in LILRB4 ligand binding 
could be tested by carrying out tetramer staining studies using LILRB4 moieties bearing 
mutations in relevant residues from each site. 
 
In Chapter 5, I first attempted to obtain comparable structural information on the D1 domains 
of other Group II LILRs, but ultimately adopted an NMR-based approach to analyse the 
structure of the Group II receptor LILRA4, which is expressed exclusively on plasmacytoid 
dendritic cells.  LILRA4 was of particular interest for structural analyses because a recent 
potentially seminal study by Cao et al had identified its ligand. LILRA4, which negatively 
regulates pDC function, was found to recognise BST2, a type I IFN-induced cell surface 
protein with roles in antiviral defense.  LILRA4 interactions with BST2 potentially function 
as a feedback inhibition loop to limit pDC cytokine production when IFN levels are sufficient.  
However, since BST2 was also found to be expressed on various tumour lines, this study 
raises the question of whether upregulation of BST2 on tumours could provide an axis of 
immunosuppression mediated through LILRA4 inhibition of pDC function.  
 
 In addition to these important immunological implications, the molecular and structural basis 
of LILRA4/BST2 interaction is of considerable interest, not least as a prototypic example of 
Group II LILR/ligand interaction.  While my NMR-based experiments indicated the LILRA4 
D1 domain has similar secondary structural features relative to other LILR D1 domains, and 
also highlighted regions of potentially high flexibility, clearly additional NMR analyses 
would be required for a full structure determination of the LILRA4 D1 domain. Analysis of 
the binding properties of LILRA4/BST2 interaction could also be highly informative about 
the mode of recognition, and to date the only data published on the interaction involved 
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binding of dimeric LILRA4-Fc protein to immobilised BST2. Unfortunately, I was unable to 
generate monomeric D1-D4 LILRA4 protein, and was unable to detect interaction using 
recombinant LILRA4 D1D2.  One obvious explanation for this data is involvement of D3 and 
D4 in this interaction; however another possibility is that the LILRA4/BST2 interaction is 
extremely weak.  This second possibility is consistent with the finding that LILRA4-Fc binds 
to BST2 with an apparent Kd in the µM range, and with the fact that MHC Class I interactions 
with other “activatory” (i.e. ITAM-associating) LILRs and KIRs are thought to involve 
extremely weak interactions.  Clearly further analyses are required to address this issue, and 
to fully define the molecular and structural basis of LILRA4/BST2 interaction. 
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